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Rationale
Congenital heart diseases
Worldwide, birth defects are common and affect approximately 6% of total births (1). Congenital 
heart diseases (CHDs) are the most common birth defects with approximately 1.35 million children 
born each year corresponding to a birth prevalence rate around 9 per 1,000 live births (1,2). They are 
the leading cause of infant mortality in the United Stated and Europe, despite all medical advances 
over the years. As a result of novel surgical procedures and improvement in intensive care units, 
mortality has decreased and many children survive into adulthood (3). CHDs do not only have a 
serious impact on the child, but also on family, society, health care and insurances (4,5). 
The most prevalent CHD is the ventricular septal defect (VSD) accounting for approximately 40% of 
CHDs (6). A VSD is an opening in the septum between the left and right ventricle of the heart. The 
perimembranous type of VSD (pVSD) is located in the membranous part of the ventricular septum 
and accounts for 80% of all VSDs, which corresponds to about one-third of all CHDs (Figure 1) (7). 
Figure 1 | Location of perimembranous ventricular septal defect in the human heart
The heart is the first organ to function within an embryo and starts to beat spontaneously around 
22 days after fertilisation (8). The morphologic development of the embryonic heart is essentially 
completed after 7 weeks of gestation, although the heart will continue to grow throughout 
gestation. Since the human heart is completed so soon in gestation, CHDs are the result of abnormal 
development very early in pregnancy.
The pathogenesis of CHDs is complex and largely unknown with approximately only 15% than can 
be traced to a known cause (9). Only a small proportion of CHDs is associated with chromosomal 
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abnormalities (3-5%), single gene defects (3-5%) and teratogens (2-3%) (1). The majority of CHDs 
have a multifactorial origin and are the result of interactions between genes and environment (6). 
CHDs can be classified as nonsyndromic and syndromic. The prevalence of CHDs is strongly increased 
in individuals with Down syndrome (DS) as approximately 50% of children born with DS have a CHD. 
Cardiovascular risk factors
Cardiovascular disease (CVD) has evolved into a global burden with 17.5 million people dying 
each year from CVD, an estimated 31% of all deaths worldwide (10). The most important CVD risk 
factors are smoking, high blood pressure, high cholesterol, physical inactivity, obesity, diabetes and 
poor nutrition (11). These CVD risk factors are also very common in women of reproductive age: 
physical inactivity (48.5%), obesity (31.8%), smoking (20.2%), high cholesterol (11.3%), hypertension 
(6.9%) and diabetes (3.1%) (12). In terms of human reproduction, these risk factors have impact on 
the development of pregnancy complications such as fetal growth restriction, preterm birth and 
congenital malformations. It has become clear that many CVDs that present in adulthood actually 
have their origins during fetal life, infancy and childhood (11,13). 
Periconception environment 
The periconception period is a highly sensitive time window during early human development. The 
gametes and embryo are sensitive to external exposures such as nutrition and unhealthy lifestyle 
like smoking and stress (14). During this stage, the embryo has the ability to adapt through various 
mechanisms to changing environmental conditions which may have long-term consequences that 
can extend into adulthood. Adverse exposures may increase the risk of congenital malformations 
including CHDs. Both the use of a folic acid supplement as well as a one-carbon-rich dietary pattern 
significantly reduces the risk of having offspring with a neural tube defect or CHD (15,16). In this 
thesis the periconception period is defined as 4 weeks prior to conception lasting through to 
8 weeks after conception. With primary prevention as main focus, risk factors for abnormal heart 
development should be identified during the preconception period. 
Gene-environment interactions
Like many complex diseases, CHDs are thought to be the result of complex interactions between an 
individual’s genetic blueprint (nature) and environmental influences (nurture). Gene-environment 
interactions are complex since both maternal and paternal environmental exposures can interact 
with either the mother’s genes or infant’s genes and alter the risk of CHD (Figure 2) (17). One of the 
proposed mechanisms of gene-environment interactions is epigenetics.
Genetics vs. Epigenetics
In humans, genes make up the blueprint containing all information to build the human body. Genes 
are made up of pieces of DNA (deoxyribonucleic acid) and consist of four types of nucleotide bases, 
that is adenine (A), cytosine (C), guanine (G) and thymine (T). Genetics is based on variations in the 
DNA sequence. If a protein has to be synthesised, the gene has to be read first (Figure 3A). Changes 
in gene expression will results in different cell function or phenotype. 
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Figure 2 | Gene-environment life course epidemiology
Epigenetics is the study of heritable variations that occur without variation in the DNA sequence. 
Hence, the term epigenetics – from the Greek “upon” – refers to changes upon genetics. One of the 
best studied epigenetic mechanisms is DNA methylation which was described for the first time in 
1975 (18,19). DNA methylation is a biochemical process where a methyl (CH3) group is added to 
the DNA, in humans often to the fifth atom of a cytosine (Figure 4). This type of DNA methylation is 
also called CpG methylation, which stands for a cytosine nucleotide next to a guanine nucleotide 
separated by a phosphate (Cytosine-phosphate-Guanine). There are over 28 million CpG loci in the 
human genome of which 70-80% is methylated (20). DNA regions with a high frequency of CpG loci 
are called CpG islands and are often found near the promotor region of a gene (Figure 5).
The process of DNA methylation does not change the DNA sequence itself but gene expression 
can be altered (Figure 3B). DNA methylation is thought to influence gene expression at the level of 
transcription, however, other steps in the process may also be regulated epigenetically (21). DNA 
methylation is one of several epigenetic mechanisms that cells use to control gene expression and is 
very important during human embryogenesis. Since DNA methylation is sensitive to environmental 
changes, epigenetic mechanisms can explain how humans can respond to the environment through 
changes in gene expression. That is, epigenetic changes can turn on or off genes. In humans there 
are two important developmental time windows were methylation is reprogrammed genome-wide 
(22). This is in the germ cells and in preimplantation embryos. 
Methyl groups for DNA methylation are primarily supplied from dietary methyl donors and as 
cofactors via one-carbon metabolic pathways (14). Maternal diet is an important factor that can 
influence the epigenome and emphasises the importance of preconceptional intake of foods such 
as vegetables, fruits and nuts since they are rich in one-carbon metabolites (14). 
Gametes   Zygote   Embryo Fetus   Infancy   Childhood     Adolescence     Adulthood        Elderly
Maternal DNA
Paternal DNA
Ovum
Maternal environment
Sperm
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Figure 3 | Gene expression: from gene to protein
Panel A shows the process of gene expression. Panel B shows epigenetic up- and down regulation of gene 
expression. 
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Figure 4 | DNA methylation: a methyl group (CH3) is added to the 5th atom of a cytosine
DOHaD paradigm
The developmental origins of health and disease (DOHaD) hypothesis predicts that environmental 
exposures experienced early in life have the potential to modify the risk of developing later-onset 
diseases (23). Periconception, prenatal and early postnatal life conditions may affect the vulnerability 
of the individual for developing cardiovascular and metabolic diseases in later life (24). One of the 
proposed mechanisms of DOHaD is epigenetic modification as a result of altered DNA methylation. 
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Figure 5 | Gene structure with location of CpG islands (http://methhc.mbc.nctu.edu.tw/php/index.php)
Methodology
Epidemiology
The word epidemiology is derived from the Greek epi meaning “upon”, demos meaning “people” 
and logos meaning “study” and therefore literally means “studies upon people”. Epidemiology 
is the science that studies the patterns, causes, and effects of health and disease conditions in a 
defined population (25). Epidemiologic observations mainly relate to groups of people. Statistical 
associations between a risk factor and a disease do not necessarily imply a causal relationship. The 
Bradford Hill criteria provide a way to determine if an observed association is likely to be causal (26). 
Inherent to the study design different types of bias and confounding are to be considered. 
Epigenome-wide association studies vs. Candidate-gene studies
Epigenome-wide association studies (EWAS) aim to systematically detect the association of a disease 
with a CpG. Because the EWAS approach is hypothesis-free, the power is to detect new CpG loci 
associated with CHD. If the methylation change for a certain CpG is statistically different between 
two groups the CpG is associated with the disease. The level of statistical significance is calculated 
using Bonferroni correction. False discovery rate (FDR) control can be used as a less stringent method. 
In hypothesis-driven candidate-gene studies, genes are selected based on prior knowledge on its 
relevance in the mechanism of the disease being studied. The advantage of candidate-gene studies 
is that they require a smaller sample size to achieve adequate statistical power. 
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Epigenetic technology
In order to measure DNA methylation the isolated DNA has to be pretreated first. Different 
pretreatments are available, mostly used are sodium bisulphite treatment, restriction enzyme 
treatment and affinity enrichment. After this step, different methods can be used to study DNA 
methylation at a global (Alu, LINE-1, LUMA), gene-specific (pyrosequencing, Sequenom’s EpiTYPER, 
methylation specific PCR) or genome-wide level (next generation sequencing or microarrays such as 
Illumina BeadChips and Tiling Array). 
In this thesis all DNA has been pretreated with sodium bisulphite. After this, the Illumina Infinium® 
HumanMethylation450 BeadChip was used to measure genome-wide methylation (Chapter 4 and 
5). For validation of the top CpG hits we used pyrosequencing (Chapter 4). For gene-specific analysis 
we used EpiTYPER (Chapter 7).
Core study material
Most of the aims of this thesis were addressed in the HAVEN study or in a subset of the control 
children of the same HAVEN study. Our study on CVD risk factors and embryonic growth trajectories 
is based on the Rotterdam Periconception Cohort (Predict study).
HAVEN study
The HAVEN study (Hart Afwijkingen, Vasculaire status, Erfelijkheid en Nutriënten) is a case-control 
family study performed in the Western part of the Netherlands. This study was designed to 
investigate environmental and genetic determinants in the pathogenesis and prevention of CHD. 
Data has been collected from June 2003 until January 2010 at the Department of Obstetrics and 
Gynaecology at the Erasmus MC, University Medical Centre in Rotterdam, the Netherlands. Case 
children were recruited in collaboration with the Departments of Paediatric Cardiology of the 
Erasmus MC, University Medical Centre in Rotterdam, Leiden University Medical Centre in Leiden, VU 
University Medical Centre and Academic Medical Centre in Amsterdam, the Netherlands. Diagnoses 
were ascertained by a paediatric cardiologist during the first year of life by ultrasound and/or cardiac 
catheterisation and/or surgery. Control children were recruited from the public health care centres 
of ‘Careyn’ in the Rotterdam area in the Netherlands. Children were eligible as controls if they did not 
have a congenital or chromosomal malformation ascertained by their physician at the child health 
care centre. Between 2003 and 2010 387 cases and 419 controls were included. 
Rotterdam Periconception Cohort 
The Rotterdam Periconception Cohort (Predict study) is a prospective periconception cohort 
conducted at the Department of Obstetrics and Gynaecology at the Erasmus MC, University Medical 
Centre in Rotterdam, the Netherlands (27). All women of at least 18 years of age with ongoing 
pregnancies of 6 to 8 weeks of gestation were eligible for participation and included in 2009 and 2010. 
A total of 259 pregnancies were included. Women received weekly transvaginal three-dimensional 
ultrasound scans from enrolment up to the 13th week of pregnancy. Crown-rump lengths were 
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measured using the BARCO I-Space (Barco N.V., Kortrijk, Belgium), a four-walled CAVETM-like (Cave 
Automatic Virtual Environment) virtual reality system, allowing depth perception and interaction 
with the projected images using stereoscopic imaging. 
Blood vs. Target tissue
For the measurement of DNA methylation it is important to choose the appropriate tissue given 
tissue-specific gene regulation. However, it is of course not possible to obtain healthy heart tissue 
from healthy control children. Therefore, whole blood is collected in the HAVEN study as a proxy 
tissue from both case and control children to measure leukocyte DNA methylation. Blood is easily 
accessible and has a shared embryonic development with heart tissue since the lateral plate 
mesoderm in human embryos gives rise to both the heart and blood cells in the circulatory system.
Hypothesis
Data has shown that the developing cardiovascular system is sensitive to poor maternal nutrition 
and lifestyle conditions during the periconception period, in the womb and in early postnatal life 
(28). We hypothesised that CHD and CVD share variations in vascular and metabolic pathways. 
These gene-environment interactions may result in aberrant leukocyte DNA methylation which 
may be associated with increased risk of either CHD or CVD and as such can explain inter- and 
transgenerational effects.
Aims of the thesis
CHDs are the most common birth defects worldwide with over 1 million children born each 
year. Since the pathogenesis is still largely unknown we aimed to investigate environmental and 
epigenetic determinants associated with CHD. CVD risk factors increase with age, however, they are 
becoming more common at a younger age. In women of reproductive age they can have impact on 
pregnancy course and outcome. We examined intergenerational effects of CVD risk factors on the 
offspring. Epidemiologic and epigenetic studies are used to address the following aims:
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Part I – Congenital heart diseases 
1. To study intergenerational effects of grandparental CVD on CHD risk in the offspring.
2. To investigate the influence of parental nongenetic risk factors on CHD risk in the offspring. 
3. To explore epigenome-wide DNA methylation using an hypothesis-free approach in very young 
children with nonsyndromic and syndromic CHD. 
Part II – Cardiovascular risk factors
4. To investigate associations between maternal CVD risk factors and embryonic growth. 
5. To assess gene-specific DNA methylation in young children and associations with serum lipid 
levels.
Outline of the thesis
In Part I we study CHDs in young children. Chapter 2 describes the association between CVD in 
grandparents and the risk of having a grandchild with a CHD. Chapter 3 describes associations 
between nongenetic parental conditions and pVSD. Chapter 4 describes an EWAS investigating 
CpG loci associated with pVSD. Chapter 5 addresses an EWAS in children with both pVSD and Down 
syndrome. 
In Part II we address CVD risk factors. Chapter 6 describes the maternal CVD risk profile in association 
with embryonic growth in pregnancies conceived spontaneously and after in vitro fertilisation with 
or without intracytoplasmic sperm injection. In Chapter 7, we investigate the early life lipid profile in 
relation to metabolic programming in very young children. Chapter 8 covers the general discussion 
of the main findings and suggestions for future research are presented. In Chapter 9 we provide a 
summary.
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Abstract
Background Hyperglycaemia, dyslipidaemia and hyperhomocysteinaemia are associated with 
both adult cardiovascular disease (CVD) and having a child with a congenital heart disease (CHD). 
We investigated associations between CVD in grandparents and the risk of CHD in grandchildren. 
Methods In a case-control family study we obtained detailed questionnaire information on CVD 
and CHD in 247 families with a CHD child and 203 families without a CHD child. 
Results Grandparents with CVD or intermittent claudication (IC) were significantly associated with 
an increased risk for CHD in grandchildren (OR 1.39 (95% CI 1.03-1.89) and OR 2.77 (95% CI 1.02-7.56), 
respectively). The risk for CHD grandchildren was particularly increased in paternal grandfathers with 
CVD (OR 1.85 (95% CI 1.01-3.37)). Overall, having a grandparent with CVD increased the risk of CHD 
in the grandchild by 1.65 (95% CI 1.12-2.41). After adjustment for potential maternal confounders 
this risk was 1.44 (95% CI 0.94-2.21). Having two or more grandparents with CVD was associated with 
an approximately threefold risk for CHD grandchildren (OR adjusted 2.72 (95% CI 1.08-6.89)). 
Conclusions Our data suggest that CVD and IC in grandparents are associated with an increased 
risk of having a CHD grandchild. These first findings may be explained by shared causality of 
derangements in metabolic pathways and are in line with the fetal origins of health and disease. 
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Introduction
The worldwide epidemic of cardiovascular diseases (CVDs) remains the leading cause of death and 
represents 30% of all global deaths (29). Moreover, an estimated 1 million children are born each 
year with congenital heart diseases (CHDs) – the most common cause of death from congenital 
malformations worldwide (30). To prevent both diseases in the future, risk factors have to be 
identified. Both animal and human studies show that common environmental exposures, including 
lifestyles, can derange metabolic pathways in particular in combination with genetic susceptibilities 
during vulnerable periods in life and as such are implicated in the pathogenesis of both CVD and 
CHD (31,32). 
We have previously shown a significant association between maternal dyslipidaemia and an 
increased risk of a child with CHD (33). This finding is in line with other metabolic risk factors for CHD 
offspring, such as maternal hyperhomocysteinaemia and hyperglycaemia (34,35). It is striking that 
the same metabolic derangements in later life are associated with adult CVD (36,37). 
Therefore, we hypothesise that CVD and CHD share variations in metabolic causal pathways, owing 
to interactions between poor lifestyles and genetic susceptibilities clustering in families. The 
underlying mechanism might be a derangement of epigenetic programming, which is substantiated 
by the observed transgenerational effects of exposure to famine (38-40). A threefold increase in 
coronary heart disease and a more atherogenic lipid profile especially in women were found in the 
elderly whose mothers were undernourished early in pregnancy during the Dutch famine (41,42). 
Shared metabolic variations of CVD and CHD can affect putative mechanisms of epigenetic (re)
programming of the germ line (i.e. grandparents) and embryonic cardiac tissue (i.e. grandchild) 
thereby mediating the risk for both diseases. 
The relatively low prevalence of CHD, that is 4-8 per 1000 live births makes a prospective 
preconceptional cohort study unfeasible. Therefore, we conducted a case-control family study to 
investigate associations between CVD in grandparents and the risk of CHD offspring. 
Methods 
Study population
This study was part of the HAVEN study, a case-control family study designed to investigate 
environmental and genetic determinants in the pathogenesis and prevention of CHD, and has been 
described in detail before (33,35). 
In addition to this study, grandparents of 806 participating families were invited to participate in the 
current study of which 552 families (68%) responded (Figure 1). Of these families, 91 families (11%) 
did not want to participate and before the analyses we excluded 11 families (1%) without any living 
grandparent. This resulted in 450 (56%) families for further analyses. Of these 450 families with 1800 
grandparents 250 (14%) did not respond and 1550 (86%) responded by returning the questionnaire. 
A total of 214 grandparents from the latter group were deceased and therefore excluded which 
leaves 1336 grandparents for further analyses.
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Number of families invited: n=806
Cases: n=387
Controls: n=419
Response: n=552
Cases: n=291
Controls: n=261
Non-response: n=254
Cases: n=96
Controls: n=158
No participation: n=91
Cases: n=41
Controls: n=50
Number of families participating: n=461
Cases: n=250
Controls: n=211
No living grandparent: n=11
Cases: n=3
Controls: n=8
Study population for further analyses
Number of families participating with at least
one living grandparent: n=450
Cases: n=247
Controls: n=203
Maternal grandmothers: n=373
Case n=201
Control n=172
Paternal grandmothers: n=346
Case n=195
Control n=151
Paternal grandfathers: n=293
Case n=167
Control n=126
Maternal grandfathers: n=324
Case n=179
Control n=145
F
A
M
I
L
I
E
S
I
N
D
I
V
I
D
U
A
L
S
Figure 1 | Flowchart of the HAVEN study population
Questionnaires
All participating grandparents filled out a detailed paper questionnaire at home on general 
characteristics and their own medical history as well as that of their parents, that is great-grandparents. 
Questions on medical history were derived from questionnaires used on patients with heterozygous 
familial hypercholesterolaemia (43). From these questionnaires we extracted date of birth, medical 
history, medical surgery, medication use, special diet, smoking, and family medical history of CVD 
and CVD-related diseases. 
The medical history of grandparents comprised self-reported CVD, defined as any acute, chronic, 
ischaemic, pulmonary or other form of heart and vascular diseases, based on the National Health 
Interview Survey of the Centres for Disease Control and Prevention (44). Information on the CVD-
related diseases hypertension, intermittent claudication (IC), cerebrovascular accident (CVA), 
thrombosis, and pulmonary embolism was obtained and analysed separately. The medical history 
of great-grandparents comprised information on CVD only. To validate the diagnosis, the year 
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of diagnosis and treatment – that is medication use, special diet and or surgery – was reported. 
Medication use was reported as the name of the drug, date of prescription, amount prescribed 
and dose regimen. All drugs are coded according to the Anatomical Therapeutic Chemical (ATC) 
Classification System of the WHO Collaborating Centre for Drug Statistics Methodology. The use of 
a special diet was defined as cholesterol and or fat limited diet, low-sodium diet, a weight-reducing 
diet or other special diet. In addition, information was collected on the period in which the special 
diet was used and whether it was prescribed by a dietitian or doctor. Smoking was reported as the 
year when people started smoking, the amount and kind of tobacco products smoked per day, and 
the moment of quitting smoking. A smoker was defined as someone who smoked currently or had 
a history of smoking. When a first- or second-degree family member was deceased, the cause and 
age of death were reported. 
We did not obtain data on CVD and CVD-related diseases in mothers and fathers of the case 
and control children, because they were too young to have already experienced these diseases. 
Other details on mothers, fathers and children were obtained as described previously (35,45). 
Periconceptional folic acid supplement use was defined as the daily intake of at least 400 µg in the 
entire periconception period, which was defined as 4 weeks before conception until 8 weeks after 
conception. Total plasma homocysteine and total serum cholesterol concentrations of venous blood 
samples from the mothers were obtained and published previously (33). 
Statistical analyses
We compared case and control families using the Student’s t-test and Mann-Whitney U test 
for continuous variables and the chi-square test for categorical variables. When the number of 
observations for analysis was less than five we used Fisher’s exact test. 
We used univariable logistic regression analyses to study the associations between different risk 
factors including CVD in grandparents, and the risk of CHD in grandchildren. Odds ratios (OR) with 
95% confidence intervals (95% CI) were calculated. 
A stratified analysis for the two maternal and two paternal grandparents was performed to investigate 
a significant grandparent-of-origin effect. Confounding of maternal factors was investigated 
using multivariable logistic regression analyses. We adjusted for the following potential maternal 
confounders: age at conception of the index child, educational level, total homocysteine and total 
cholesterol concentrations, and periconceptional folic acid supplement use. We also adjusted for 
CHD in the parents of the child. 
Furthermore, we investigated whether the risk of CHD in grandchildren increased with more CVD 
affected grandparents using univariable and multivariable logistic regression analyses. In these 
analyses, we adjusted for the same maternal confounders and additionally for the number of 
grandparents that were ascertained per child. 
A P value <0.05 was considered statistically significant. All statistical analyses were performed using 
IBM SPSS Statistics 20.0 for Windows software (IBM, Armonk, NY, USA). 
The study protocol was approved by the Central Committee for Human Research (CCMO) in The 
Hague, The Netherlands, and by the Institutional Review Boards (Medical Ethics Committees) of all 
participating hospitals. All parents and grandparents gave their written informed consent. Mothers 
and their partner gave written informed consent on behalf of their participating child.
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Results
A total of 247 case and 203 control families were included for analysis (Figure 1). General characteristics 
of the children and their parents are summarised in Table 1. CHD phenotypes of the case children 
comprised perimembranous ventricular septal defect (n=60), transposition of the great arteries 
(n=48), pulmonary valve stenosis (n=42), coarctation of the aorta (n=28), tetralogy of Fallot (n=24), 
atrioventricular septal defect (n=20), hypoplastic left heart syndrome (n=11), aortic valve stenosis 
(n=6) and miscellaneous (n=8). Case children showed a significantly lower birth weight adjusted 
for gestational age compared with control children. Case and control mothers were significantly 
different for age at birth of the index child and CHD in the family. Case and control fathers were 
significantly different for educational level. 
The risk factors of living grandparents are presented in Table 2. The number of grandparents 
participating per child did not differ statistically significantly between case and control families 
(P=0.711; Supplementary Table S1). CVD and IC were more common in the grandparents of CHD 
children (17% versus 13%, P=0.034 and 2% versus 1%, P=0.038, respectively). Grandparents with 
either CVD or IC were significantly associated with an increased risk for CHD grandchildren, OR 1.39 
(95% CI 1.03-1.89) and OR 2.77 (95% CI 1.02-7.56), respectively. The prevalence of CVD in the parents 
of these grandparents, that is great-grandparents, was not significantly different between the case 
and control families. 
Table 3 shows the results of the stratified analysis for the four different grandparents. We observed a 
significant association between smoking in maternal grandmothers and the risk of a CHD grandchild 
(OR 1.73 (95% CI 1.02-2.93)). CVD in paternal grandfathers was associated with an increased risk for 
a CHD grandchild (OR 1.85 (95% CI 1.01-3.37)). No significant associations were observed in the 
stratified analysis for great-grandparents. 
There was a 1.6-fold higher CHD risk (OR 1.65 (95% CI 1.12-2.41)) when at least one of the 
grandparents of the child suffered from CVD. When we adjusted the association for potential 
maternal confounders, the OR attenuated to 1.44 (95% CI 0.94-2.21).
Stratification for the number of CVD affected grandparents showed that children with one 
grandparent with CVD had a 1.5 fold increased CHD risk (OR 1.51 (95% CI 1.01-2.26), case/control 
children n=93/62) and with two or more CVD affected grandparents a more than 2.5 fold increased 
CHD risk (OR 2.58 (95% CI 1.15-5.78), case/control children n=23/9). Adjustment for maternal 
confounders and the number of grandparents ascertained per child attenuated the association 
between CHD risk and one grandparent affected by CVD (OR 1.29 (95% CI 0.83-2.02)). The association 
between CHD risk and two or more grandparents affected by CVD became stronger (OR adjusted 
2.72 (95% CI 1.08-6.89)).
Because data were self-reported, we cross-checked CVD diagnoses in both case and control 
grandparents with treatment data (Supplementary Table S2). Of the grandparents with CVD, 
81-100% used medication from the ATC group C (cardiovascular system) or underwent CVD-related 
interventions/surgery or followed a special diet for their CVD. 
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Table 1 | General characteristics of case families of a child with CHD and control families of a non-malformed 
child
Cases  
(n=247)
Controls  
(n=203 )
P value
Characteristics of children
Age – months (SD) 16.6 (3.3) 15.9 (2.0) 0.088
Male gender 147 (60) 117 (58) 0.687
Birth weight adjusted for GA (median, min-max) 3390 (865-5 100) 3520 (2235-5180) 0.000
Ethnicity 0.492
Dutch native 213 (86) 180 (89)
European Others 19 (8) 10 (5)
Non-European 15 (6) 13 (6)
Characteristics of mothers
Age at birth of index child – years (SD) 35.1 (4.3) 34.0 (4.2) 0.019
Educational level 0.052
Low 45 (18) 22 (11)
Intermediate 104 (42) 103 (51)
High 98 (40) 78 (38)
CHDa 4 (2) 0 (0) 0.131
CHD family historyb 36 (15) 11 (5) 0.002
Periconceptional
Folic acid supplement usec 42 (17) 37 (18) 0.734
Smoking 42 (17) 33 (16) 0.832
Total homocysteine, mean (SD) (n=384) 10.5 (4.4) 9.8 (3.1) 0.056
Total cholesterol, mean (SD) (n=384) 4.9 (0.9) 4.8 (0.9) 0.138
Characteristics of fathers
Age at birth of index child – years (SD) 37.4 (4.3) 36.9 (4.7) 0.264
Educational level 0.034
Low 58 (23) 35 (17)
Intermediate 81 (33) 90 (44)
High 108 (44) 78 (38)
CHDa 2 (1) 0 (0) 0.504
CHD family historyb 27 (11) 14 (7) 0.139
Smoking 75 (30) 69 (34) 0.408
Values are means or numbers (percentages) unless otherwise specified. 
a Congenital heart disease defined as perimembranous ventricular septal defect, transposition of the great arteries, pulmonary 
valve stenosis, coarctation of the aorta, tetralogy of Fallot, atrioventricular septal defect, hypoplastic left heart syndrome, aortic 
valve stenosis.
b Any congenital heart disease of family members in the first, second or third degree. 
c Adequate periconceptional folic acid supplement use 4 weeks prior to conception until 8 weeks after conception.
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Table 2 | Risk factors of grandparents for having a CHD grandchild
Case 
 grandparents 
(n=742)
Control 
grandparents 
(n=594)
Missing data  
Case/Control 
grandparents 
n (%)
OR (95% CI)
Grandparents (n=1336)
Age – years (range) 65 (46-88) 64 (47-85) 11/5 (1/1) 1.01 (1.00-1.03)
Gender 
Male 346 (47) 270 (45) 0/0 (0/0) 1.04 (0.84-1.29)
CVD 127 (17) 77 (13) 5/2 (1/0) 1.39 (1.03-1.89)
Hypertension 217 (29) 177 (30) 5/2 (1/0) 0.98 (0.77-1.24)
IC 17 (2) 5 (1) 5/2 (1/0) 2.77 (1.02-7.56)
CVA 26 (4) 15 (3) 5/2 (1/0) 1.41 (0.74-2.68)
Thrombosis/ pulmonary embolism 20 (3) 18 (3) 5/2 (1/0) 0.89 (0.47-1.70)
Smoking 133 (18) 90 (15) 6/2 (1/0) 1.23 (0.92-1.65)
Great-grandparents 
Great-grandfather CVD (n=1237) 267 (39) 207 (37) 59/40 (9/7) 1.08 (0.85-1.36)
Great-grandmother CVD (n=1260) 206 (30) 148 (26) 45/31 (6/5) 1.18 (0.92-1.51)
CVD, cardiovascular disease. IC, intermittent claudication. CVA, cerebrovascular accident. Values are means or numbers 
(percentages) unless otherwise specified. 
Discussion 
This case-control family study suggests that both CVD and IC in grandparents are associated with 
an increased risk for CHD in grandchildren. Especially having two or more grandparents with CVD 
increases the risk for CHD in grandchildren. These findings support our hypothesis that CVD and 
CHD share common metabolic or other pathways. The heritability of lifestyle factors in the same 
way as genetic factors affecting these metabolic pathways should be considered with respect to 
both the high prevalence of poor nutrition, smoking and other lifestyles in the general population, 
and the relatively small numbers of genetic variations identified for CVD and CHD (46-48). Of interest 
in this regard is also the established association between maternal grandmother smoking and CHD 
in the grandchild. However, additional adjustment for maternal or grandparental and particularly 
grandmaternal smoking did not significantly affect the results (Supplementary Table S3). Smoking 
is a proxy measure for socioeconomic status, which is clustering in families and as such should also 
be considered as a risk factor for both CVD and CHD. Adjustment for maternal educational level as 
a proxy for socioeconomic status did not attenuate the risk for CHD in grandchildren. However, this 
does not rule out the contribution of poor lifestyles in families to the risk for both CVD and CHD. 
Our results show the highest CHD risk in grandchildren in which the paternal grandfather suffered 
from CVD. This observation is in line with studies showing that the paternal diet can affect cholesterol 
and lipid metabolism in the offspring (49). However, underdiagnosis of CVD in women is an issue to 
be considered, in particular in grandmothers. 
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Besides lifestyle risk factors it should be emphasised that other environmental factors may also be 
involved, such as psychological stresses and pollution, especially those linked to the socioeconomic 
status. After fertilisation, the somatic cell line is reprogrammed among others into the cardiac 
tissues, which will form the embryonic heart (50). After that, the cardiac cells will be fixed in tissue-
specific patterns of gene expression through subsequent generations of cell division. During this 
critical window epigenetic alterations in the programming of embryonic growth and/or specific 
cardiovascular growth genes caused by poor environmental exposures may contribute to CHD 
and increase the susceptibility of developing CVD in later life. The cardiovascular system consists of 
many different cell types from which both CVD and CHD originate. All differentiated cell types have 
their own unique epigenetic mark, which reflects not only the developmental history and previous 
environmental exposures, supported by our observed association with maternal grandmother 
smoking, but also its phenotype (50). In this context, the concept of the fetal origins of CVD is an 
attractive hypothesis (51). This is in line with findings in patients with CHD showing both a higher 
susceptibility to develop ischaemic heart disease and a higher prevalence of CVD risk factors (52). 
However, this study is a first epidemiological attempt to determine an association between CVD and 
CHD and should be interpreted with caution. Nevertheless, potentially modifiable risk factors, such 
as nutrition and smoking, are of great importance and should be further investigated. 
Within families ethnic and cultural factors determine environment. In our study population, 94% 
of the families are from European origin (87% Dutch natives, 6% European others). Therefore our 
results are unlikely to be caused by differences in ethnicity or culture. However, within families 
classic genetic factors cannot be ignored. Familial transgenerational risks are not only determined 
by shared environment, but also by shared alleles. Therefore, familial transgenerational risks are the 
result of a combined effect of susceptibility genes, that is risk alleles, and environmental risk factors 
clustering in families (53). It cannot be excluded that within the case families some major alleles are 
being selected with a dominant inheritance, which increases risks within these families compared 
with the general population. Therefore, a genetic contribution by the transfer of risk alleles should 
be considered as well. 
It has been shown that maternal environmental factors during early pregnancy modify the risk for 
CHD in the offspring. A well-known example is the periconceptional use of a folic acid supplement 
to reduce the risk of having a child with CHD (31,54). After adjustment in our analyses for several 
maternal factors, the risk of CHD in the child still remained significant for the highest risk group. 
Therefore, it is not very likely that the association between CVD and CHD is owing to confounding of 
the investigated maternal factors. However, residual confounding of unobserved risk factors cannot 
be completely excluded. We selected as potential confounders a subset of maternal environmental 
factors, although, it can be assumed that paternal risk factors contribute as well (55). Owing to small 
sample sizes in the high risk groups and the potential of overadjustment we had to limit the number 
of potential confounders. Moreover, there are several contradictory studies on CHD risk factors and 
especially paternal risk factors which make a valid selection of true confounders very difficult. 
The questions about self-reported CVD diagnoses are based on the National Health Interview Survey 
of the Centres for Disease Control and Prevention. These data were crosschecked using self-reported 
CVD treatment information. Of all the grandparents with CVD, 81-100% used medication from the 
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ATC group C (cardiovascular system), a special diet related to CVD, and/or underwent a CVD related 
intervention/surgery (Supplementary Table S2). CVD was significantly correlated with these medical 
data (data not shown). The use of medication could not be confirmed with pharmacy data. However, 
because of the good agreement of self-reported CVD and medical data we do not expect recall bias 
between case and control grandparents. 
We did not study CVD in parents because they were too young to have already experienced CVD 
(Table 1). Our results are based on 1336 grandparents of 450 children which is a complete data 
set for 74% grandparents with a comparable number of cases and controls (Supplementary Table 
S1). This means that data of 464 grandparents were not analysed, that is 250 alive or deceased 
non-responders and 214 excluded deceased grandparents. The strength of the study is that in the 
excluded group of deceased grandparents the distribution of cases and controls were comparable 
(cases n=124 and controls n=90, P=0.511), as well as the number of CVD-related deaths (cases 
n=34 and controls n=23, P=0.761). Data on other diseases in this group were incomplete (49%) and 
therefore not further analysed. A sensitivity analysis restricted only to children with data on all four 
grandparents attenuated the ORs to close to 1.0 although with wide confidence intervals because 
of small sample sizes. Another strength of our study is that the participants were not aware of the 
diseases of interest as an extensive questionnaire on multiple diseases was completed. Therefore, 
we conclude that it is not very likely that selection and recall bias have confounded our results 
although bias because of missing grandparents cannot be ruled out. 
Here we show that families in which grandparents are affected by CVD and IC have an increased risk 
for having grandchildren with CHD. These interesting findings may stimulate further research into 
modifiable environmental risk factors of underlying common metabolic pathways to prevent both 
CHD and CVD in future generations.
Supplementary material
Table S1 | Number of living grandparents participating per child
Number of grandparents 
participating per child
Case children  
n=247
Control children  
n=203
Total children  
n=450
1 grandparent 14 (6%) 17 (8%) 31 (7%)
2 grandparents 73 (30%) 61 (30%) 134 (30%)
3 grandparents 58 (23%) 45 (22%) 103 (23%)
4 grandparents 102 (41%) 80 (39%) 182 (40%)
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Table S2 | Validation of self-reported CVD (n=204) in grandparents by treatment 
Maternal Paternal
Grandmother Grandfather Grandmother Grandfather
Cases 
n=26
Controls 
n=13
Cases 
n=43
Controls 
n=31
Cases 
n=17
Controls 
n=14
Cases 
n=41
Controls 
n=19
Medication use, n (%):
Cardiovascular systema 20 (77) 11 (85) 37 (86) 28 (90) 13 (76) 10 (71) 38 (93) 18 (95)
C01 Cardiac therapy 6 (23) 3 (23) 9 (21) 10 (32) 5 (29) 3 (21) 8 (20) 4 (21)
C02 Antihypertensives – – 1 (2) – 1 (6) – 1 (2) 1 (5)
C03 Diuretics 2 (8) 5 (39) 4 (9) 6 (19) 3 (18) 6 (43) 6 (15) 3 (16)
C07 Beta blocking agents 15 (58) 9 (69) 21 (49) 17 (55) 7 (41) 6 (43) 27 (66) 10 (53)
C08 Calcium channel blockers 4 (15) 2 (15) 8 (19) 8 (26) 3 (18) 1 (7) 11 (27) 3 (16)
C09 Agents acting on the  
renin-angiotensin system
12 (46) 6 (46) 22 (51) 20 (65) 6 (35) 6 (43) 26 (63) 14 (74)
C10 Lipid modifying agents 14 (54) 4 (31) 26 (61) 18 (58) 6 (35) 4 (29) 24 (59) 14 (74)
Interventions / Surgeries, n (%):
CVD-related 8 (31) 2 (15) 20 (47) 17 (55) 3 (18) 5 (36) 19 (46) 9 (47)
Coronary catheterisation 5 (19) 2 (15) 4 (9) 2 (6) 1 (6) 1 (7) 6 (15) 3 (16)
Coronary artery bypass graft 1 (4) – 3 (7) 4 (13) – 1 (7) 7 (17) 2 (11)
Cardiac ablation – – 1 (2) 1 (3) – – – –
Heart valve repair or  
replacement surgery
1 (4) – 5 (12) – 1 (6) – 2 (5) –
Heart surgery – – 1 (2) 2 (6) – – – 1 (5)
Aneurysm – – 1 (2) – – – – 1 (5)
Cardiac pacemaker insertion – – 1 (2) 2 (6) – 1 (7) 1 (2) –
Carotid artery stenting – – – 1 (3) – – – –
ICD placement – – 1 (2) 1 (3) – 1 (7) – –
Percutaneous intervention for lower 
extremity peripheral vascular disease
1 (4) – – 1 (3) – – – –
Multiple interventions/surgeries;  
combination of the above
– – 3 (7 3 (10) 1 (6) 1 (7) 3 (7) 2 (11)
Special diet use, n (%): 6 (23) 4 (31) 6 (14) 11 (35) 8 (47) 6 (43) 15 (37) 8 (42)
Any CVD-related medication/
intervention/special diet use, n (%)
21 (81) 12 (92) 40 (93) 29 (94) 16 (94) 13 (93) 40 (98) 19 (100)
a ATC Group C: 1 or more medicaments per person. 
None of the grandparents used medication from ATC groups ‘C04 Peripheral vasodilators’ or ‘C05 Vasoprotectives’
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Table S3 | CVD in grandparents and the risk of having a CHD grandchild, adjusted for maternal and 
grandparental smoking
Maternal smoking
n=450 
Unadjusted
n=450 
Adjusted for maternal smoking
Grandparents OR P value Adjusted OR P value
CVD 1.6 (1.1-2.4) 0.010 1.6 (1.1-2.4) 0.011
n=450 
Unadjusted
n=450 
Adjusted for maternal smoking
Grandparents OR P value Adjusted OR P value
No CVD 1.0 (ref ) 1.0 (ref )
1 CVD 1.5 (1.0-2.3) 0.044 1.5 (1.0-2.3) 0.045
>1 CVD 2.6 (1.2-5.8) 0.022 2.6 (1.1-5.8) 0.022
Grandparental smoking
n=1336 
Unadjusted
n=1336 
Adjusted for grandparental 
smoking
n=1336 
Adjusted for maternal 
grandmother smoking
Grandparents OR P value Adjusted OR P value Adjusted OR P value
CVD 1.4 (1.0-1.9) 0.034 1.4 (1.0-1.9) 0.024 1.4 (1.0-1.9) 0.028
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Abstract 
Background The perimembranous ventricular septal (pVSD) defect is the most common 
congenital heart disease (CHD) phenotype. Several parental factors are associated with pVSD risk 
in the offspring. To contribute to the future prevention of pVSDs, we investigated associations with 
nongenetic parental conditions. 
Methods In a case-control study with standardised data collection at 17 months after birth, 115 
parents of a child with pVSD and 484 parents of a healthy child completed questionnaires about 
periconceptional nongenetic conditions. Univariable and multivariable logistic regression analyses 
were used to estimate odds ratios (OR) with 95% confidence intervals (95% CI).
Results Complete data were available for 588 families (98%). Maternal risk conditions associated 
with pVSD offspring were a positive family history of CHD (OR 2.61 (95% CI 0.98-6.91)), medication use 
(OR 1.80 (95% CI 1.13-2.85)) and advanced age (OR 1.07 (95% CI 1.02-1.12)). Exposure to phthalates 
(OR 1.93 (95% CI 1.05-3.54)) was the only paternal risk condition associated with pVSD offspring.
Conclusions Four periconceptional parental conditions contributed to pVSD risk in the offspring. 
Couples planning pregnancy should be counselled on these risk conditions which are partially 
modifiable to contribute to the future prevention of pVSDs.
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Introduction
Congenital heart diseases (CHD) are the most frequent birth defects with a worldwide birth 
prevalence rate of 0.6 to 1.9 in 100 newborns per year (56,57). CHD remains the leading cause of 
morbidity and mortality among infants (58). The most prevalent CHD phenotype is the ventricular 
septal defect (VSD) accounting for approximately 40% of CHD (6). The perimembranous ventricular 
septal defect (pVSD) is a more severe type than the muscular ventricular septum defect, which often 
spontaneously closes during life (7).
The pVSD is an outflow tract defect originating in early pregnancy with a multifactorial aetiology 
in which only 15% can be attributed to a known maternal and sometimes paternal cause (9). 
Derangements in migration of cardiac neural crest cells to the endocardial ridges of the proximal 
outflow tract are suggested to be involved (59). The one-carbon pathway is important during 
embryogenesis and influenced by both genetic variations and environmental conditions, such as 
nutrition – in particular folate intake, lifestyle factors, and medication use. We and others showed 
in epidemiological and experimental embryo studies that a derangement of this pathway during 
the periconceptional period leading to a mild to moderate hyperhomocysteinaemia and global 
hypomethylation, contributes to the development of pVSD due to an altered behaviour of the neural 
crest cells (35,60-62). Moreover, it has been shown that strong adherence to a dietary pattern rich in 
folate, methionine and choline, and folic acid supplement use reduces the risk of CHDs including 
pVSD, which can be explained in part by a restoration of a deranged one-carbon metabolism (16,63). 
Environmental conditions associated with the pVSD phenotype comprise maternal pregestational 
diabetes mellitus, the use of assisted reproductive technology and exposure to medication, alcohol, 
drugs and fever (64). 
To predict risks for any outcome, a cohort study is the gold standard. However, because pVSD is a 
rare disease, a cohort study is not feasible and a case-control study is the accepted alternative. 
From this background, our aim was to further improve preconceptional care by identifying in a case-
control study a risk profile of periconceptional parental conditions in association with pVSD in the 
offspring. 
Methods
Study population
This study was part of the HAVEN study, a Dutch case-control family study designed to identify 
risk factors in the pathogenesis and prevention of CHDs. The study design has previously been 
described in detail (35,65). In summary, the study has been conducted from 2003 onward at the 
Department of Obstetrics and Gynaecology of the Erasmus University Medical Centre, in Rotterdam, 
the Netherlands. Case children and both parents were recruited from four university medical centres 
in the Netherlands. Diagnoses were ascertained by a paediatric cardiologist during the first year of 
life by ultrasound and/or cardiac catheterisation and/or surgery. Cases were defined as isolated CHD 
when they did not have another major structural congenital malformation besides their CHD. In line 
Processed on: 27-10-2016
505572-L-sub01-bw-Wijnands
36 | Chapter 3
with the role of the one-carbon pathway and to create homogeneity of the CHD phenotype, we 
included for the present study only parents and their child with pVSD . 
Control children and their parents were enrolled in collaboration with the child health centres at 
which each child in the Netherlands is regularly checked on growth and development. Children 
were eligible as controls if they did not have a congenital or chromosomal malformation ascertained 
by their physician at the child health care centre. 
Both case and control children were eligible for inclusion if they were singletons, their parents were 
familiar with the Dutch language in reading and writing, and there was no familial relationship 
between cases and controls. Participants visited the hospital at the standardised study moment of 
around 17 months after delivery. 
Data collection
All case and control parents completed a general questionnaire at home. During the hospital 
visit these questionnaires were checked by the researcher for completeness and consistency. The 
periconception period as window of exposure to parental conditions was defined as 4 weeks before 
conception until 8 weeks after conception and covers the critical period of embryonic cardiogenesis. 
Educational level and ethnicity were classified according to the definitions of Statistics Netherlands 
(66,67). Family history of CHD was considered positive if a relative in the third degree or closer was 
diagnosed with pVSD, transposition of the great arteries, coarctation of the aorta, atrioventricular 
septal defect, tetralogy of Fallot, aortic valve stenosis, pulmonary valve stenosis, or hypoplastic 
left heart syndrome. We defined alcohol, smoking and medication use as any use during the 
periconception period. A medication subgroup was made for the use of folate antagonists. Folic 
acid supplement use was defined as daily intake of at least 400 µg during the entire periconception 
period, either in a multivitamin preparation or as a single tablet. Inconsistent users were classified 
as nonusers. Standardised anthropometric measurements were performed during the hospital visit, 
including weight, height and blood pressure. We assessed occupational exposures to chemicals 
by applying a job-exposure matrix with a focus on endocrine disrupting chemicals, as published 
previously (65). 
Statistical analysis
Baseline characteristics were compared between case and control parents and children. Categorical 
variables were analysed using the chi-square test and Fisher exact test. Continuous variables were 
tested for normal distribution using the Kolmogorov-Smirnov test after which we used either the 
parametric Student’s t-test or the nonparametric Mann-Whitney U test. 
Univariable logistic regression analysis was used to determine the risk conditions significantly 
associated with pVSD. Odds ratios (OR) with 95% confidence intervals (95% CI) were estimated. The 
selection of risk conditions to estimate the risk of having a pVSD child was based on our studies 
within the HAVEN study and those of others. 
The potential maternal risk conditions that were investigated are: age, parity (primipara and 
multipara), educational level, BMI, diabetes mellitus, ethnicity, positive family history of CHD, 
blood pressure, smoking, folic acid supplement, alcohol and medication use, and occupational 
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exposures to pesticides, phthalates, alkylphenolic compounds, polychlorinated compounds, and 
heavy metals. The potential paternal risk conditions that were investigated are: age, educational 
level, ethnicity, positive family history of CHD, smoking, alcohol use, and occupational exposure to 
pesticides, phthalates, alkylphenolic compounds, polychlorinated compounds and heavy metals. 
The dichotomous dependent variable was the case/control indicator. Discrete variables were treated 
categorically and continuous variables were treated continuous. 
The final multivariable logistic regression model was derived after hierarchical backward elimination 
of all covariates with P value <0.10. Possible interactions were tested and interactions with P value 
<0.10 were entered in the model. The area under the receiver operating curves (AUC) was used to 
estimate how well the model discriminates between case and control families. 
The analysis was repeated for isolated pVSD only, that is excluding syndromal and chromosomal 
pVSD. Because less than 2% of the data was missing we did not impute missing values. This led to 
the exclusion of 11 individuals (eight controls and three cases) in the multivariable analysis. A P value 
<0.05 was considered statistically significant and all tests were two-tailed. Analyses were performed 
with IBM SPSS Statistics Version 20.0 for Windows software (IBM, Armonk, NY, USA). 
Results
A total of 115 case children with pVSD and 484 control children and both parents were analysed 
(data from three fathers was missing). The total group of pVSDs consisted of 90 isolated and 
25 nonisolated defects. Of the 25 nonisolated pVSDs, 15 children suffered from one of the following 
syndromes: Down syndrome (n=10), 22q11 deletion (n=2), Noonan (n=1), 22q13 duplication (n=1) 
and miscellaneous (n=1). The remaining 10 nonisolated pVSDs had other defects that could not be 
traced to a known syndrome, such as hip dysplasia, club foot, craniosynostosis and fourth nerve 
palsy.
Case children were compared with control children significantly older at the study moment (16.9 
(3.7) vs. 16.1 (2.3) months; P=0.024) and had a lower birth weight adjusted for gestational age at 
birth (3,214 (675) vs. 3,531 (657) grams; P=<0.001). Gender was comparable between case and 
control children (n=54 (47%) and 273 (56%) males, respectively; P=0.067). 
The baseline characteristics of the parents are shown in Table 1. In the case group, mean maternal 
age was significantly higher compared with controls (31.5 vs. 30.4 years respectively (P=0.028)). 
Case mothers had a significantly shorter duration of pregnancy with a median of 39 weeks versus 
40 weeks (P=0.004) and used more often medication, 33% versus 21% respectively (P=0.005). 
Folate antagonists were more used by case mothers compared with control mothers, 7% versus 3% 
(P=0.015). 
Univariable logistic regression analysis revealed that maternal family history of CHD, medication 
use, alcohol and age, and paternal exposure to alkylphenolic compounds and phthalates were 
significantly associated with pVSD in the child (Table 2). 
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Table 1 | Periconceptional parental conditions of children with a perimembranous ventricular septal defect 
and healthy control children 
Variables Cases  
n=115
Controls   
n=484
P value
Mothers
Age at birth of index child in years (range)a 32 (19-46) 30 (18-45) 0.028 
Educational levelb 0.423
Low 28 (24) 106 (22)
Intermediate 49 (43) 239 (49)
High 38 (33) 139 (29)
Ethnicityb 0.477
Dutch natives 92 (81) 378 (78)
European others 8 (7) 29 (6)
Non-European 13 (12) 77 (16)
Parityb 0.257
Primipara 48 (42) 241 (50)
Multipara 67 (58) 242 (50)
Pregnancyb
Spontaneous pregnancy 109 (95) 460 (95) 0.941
Previous abortion 24 (21) 126 (26) 0.251
BMI (kg/m²) median (range)c 24 (17-41) 24 (16-52) 0.796
Diabetes mellitusd 2 (2) 5 (1) 0.624
Blood pressurea
Systolic median (range) 118 (95-145) 115 (80-155) 0.350 
Diastolic median (range) 74 (55-94) 74 (50-104) 0.987 
Positive family history of CHDb 7 (6) 13 (3) 0.068 
Periconception
Medicationb
 Folate antagonistb
38 (33)
8 (7)
101 (21)
16 (3)
0.005
0.015
Alcoholb 46 (41) 154 (32) 0.092
Smokingb 17 (15) 101 (21) 0.146
Adequate folic acid supplement intake (yes)b 15 (13) 65 (13) 0.940 
Fathers
Age at birth of index child in years (range)a 34 (23-47) 34 (20-56) 0.793
Positive family history of CHDb 6 (5) 16 (3) 0.322
Educational levelb 0.231
Low 27 (24) 128 (27)
Intermediate 40 (35) 196 (41)
High 47 (41) 158 (33)
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Table 1 | (Continued)
Variables Cases  
n=115
Controls   
n=484
P value
Ethnicityb 0.484
Dutch natives 96 (84) 381 (79)
European others 6 (5) 33 (7)
Non-European 12 (11) 67 (14)
Periconception
Alcoholb 87 (77) 373 (78) 0.899
Smokingb 36 (32) 178 (37) 0.305
CHD, congenital heart disease. Values are n (%) unless stated otherwise. a Student’s t-test b Chi-square test c Mann-Whitney U test 
d Fisher Exact test.
Table 2 | Periconceptional parental conditions and associations with perimembranous ventricular septal 
defects in the offspring
Variable Unadjusted odds ratio (95% CI) P value
Maternal
Age (years) 1.05 (1.01-1.10) 0.028
Parity
Nulliparous reference group
Multiparous 1.39 (0.92-2.10) 0.117
Educational level
Intermediate reference group
Low 1.29 (0.77-2.16) 0.337
High 1.33 (0.83-2.14) 0.233
BMI (kg/m²) 0.99 (0.95-1.04) 0.796
Diabetes mellitus 1.70 (0.32-8.85) 0.531
Ethnicity 0.530
Dutch native reference group
European other 1.13 (0.50-2.56) 0.763
Non-European 0.69 (0.37-1.30) 0.255
Family history of CHD 2.35 (0.92-6.03) 0.076
Systolic blood pressure (mmHg) 1.01 (0.99-1.03) 0.350
Diastolic blood pressure (mmHg) 1.00 (0.98-1.03) 0.987
Lifestyle; preconception use of
Folic acid supplement 0.97 (0.54-1.75) 0.924
Alcohol 1.44 (0.94-2.19) 0.093
Smoking 0.66 (0.38-1.16) 0.148
Medication use 1.87 (1.20-2.92) 0.006
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Table 2 | (Continued)
Variable Unadjusted odds ratio (95% CI) P value
Exposure to
Phthalates 1.06 (0.22-5.07) 0.941
Alkylphenolic compounds 0.34 (0.08-1.47) 0.149
Paternal
Age (years) 1.01 (0.97-1.05) 0.793
Educational level
Low reference group
Intermediate 0.97 (0.57-1.66) 0.904
High 1.41 (0.83-2.39) 0.202
Ethnicity
Dutch natives reference group
European others 0.72 (0.29-1.78) 0.476
Non-European 0.71 (0.37-1.67) 0.306
Positive family history of CHD 1.62 (0.62-4.23) 0.327
Smoking 1.26 (0.81-1.95) 0.306
Alcohol 1.03 (0.63-1.68) 0.899
Exposure to
Pesticides 1.85 (0.79-4.34) 0.157
Phthalates 1.96 (1.09-3.50) 0.024
Alkylphenolic compounds 2.08 (1.01-4.26) 0.046
Heavy metals 4.28 (0.27-68.94) 0.305
Polychlorinated compounds 1.37 (0.67-2.79) 0.383
No mothers were exposed to pesticides, heavy metals or polychlorinated compounds.
The results of the multivariable analysis are shown in Table 3. Maternal family history of CHD (OR 2.61; 
95% CI 0.98-6.91; P=0.054), medication use (OR 1.80; 95% CI 1.13-2.85; P=0.013) and age (OR 1.07; 
95% CI 1.02-1.12; P=0.007), and paternal phthalates exposure (OR 1.93; 95% CI 1.05-3.54; P=0.034) 
were associated with the risk of pVSD offspring. Figure 1 shows the identified parental risk profile by 
the receiver operating characteristic curve obtained from the final multivariable logistic regression 
model (AUC=62.7%; 95% CI 57.0-68.5; P=0.000). The Nagelkerke R2 was 0.057.
The same multivariable analysis for isolated pVSDs only, showed comparable results and included 
maternal family history of CHD (OR 3.14; 95% CI 1.13-8.73; P=0.028), medication use (OR 1.76; 95% CI 
1.06-2.93; P=0.030), age (OR 1.06; 95% CI 1.01-1.12; P=0.016), and paternal phthalates exposure (OR 
2.24; 95% CI 1.20-4.29; P=0.015). The accuracy of the model was comparable (AUC=64.1%; 95% CI 
57.7-70.5; P=0.000). 
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Table 3 | Multivariable logistic regression results
β S.E. Sig. Odds ratio 95% CI 
Maternal
Positive family history of CHD 0.958 0.497 0.054 2.61 0.98-6.91
Medication use 0.586 0.235 0.013 1.80 1.13-2.85
Age 0.063 0.023 0.007 1.07 1.02-1.12
Paternal
Phthalates 0.657 0.310 0.034 1.93 1.05-3.54
Hosmer-Lemeshow goodness-of-fit χ2 2.209; P 0.974, Nagelkerke R2 0.057
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Figure 1 | Receiver operating characteristic curve of the model for perimembranous ventricular septal defects, 
calculated with multivariable analysis. The area under the curve for this model was 62.7% (95% CI 57.0-68.5)
Discussion
This study shows that maternal positive family history of CHD, medication use and age, and 
paternal exposure to phthalates contribute to the risk of pVSD and isolated pVSD offspring only. 
These risk factors – except a positive family history – have been associated with derangements of 
one-carbon metabolism which is an underlying mechanism of CHD. Advanced maternal age can 
alter one-carbon metabolism and lead to moderate to severe hyperhomocysteinaemia by reducing 
the bioavailability of substrates, cofactors and intermediates. Hyperhomocysteinaemia influences 
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oxidative, vascular, apoptotic, inflammatory and methylation pathways, and protein, lipid and DNA 
synthesis. Generic medication use can antagonise enzymes in folic acid metabolism, or influence 
folic acid absorption or degradation and inhibit the folic acid methylation cycle. Paternal phthalates 
exposure is epigenetically toxic and can cause epigenetic modifications.
The main strengths of our study are the homogeneity of the pVSD phenotype and the standardised 
data collection in cases and controls at the fixed moment of 17 months after birth, which equates 
to approximately two years after the periconception period. Other studies have also observed 
associations but mostly of a heterogeneous group of CHD phenotypes often due to the limited case 
numbers, which makes it difficult to observe true associations. Furthermore, the risk conditions are 
studied in a defined exposure window for this phenotype. This is helpful to reduce recall bias and 
seasonal influences. This strict approach also minimises the chance of misclassification of cases and 
controls because most malformations are diagnosed in the first year of life. 
Some methodological issues have to be considered. We were not able to estimate maternal diabetes 
mellitus as risk factor because this health condition was rare in our study group (n=7). Rare risk 
factors are hard to study in a case-control design. Medication data included both prescribed and 
over-the-counter medication. Medications most frequently used were amoxicillin, carbamazepine, 
clarithromycin, clomifene, fluoxetine, fluticasone, ibuprofen, levothyroxine, meclozine, methyldopa, 
paracetamol, paroxetine and valproic acid. These medication data could not be verified in pharmacy 
records. Therefore, we consider medication use as measure of health more than a direct effect of the 
medication itself. In case mothers 33% and in control mothers 21% used any medication (P=0.005), 
of which the latter proportion was lower than the 37% reported in the general population in the 
Netherlands in 2004 (68). Therefore, possible recall bias and type II errors cannot be excluded which 
makes caution in place especially due to the case-control design of this study.
The explained variance of the four risk conditions for pVSD is 5.7% from which we conclude that 
based on our model of parental conditions not all risk conditions are identified. However, so far 
only 15% of pVSD can be attributed to a known maternal or paternal cause. Therefore, a conclusive 
AUC is not feasible at this moment. The AUC could be improved by including genetic risk conditions 
and diseases such as maternal diabetes mellitus, phenylketonuria and rubella. Unfortunately, these 
conditions are relatively rare and therefore hard to study. However, to explain the aetiology of the 
remaining 85% of pVSD cases it is imperative that more research on pVSD has to be performed 
because it is the most frequent birth defect with lifelong health consequences. Nevertheless, our 
model is useful for preconception counselling of parents-to-be. Risk identification makes it possible 
to inform couples about the risks of modifiable conditions – in particular lifestyles – and to offer 
possibilities for modification. 
Results from logistic regression analyses show that the risk of pVSD increases significantly with 
advanced maternal age. There has been little consistency in studies concerning maternal age 
and the risk of having a child with CHD and pVSD, and increased risk has been described for both 
advanced and younger age (64,69,70). Because maternal age at the time of first birth has increased 
with almost four years during the last decades, it is important to inform future parents about their 
higher risk of having a child with pVSD (71).
Positive family history of CHD revealed the strongest maternal risk factor for pVSD offspring. We 
defined a positive family history as a relative in the third degree or closer with one of our eight 
included CHD phenotypes. The relevance of this choice has been described by others where they 
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found that within different degrees of relatives the odds ratios ranged from 1.18 (95% CI 1.05-1.32) 
for a third-degree relative up to 9.25 (95% CI 7.63-11.2) for twins of the same sex (72). Although this 
risk condition is supportive for a genetic contribution, it should be emphasised that familial risk is 
not only determined by genetic factors but also by the accumulation of nongenetic risk conditions 
through a shared environment. To minimise possible confounding of CHD clustering in families 
due to single-gene or chromosomal defects, we repeated the analysis for isolated pVSD without 
any other structural congenital anomaly or chromosomal defect. This analysis showed comparable 
results suggesting that nongenetic conditions might indeed contribute to the risk of pVSD offspring. 
The association between pVSD and paternal exposure to phthalates was described earlier by our 
group in the total group of cardiac outflow defects (65). Occupations probably exposed to phthalates 
and therefore at risk are plastic workers, painters, electricians, hairdressers and printers. Electricians 
should avoid exposure to phthalates from fumes when soldering and hairdressers should avoid 
exposure to cosmetic products such as hair sprays with phthalates. Unfortunately, other studies on 
paternal occupational exposures and pVSD are not available. 
We conclude that preconception counselling should address the increased risks with advanced 
maternal age and paternal phthalates exposures. Women should not unnecessarily delay pregnancy. 
Maternal prescription and over-the-counter medication should be evaluated by a health care giver 
and the option to quit should be considered. Also CHD in the family should be evaluated thoroughly 
and provides, if positive, opportunities for early detection. The implementation of the findings of 
this study in preconception care can contribute to the future prevention of pVSDs.
Supplementary material
Table S1 | Specification folate antagonists
Antibacterials trimethoprim, sulfonamides
Antidepressants fluoxetine, fluvoxamine, paroxetine, citalopram, sertraline, imipramine, 
desipramine, amitriptyline, nortriptyline, clomipramine, bupropion, 
trazodone, mirtazapine, maprotiline, reboxetine, venlafaxine
Antiepileptics clobazam, clonazepam, ethosuximide, phenobarbital, primidone, 
gabapentin, pregabalin, lacosamide, lamotrigine, topiramate, vigabatrin, 
carbamazepine, phenytoin, levetiracetam, oxcarbazepine, valproic acid
Antimalarials atovaquone/ proguanil, proguanil, pyrimethamine
Antivirals for HIV infections zidovudine, abacavir, lamivudine, didanosine, zalcitabine, stavudine, 
efavirenz, nevirapine, saquinavir, nelfinavir, indinavir, ritonavir, amprenavir
Chemotherapy methotrexate, pemetrexed, raltitrexed, pralatrexate 
Drugs for obstructive airway disease salbutamol, salmeterol, terbutaline, indacaterol, formoterol, ephedrine, 
betamethasone, cortisone, dexamethasone, hydrocortisone, 
methylprednisolone, prednisolone, prednisone, triamcinolone, 
fludrocortisone
Lipid modifying agents colestyramine
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Abstract 
Background Congenital heart diseases (CHDs) are the most common birth defects worldwide 
and leading cause of infant mortality in the Western world. The perimembranous ventricular septal 
defect (pVSD) is the most prevalent CHD, however its pathogenesis is largely unknown. Epigenetics 
may provide an underlying mechanism of the gene-environment interactions involved explaining 
tissue-specific derangements in embryogenesis.
Methods We performed an epigenome-wide association study in peripheral white blood cells of 
young children to identify novel 5’-cytosine-phosphoguanosine (CpG) loci in association with pVSD. 
We investigated 455,741 CpG loci in 84 case children with pVSD and 196 healthy control children at 
17 months of age using the Illumina Infinium® HumanMethylation450 BeadChip (450k array).
Results Using Bonferroni correction, we identified one CpG locus on chromosome 1 within the 
gene body of PRDM16 (PR domain containing 16) that was higher methylated in pVSD children 
(+4.8% in cases, P=9.17E-08). This finding was validated by bisulphite pyrosequencing (+4.5% in 
cases, P=0.007). At 15% FDR (false discovery rate), we identified seven additional CpG loci mapped 
to eight genes on five chromosomes. Absolute methylation differences were observed in CpG loci 
mapped to ESAM (-2.2% in cases, P=8.09E-07), PPFIA4 (+2.4% in cases, P=8.46E-07), NFIA (-0.8% in 
cases, P=9.13E-07), HNRNPU (-0.7% in cases, P=1.87E-06), HIF3A (-2.8% in cases, P=2.08E-06), CDK4 
(-0.4% in cases, P=2.11E-06) and MOAP1 and C14orf109 (-0.4% in cases, P=2.42E-06).
Conclusions We demonstrate an association between one higher methylated CpG locus within 
PRDM16 and increased risk of pVSD. PRDM16 functions as a repressor of TGFβ signaling controlling 
tissue morphogenesis crucial during cardiogenesis. Moreover, differential methylation of CpG loci 
mapped to eight genes involved in cardiogenesis, embryogenesis or related to severe congenital 
heart defects was shown. These findings provide novel insights in understanding the pathogenesis 
of pVSD which is of interest for future prediction and prevention.
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Introduction
Worldwide approximately 1 million children are born each year with a congenital heart disease 
(CHD), which is not only the most prevalent birth defect but also the leading cause of infant mortality 
in the Western world (1). The most prevalent CHD phenotype is the ventricular septal defect (VSD) 
accounting for approximately 40% of CHD (6). The perimembranous type of VSD (pVSD) accounts for 
80% of all VSDs (7). pVSD originates from the endocardial outflow tract cushions failing to fuse with 
the atrioventricular cushion mass on top of the muscular interventricular septum.
The pathogenesis of pVSD is complex and largely unknown. Mendelian transmission of CHDs in 
families is described, however, genetic research including genome-wide association studies 
revealed only a small number of genes implicated in pVSD pathogenesis (73). Also chromosomal 
anomalies – in which Down syndrome is most common – or teratogens contribute little to pVSD risk. 
In 80% of cases there is no identifiable cause for pVSD and it is assumed that they are the result of a 
combination of subtle genetic variations and environmental exposures (74,75). 
Poor periconceptional maternal nutrition, characterised by low intakes of food groups rich in 
folate and other B-vitamins, antioxidants and choline significantly contribute to CHD risk in the 
offspring (16,76-79). Folate, but also vitamin B12, vitamin B6, methionine and choline, are important 
in one-carbon metabolism (1-C) providing methyl moieties for the synthesis of proteins and DNA, 
and methylation of DNA (14). Evidence for derangements in epigenetic programming by DNA 
methylation as an underlying mechanism for birth defects – including CHDs – is accumulating 
since derangements particular in 1-C metabolism result in disturbed embryogenesis (14). Maternal 
global hypomethylation has been associated with an increased risk of CHD (80). In a previous study 
we demonstrated that complex CHD in children is associated with higher concentrations of the 
methylation biomarkers S-adenosylmethionine, S-adenosylhomocysteine and folate in blood (81). 
Since DNA methylation is important for human embryogenesis, we hypothesise that tissue specific 
derangements in DNA methylation contribute to pVSD. So far, a small number of CpG loci have 
been associated with pVSD. The introduction of the Illumina Infinium® HumanMethylation450 
BeadChip (450k array) (Illumina, Inc) enables the simple and rapid measurement of 482,421 CpG loci 
and 3,091 CpH loci in the human genome across large numbers of samples (82). We performed an 
epigenome-wide association study (EWAS) in DNA derived from peripheral white blood cells (PWBC) 
– derived from the same mesodermal layer as the heart – of very young children to identify novel 
loci associated with pVSD.
Methods
Study population
Sampling of the participants for this case-control study has been previously described in detail (35). 
In summary, participants were non-related case and control children born between January 2002 
and June 2007 in the Western part of the Netherlands. All case children with pVSDs were diagnosed 
by two paediatric cardiologists using echocardiography and/or cardiac catheterisation and/or 
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surgery data. For the present study only isolated pVSD were included to eliminate any chromosomal 
or syndromal effect. Control children had no major congenital malformations or chromosomal 
abnormalities according to the medical records and regular health checks by physicians of the public 
child health centres. During a standardised hospital visit around 17 months of age, venous blood 
samples were drawn from the children and the questionnaires filled out by the mother at home 
were checked for completeness and consistency. The study was approved by the Central Committee 
for Human Research (CCMO) in The Hague, The Netherlands, and by the Institutional Review Boards 
(Medical Ethics Committees) of the Erasmus MC, University Medical Centre in Rotterdam, Leiden 
University Medical Centre in Leiden, VU University Medical Centre and Academic Medical Centre 
in Amsterdam, the Netherlands. All parents gave written informed consent on behalf of their 
participating child.
DNA isolation and methylation protocol
Genomic DNA was isolated from 0.2 mL EDTA-whole blood using the Total Nucleic Acid Extraction 
kit on a MagNA PureLC (Roche Molecular Biochemicals). Isolated genomic DNA (500 ng per sample) 
was sodium bisulphite treated using the EZ-96 DNA methylation kit (Shallow) according to Illumina’s 
protocol (Zymo Research). The Illumina Infinium® HumanMethylation450 BeadChips were processed 
according to the manufacturer’s protocol. 
Preprocessing of data
A quality control protocol was conducted in Illumina GenomeStudio software using the methylation 
module. It included a sample call rate check, colour balance check and control dashboard check. 
DNA methylation levels of probes on the sex chromosomes were used to match the gender of 
the child in order to identify sample mix-ups. The dasen procedure, which combines background 
adjustment and between-array normalisation applied to Type I and Type II probes separately, was 
used to normalise the methylation data (Bioconductor package wateRmelon) (83). Probes with 
detection P values >0.01 in more than 5% of the samples (n=1,721), probes with single-nucleotide 
polymorphisms (MAF>0.05, European population, 1000 Genomes Project) (n=17,196), and probes 
on the sex chromosomes (n=11,648) were excluded from analysis. 
Statistical analysis
Methylation β-values were converted to M-values using: M-value=log2 (β-value/(1-β-value)) 
(84). To test for the association between disease status and CpG methylation, a multiple linear 
regression model was fitted using the methylation M-value as the outcome and disease status as 
the independent variable, adjusting for gender and age of the child and maternal smoking status 
and the potential confounders bisulphite plate and blood cell mixtures (R package ‘CpGassoc’) (85). 
The proportions of leukocyte subtypes were estimated using Houseman’s method with the model 
trained on the data set of purified leukocytes from Reinius et al. (86,87). Top 500 cell type-informative 
CpGs were used for estimation. We then included the proportions of the differential subtypes as 
covariates in the regression model.
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Bonferroni correction for 455,741 tests was used to adjust the level of significance and associations 
were considered epigenome-wide significant where P values were less than 1.1e-7. Benjamini-
Hochberg false discovery rate (FDR) control procedure was also applied as a less stringent method for 
selecting top candidates. One-sided Kolmogorov-Smirnov (KS) test was used to test for enrichment 
of differential CpGs in a particular type of region based on the distribution of regional P values in 
comparison to the overall P value distribution. To reduce the effect of correlation between CpGs, 
we only sampled one CpG from a sub-region based on the annotation file provided by Illumina 
(HumanMethylation450 v1.2 Manifest File). 
Gene Ontology (GO) term enrichment analysis was performed using Elim-KS method as implemented 
in the Bioconductor package TopGO (88). The minimum P value of the CpGs from a given gene is 
considered as the score for that gene for enrichment analysis. We focused on GO terms of biological 
processes. GO terms with less than 10 genes were excluded for testing. Benjamini-Hochberg FDR 
control procedure was used to select significant GO terms.
Mediation analysis was conducted to test the hypothesis that the effects of the prenatal conditions 
and exposures (E) maternal age at conception of the index-pregnancy, gestational age and birth 
weight (adjusted for gestational age) on disease outcome are mediated by methylation (M) 
adjusting for covariates (X) including the gender and age of the child, maternal smoking, bisulphite 
plate membership and leukocyte proportions. Mediation analysis based on structural equation 
modelling (SEM) was carried out using the R package ‘lavaan’. Specifically, two models were fitted (1) 
logit[Pr(outcome)] =α0 + α1 E + α2 M + α3’ X and (2) M = γ0 + γ1E + γ2’ X +ε. Then α2 γ1 measures the 
mediation (indirect) effect of prenatal exposures through methylation and α2 γ1 + α1 measures the 
total effect. A Wald test was performed to test for the direct effect and the indirect mediation effect 
of methylation. We constructed MPC, the first principle component (PC) of the methylation of the top 
CpGs adjusted for covariate effects (X), to represent the overall methylation variation due to sources 
other than the covariates. Mediation analysis was then carried out on MPC. By using MPC, we can pool 
individually weak signals as well as reduce multiple testing burden.
To place Bonferroni significant CpGs and corresponding genes in the context of their molecular and 
functional interactions we used Ingenuity Pathway Analysis (IPA) tools (Ingenuity Systems®, www.
ingenuity.com). Only downstream targets of the genes were used in the visualisation of networks. 
Statistical analyses were performed in the R environment for statistical computing (R 3.0.1).
Bisulphite pyrosequencing validation
The top three candidate CpG loci identified by the 450k array were validated in the same samples 
(cases n=31, controls n=61) using bisulphite pyrosequencing. After bisulphite conversion (250 ng 
per sample) using the EZ-96 DNA Methylation kit (Deep) (Zymo Research), the regions of interest 
including the exact same single CpGs were PCR amplified using the PyroMark PCR kit. Bisulphite-
specific forward, reverse and sequence primers were designed using PyroMark Assay Design 2.0 
software (Supplementary Table S1). Human methylated genomic control DNA (EpigenDx) was 
used to validate the assay with samples methylated respectively 0%, 25%, 50%, 75% and 100%. 
Pyrosequencing was performed using the PyroMark Q24 platform (Qiagen). PCR and subsequent 
steps were performed in duplicate. Mean DNA methylation of the two duplicate measurements was 
used to compare cases and controls using the Student’s t-test. 
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Results
Characteristics of the children
From a total of 296 samples we excluded 4 technical samples with 50% methylated DNA and 
6 duplicate samples. Furthermore, 3 samples were excluded because they failed the quality control 
protocol and 3 samples due to mismatch of the gender which indicates sample mix-ups. In total, 
84 case children and 196 control children were included for analyses. Characteristics of the children 
and their mothers are shown in Table 1. 
Table 1 | Characteristics of children and mothers
Cases 
(n=84)
Controls 
(n=196)
P value
Child
Age at study moment, months 17.0 16.4 0.22
Female gender 46 (55) 108 (55) 1.00
Mother
Age at conception, years 31.4 30.3 0.11
Smoking 16 (19) 36 (18) 0.87
Periconceptional folic acid use 46 (55) 109 (56) 0.90
Body mass index, kg/m² 25.0 24.7 0.70
Values are means or number (percentage).
Epigenome-wide association analysis
Leukocyte proportions predicted by Houseman’s method showed differentiation of CD8+ T cells and 
natural killer (NK) cells between case and control samples, hence the proportions of CD8+ T and NK 
cells were adjusted for confounding due to cell mixtures (Supplementary Table S2). We then tested 
for association between methylation and disease outcome using linear regression adjusting for 
relevant covariates. The test statistic inflation was well controlled with a genomic control inflation 
factor of 1.02, indicating that potential confounding due to cell mixtures was effectively controlled 
(Figure 1).
Using conservative Bonferroni correction for 455,741 tests, we observed one epigenome-wide 
significant CpG locus on chromosome 1 (Figure 2). This CpG (cg17001566 / chr1:2990490) is within 
the gene body of PRDM16 (PR domain containing 16) and higher methylated in pVSD children (+4.8% 
in cases, P = 9.17E-08). Using the less stringent Benjamini-Hochberg procedure for controlling FDR at 
15%, we also identified seven epigenome-wide significant CpG loci mapped to eight genes on five 
chromosomes (Table 2, Supplementary Figure S1). Differential methylation was most pronounced 
in CpG islands, TSS 200, 5’ UTR and 1st exon regions based on the KS test (Supplementary Table S3). 
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Figure 1 | Quantile-quantile plot of linear regression test for case-control status
7
6
5
4
3
2
1
0
O
bs
er
ve
d 
-lo
g 1
0 (
P-
va
lu
es
)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 20 22 
Chromosome
cg17001566
cg20059467 cg17862152
cg02838762
cg02431260
cg07116851 cg00914777 cg26749414
Figure 2 | Manhattan plot of epigenome-wide associations with perimembranous ventricular septal defects
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Functional analysis
GO term enrichment analysis is used for functional analysis of large-scale epigenome-wide data. 
In our data set, a total of 4599 GO terms in biological processes were scored. At 5% FDR, 70 GO 
terms were enriched and are listed in Supplementary Table S4. The top ten listed GO terms include 
axon guidance and the regulation of transcription from RNA polymerase II promoter, organ 
morphogenesis, embryonic development, apoptotic processes and cardiac muscle cell proliferation. 
The PRDM16 gene with the Bonferroni significant CpG was selected to conduct a pathway analyses 
with IPA (Ingenuity Pathway Analysis). According to the gene network diagram, downstream related 
molecules included expression of CDKN1A (cyclin-dependent kinase inhibitor 1A) and SerpinE1, 
protein-protein interaction with CTBP2 (C-terminal-binding protein 2) and SKI (Sloan-Kettering 
Institute proto-oncogene), and DNA-protein interaction with HGF (hepatocyte growth factor) (S2 
Figure). PRDM16 also indirectly modifies histone H3.
Mediation analysis
To gain insight in the role of DNA methylation in pVSD pathogenesis, we examined whether the 
effects of prenatal conditions on pVSD risk are mediated by changes in DNA methylation. Mediation 
analysis using the methylation first PC suggests that the diseases risks due to the prenatal conditions 
maternal age at conception, gestational age and birth weight (adjusted for gestational age) are 
mediated (indirect effects) by DNA methylation (Table 3). The methylation PC was formed based on 
the eight CpGs identified by the EWAS at 15% FDR to summarise the overall methylation variation 
and alleviate the multiple testing burden. 
Table 3 | Mediation analysis on methylation principal components
Exposure Effects Estimate Standard error z score P value
Maternal age at conception indirect 0.067 0.045 1.50 0.134
total 0.129 0.079 1.63 0.102
Duration of pregnancy (in days) indirect -0.093 0.043 -2.17 0.030
total -0.128 0.082 -1.55 0.120
Birthweight adjusted for GA indirect -0.081 0.042 -1.91 0.056
total -0.146 0.084 -1.73 0.083
Birthweight indirect -0.119 0.041 -2.87 0.004
total -0.191 0.083 -2.32 0.021
GA, gestational age.
Bisulphite pyrosequencing validation
Next, we used bisulphite pyrosequencing in the same samples to validate our top three candidate 
CpG loci (cases n=31, controls n=61). Within PRDM16, mean methylation in both the CpG of interest 
as well as two surrounding CpGs was significantly different between cases and controls (+3.6% in 
cases, P=0.04; +3.7% in cases, P=0.01; +3.4% in cases, P=0.04) (Table 4). Within PPFIA4 and ESAM 
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the CpG of interest did not achieve significance (P=0.052 and P=0.156 respectively) but the trends 
were consistent with the 450k array. One CpG surrounding the CpG of interest within PPFIA4 was 
significantly differentially methylated between cases and controls (+1.8% in cases, P=0.04). 
Table 4 | Bisulphite pyrosequencing validation of CpG sites within PRDM16, ESAM and PPFIA4 
Locus Cases mean (SD) Controls mean (SD) P value
PRDM16
#CpG 1 n=31 n=59
47.52 (8.81) 44.43 (7.85) 0.092
#CpG 2 n=31 n=59
33.68 (7.99) 30.11 (7.49) 0.039
#CpG 3a n=31 n=59
18.91 (6.46) 15.24 (5.76) 0.007
#CpG 4 n=31 n=59
25.04 (7.75) 21.66 (7.16) 0.042
ESAM
#CpG 1a n=31 n=61
57.80 (3.63) 58.92 (3.49) 0.156
#CpG 2 n=31 n=61
10.75 (1.34) 10.66 (1.62) 0.799
#CpG 3 n=30 n=61
27.16 (2.66) 27.86 (2.90) 0.270
#CpG 4 n=31 n=61
9.11 (1.15) 9.19 (1.45) 0.795
PPFIA4
#CpG 1a n=31 n=61
2.56 (3.67) 1.22 (0.75) 0.053
#CpG 2 n=31 n=61
2.67 (4.16) 1.15 (0.81) 0.052
#CpG 3 n=31 n=60
2.43 (3.46) 1.21 (0.68) 0.060
#CpG 4 n=31 n=61
2.55 (3.09) 1.43 (0.61) 0.055
#CpG 5 n=31 n=61
4.67 (4.74) 2.83 (0.90) 0.040
a CpG of interest
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Discussion
In this study we identified a novel CpG locus (cg17001566) that reaches Bonferroni significance in the 
PRDM16 gene associated with pVSD. This CpG was validated by bisulphite pyrosequencing. Previous 
research on PRDM16 focused on its well-known function in brown fat determination and adiposity, 
however, accumulating evidence indicates the novel function of PRDM16 in cardiac development 
(89-92). Animal models and studies using human cardiac tissue have shown that disruptions in 
PRDM16 function affect cardiac development. Arndt et al. showed in both fetal and adult human 
hearts the expression of PRDM16 in cardiomyocytes and interstitial cells (93). Also in mice, PRDM16 
is expressed throughout the ventricular myocardium, including endocardium and epicardium, and 
in the ventricles of the mouse heart (94). In adult mice PRDM16 was predominantly restricted to 
the nuclei of cardiomyocytes. A genome-wide association study has linked a PRDM16 SNP to QRS 
duration implying a role in cardiac function (95). This gene has been previously described in relation 
to clefting disorders, heterochromatin integrity, cardiomyopathy and as a physiologic regulator of 
hematopoietic stem cells (HSC) (93-97).
PRDM16 functions as a repressor of TGFβ signaling (transforming growth-factor beta) which controls 
tissue morphogenesis and is crucial during embryonic development. In vitro experiments show that 
TGFβ signaling is important for the generation and remodeling of cushion mesenchymal cells of 
the outflow tract, which contributes to the ventricular septum (98). TGFβ2 knock out mice show 
severe cardiac malformations including abnormal endocardial outflow tract cushions and pVSDs 
(99). Moreover, PRDM16 is a protein that can bind regulating Smads, including TGFβ- and BMP 
(bone morphogenetic proteins)-regulated Smads, and inhibitory Smads (100). TGFβ and BMPs are 
important for cell proliferation, differentiation and apoptosis, and Smad proteins are involved in the 
mediation of these effects. Of interest is that mice with deficiencies in either Smad6 or Smad7 are 
associated with multiple cardiovascular defects, including VSDs (101).
PRDM16 downregulates SerpinE1 and the homologue of PRDM16 (minus a PR domain) EVI1 (ectropic 
virus integration site 1) downregulates SerpinB2 (102). PRDM16 and EVI1 have many similarities (103). 
In mice, at 12.5 days post-coitum when the ventricles are partially separated EVI1 is highly expressed 
in both the proximal (conal) and distal (truncal) outflow tract endocardial cushions and cardiac 
valves, whereas the surrounding endocardium, myocardium and blood vessels are negative (104).
Looking at downstream related molecules in the pathway analysis, SKI negatively regulates TGFβ 
and interacts with Smad2, Smad3 and Smad4. SKI zebrafish morphant embryos show severe cardiac 
anomalies with malformations in the outflow tract and therefore implicate the requirement for SKI 
in early cardiovascular development (105). CTBP2, which is downregulated by PRDM16, also interacts 
with EVI1 (106).
Seven CpG loci mapped to eight genes are identified at a 15% FDR threshold but did not reach 
Bonferroni statistical significance. They might provide novel insights in pVSD pathophysiology given 
their biological functions. All genes except one are involved in embryogenesis, cardiogenesis or 
related to severe CHD (S5 Table). 
Multiple GO terms in biological processes seem over-represented within our pVSD cases. The most 
enriched GO term is related to axon guidance. During heart development axon guidance cues are 
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critical for the migration of cardiac neural crest cells and generating the endocardial cushions (107). 
Recently, an abnormal axon guidance protein has been related in a case report to a patient with 
multiple congenital heart defects including a ventricular septal defect (108). Both positive and 
negative regulation of transcription from RNA polymerase II promoter seem highly over-represented 
GO terms in pVSD cases. RNA polymerase II is likely to be essential during embryonic development 
and gene transcription by RNA polymerase II is affected by DNA methylation (109,110). Also CpGs 
within genes involved in the regulation of organ morphogenesis, embryonic development, 
apoptotic processes and cardiac muscle cell proliferation seem to be over-represented in our pVSD 
cases.
Mediation effects of maternal periconceptional conditions are shown, which suggests a potential 
role for DNA methylation in the disease mechanism supporting a potential functional link between 
1-C metabolism and pVSD risk.
We validated methylation differences in the three top candidate CpG loci identified by the 450k 
array using bisulphite pyrosequencing. This quantitative real-time sequencing technology allows 
the measurement of a specific single CpG. Due to financial reasons only a subset was analysed with 
a 1:2 case:control ratio. Even with a much smaller sample size the CpG locus within PRDM16 could be 
validated. Unfortunately it was not possible to find an external replication cohort.
Some limitations of this study have to be addressed. Critical considerations on EWAS is in place, and 
some recommendations for a standardised EWAS methodology are provided by Michels et al. (111). 
Firstly, choosing the appropriate tissue is substantial given tissue-specific gene regulation, however, 
it is not possible to obtain cardiac tissue from especially healthy control children – a disadvantage 
of human studies. For that reason we used PWBC as easy to access surrogate tissue in young 
children. Ma et al. have shown that locus-specific methylation differences between tissues are highly 
consistent across individuals (112). Also, PWBC and cardiac tissue have a shared developmental 
origin since the lateral plate mesoderm in human embryos give rise to both the heart and blood 
cells in the circulatory system (113). Thus the PWBC may carry the methylation fingerprint of cardiac 
tissue. However, it remains to be elucidated whether DNA methylation derived from whole blood 
can serve as a biomarker for epigenetic regulation of cardiac tissue in clinical practice. 
Secondly, the heterogeneity of PWBC as potential confounder in epigenetic studies has to be 
considered. Differences in PWBC methylation could result from varying cell-type proportions, but is 
also dependent on the pathways and genes being studied (86,113). Therefore we applied Houseman’s 
method to correct for cell type proportions (114,115). The identified CpG loci in our study could 
not be explained by differential cell mixtures, since the methylation values are not significantly 
correlated with the predicted cell proportions. Moreover, the controlled genomic inflation factor 
(lambda=1.02) indicates that the analyses are adequately adjusted for cell mixtures. 
Thirdly, the effect sizes of DNA methylation changes are small in our study. Previous research 
has shown that small changes in DNA methylation can result in large phenotypic changes (116). 
The assumption following this reasoning is that (small) changes in DNA methylation can result in 
aberrant RNA and protein expression. Comparable to genome-wide association studies is that one 
locus or gene can only explain a small fraction of the disease risk. The pathophysiology of pVSD is 
very likely a complex process of accumulation and interaction of risk factors and the effect size of 
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one locus is expectable small. Last of all, the effect size could be attenuated by using PWBC and not 
the tissue of interest.
In summary, we have identified at Bonferroni epigenome-wide significance level one CpG locus 
within PRDM16 that shows differential methylation which is suggested to be associated with 
pVSD pathogenesis. In addition, seven additional CpG loci were identified at 15% Benjamini-
Hochberg FDR. These findings provide novel insights in understanding the pathogenesis of pVSD 
in human. Epigenetics as underlying mechanism of pVSD in a complex interplay between genetic, 
environmental and lifestyle factors offers possibilities for future personalised prediction, treatment 
and prevention. Therefore, future research is warranted to reveal whether our epigenetic findings 
can be replicated in other studies.
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Table S1 | Primer design
Gene  
Name
Genomic location1 Number of CpG sites 
analysed
Primer sequence (5’-3’)2
PRDM16 chr1:2990408-2990754 4 CpG sites F: AGGAGGTGTTTTGTTTTTTAAGTGTA 
R: AATCCCCTCCTCCTAACCT 
S: GATGTAGTAGGGAATTTAGGTA
ESAM chr11:124628803-124629011 4 CpG sites F: GGGGAGTATAGTATTTATTGGGTTAGGTT 
R: CCACTTACTTCCCTAATTTTCCTAAA 
S: AATTAGAAGGTTTTTTAAATTTTT
PPFIA4 chr1:203044827-203044953 5 CpG sites F: TTTGGGGTGTTAGGAAGAAG 
R: ATCCACCCTAAAAACCCTACA 
S: GGTGTTAGGAAGAAGT
1 Genome Research Consortium human genome build 37 (GRCh37)/UCSC human genome 19 (hg19)
2 Forward PCR primer, Reverse PCR primer and Sequencing primer designed using the PyroMark Assay Design 2.0 software. 
Reverse PCR primer: biotinylated primer. 
Table S2 | Differential cell distribution
Cell type Case Control P value
Neutrophil 0.269 (0.131) 0.272 (0.119) 0.848
CD4+ T 0.168 (0.081) 0.176 (0.067) 0.434
CD8+ T 0.241 (0.071) 0.259 (0.068) 0.043
B cell 0.150 (0.046) 0.141 (0.038) 0.114
NK cell 0.018 (0.030) 0.006 (0.017) 0.001
Eosinophil 0.030 (0.039) 0.023 (0.031) 0.202
Monocyte 0.094 (0.031) 0.088 (0.027) 0.157
Values are means (SD)
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Table S3 | One-sided Kolmogorov-Smirnov test on enrichment of differential CpGs in a particular type of 
region 
Region P value
DHS 0.398
Enhancer 0.899
CDMR 0.553
DMR 0.020
RDMR 0.728
Island 4.55E-31
N Shelf 0.998
S Shelf 0.958
N Shore 0.919
S Shore 0.996
TSS1500 0.175
TSS200 3.89E-25
5’UTR 0.003
1st Exon 9.78E-09
Body 1.000
3’UTR 0.973
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Table S5 | Overview of the literature on the genes identified at a 15% false discovery rate threshold and the 
association with embryogenesis, cardiogenesis or phenotype 
ESAM
 – Expressed in mouse embryos in the outflow tract early in development and mediates cell-cell adhesion in 
endothelial cells.
 – Hirata K, Ishida T, Penta K, Rezaee M, Yang E, Wohlgemuth J, et al. Cloning of an immunoglobulin family adhesion 
molecule selectively expressed by endothelial cells. J Biol Chem. 2001;276(19):16223-31.
PPFIA4
 – Expressed in heart tissues and belongs to the liprin-alpha gene family.
 – Serra-Pages C, Medley QG, Tang M, Hart A, Streuli M. Liprins, a family of LAR transmembrane protein-tyrosine 
phosphatase-interacting proteins. J Biol Chem. 1998;273(25):15611-20.
NFIA
 – Regulates tissue-specific gene expression during mammalian embryogenesis.
 – Chaudhry AZ, Lyons GE, Gronostajski RM. Expression patterns of the four nuclear factor I genes during mouse 
embryogenesis indicate a potential role in development. Dev Dyn. 1997;208(3):313-25.
HNRNPU 
 – Mediates the long-range regulation of Shh expression during limb development. It is proposed that distant 
cis-elements may modulate gene expression by altering the affinity of HNRNPU for certain mediator proteins and 
nuclear relocation. Children with Holt-Oram syndrome are affected with upper limb malformations and cardiac 
septation defects caused by a mutation within HNRNP.
 – Zhao J, Ding J, Li Y, Ren K, Sha J, Zhu M, et al. HnRNP U mediates the long-range regulation of Shh expression during 
limb development. Hum Mol Genet. 2009;18(16):3090-7.
 – Basson CT, Bachinsky DR, Lin RC, Levi T, Elkins JA, Soults J, et al. Mutations in human TBX5 cause limb and cardiac 
malformation in Holt-Oram syndrome. Nat Genet. 1997;15(1):30-5.
HIF3A
 – The splicing variant of HIF3A is NEPAS which is pertinent to heart development during the embryonic stages. 
Recent studies including two EWAS have described HIF3A in relation to body-mass index and (childhood) obesity.
 – Yamashita T, Ohneda O, Nagano M, Iemitsu M, Makino Y, Tanaka H, et al. Abnormal heart development and lung 
remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS. Mol Cell Biol. 
2008;28(4):1285-97.
 – Demerath EW, Guan W, Grove ML, Aslibekyan S, Mendelson M, Zhou YH, et al. Epigenome-wide association study 
(EWAS) of BMI, BMI change and waist circumference in African American adults identifies multiple replicated loci. Hum 
Mol Genet. 2015;24(15):4464-79.
 – Dick KJ, Nelson CP, Tsaprouni L, Sandling JK, Aissi D, Wahl S, et al. DNA methylation and body-mass index: a genome-
wide analysis. Lancet. 2014;383(9933):1990-8.
 – Wang S, Song J, Yang Y, Zhang Y, Wang H, Ma J. HIF3A DNA Methylation Is Associated with Childhood Obesity and ALT. 
PLoS One. 2015;10(12):e0145944.
CDK4 
 – Severe heart defects are reported in CDK4 double knockout mice.
 – Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H, et al. Combined loss of Cdk2 and Cdk4 results in 
embryonic lethality and Rb hypophosphorylation. Dev Cell. 2006;10(5):563-73.
MOAP1 
 – Induces apoptosis.
 – Tan KO, Tan KM, Chan SL, Yee KS, Bevort M, Ang KC, et al. MAP-1, a novel proapoptotic protein containing a BH3-like 
motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802-7.
C14orf109
 – Has to date not been described in relation to embryogenesis or phenotypes.
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Figure S1 | Boxplots of significant CpGs
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Figure S2 | Gene network diagram 
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Abstract
Background Approximately 50% of children born with Down syndrome (DS) have a congenital 
heart disease (CHD). Presumably trisomy 21 alone is not enough to cause CHD. The complexity of 
CHD in DS has been studied before in which gene-environment interactions seem to contribute 
to CHD risk. We investigated epigenome-wide DNA methylation at 5’-cytosine-phosphate-guanine 
(CpG) loci in blood of children with both DS and a perimembranous ventricular septal defect (pVSD) 
and in control children of the same age. 
Methods At 17 months of age, 10 case children with both DS and pVSD and 196 healthy control 
children were included for analysis. We performed an epigenome-wide association study (EWAS) in 
DNA extracted from peripheral white blood cells (PWBC) to investigate 455,741 CpG loci using the 
Illumina Infinium® HumanMethylation450 BeadChip. The differentially methylated CpG loci were 
used to test the enrichment of pVSD-associated CpG loci from a previous EWAS on pVSD in non-DS 
children. 
Results pVSD-DS cases show a distinctive methylation profile of global hypermethylation in all 
autosomes except chromosome 21. Using Bonferroni correction, we identified 3,889 differentially 
methylated CpGs within 1,625 genes. Among these, 2,096 CpGs within 869 genes showed a mean 
methylation difference of at least 10%. 1,593 of these CpGs were hypermethylated in case children 
and 503 in control children. Differentially methylated CpGs were enriched for pVSD-associated CpGs. 
Conclusion Children at 17 months of age with both DS and pVSD show global hypermethylation 
of PWBC DNA. Our data suggest that CpGs associated with pVSD in non-DS may also be involved in 
the pathogenesis of pVSD in DS. 
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Introduction
Congenital heart diseases (CHDs) are the most common congenital malformations in humans 
worldwide with a birth prevalence rate of 0.6 to 1.9 in 100 newborns per year (57). The prevalence is 
strongly increased in individuals with Down syndrome (DS) as approximately 50% of children born 
with DS have a CHD (117). The most common forms of CHD in DS are the atrioventricular septal 
defect (AVSD) and ventricular septal defect (VSD) occurring in 90% of cases. 
Since 50% of children with DS have a nonmalformed heart it can be concluded that DS alone is 
not enough to cause CHD. The complexity of CHD in DS has been investigated before in which a 
combination of both genetic variations and environmental factors contribute to CHD risk (118). 
One of the proposed mechanisms of gene-environment interactions is epigenetics in which 
DNA methylation at 5’-cytosine-phosphate-guanine (CpG) loci is the best-studied epigenetic 
modification.
In DS it has been shown that there are large gene-specific CpG methylation alterations (119). Aberrant 
DNA methylation has been found in DS chorionic villi samples, which supports derangements in 
epigenetic programming of the DS phenotype during the earliest weeks of development (120). 
Epigenetic changes of global DNA hypermethylation in DS are also found in DS placental tissue in 
early gestation (121). 
In DNA methylation, folate-mediated one-carbon metabolism is essential. The role of maternal folate 
is supported by data suggesting that a lack of maternal folic acid supplementation is associated with 
septal defects in children with DS in comparison to children with DS and no CHD (14,122). Previous 
studies indicate that abnormal folate metabolism and a single nucleotide polymorphism in the 
methylenetetrahydrofolate reductase (MTHFR) gene are maternal risk factors for DS (123-125). A 
meta-analysis of 34 studies also shows that the maternal MTHFR 677T polymorphism is a risk factor 
for DS (126). In children with DS it has been shown that plasma levels of homocysteine, methionine, 
S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are significantly decreased and 
their lymphocyte DNA is hypermethylated relative to that of normal siblings (127). Complex CHD is 
also associated with higher concentrations of the methylation biomarkers SAM, SAH and folate in 
blood. Seemingly contradictory, we have previously published that a child with DS and CHD seems 
to be associated with a global hypomethylation status (81). This is in line with the decreased SAM/
SAH ratio as a marker of maternal hypomethylation observed in the mothers of these DS children 
(60). This hypomethylation was not found in mothers with nonsyndromic CHD offspring, suggesting 
perhaps a different underlying mechanism for CHD. However, these studies use a proxy measure 
for hypomethylation and do not take into account the global hypermethylation status in DS 
outnumbering hypomethylation in single CpG loci. 
Recently, we performed an epigenome-wide association study (EWAS) on pVSD (perimembranous 
ventricular septal defects) in nonsyndromic children [Wijnands et al. unpublished]. Since CHD is not 
unique to people with DS we hypothesise that the same CpG risk loci could be identified in both DS 
and non-DS children with CHD. 
In the present study, we used the Illumina Infinium® HumanMethylation450 BeadChip (Illumina, Inc., 
San Diego, CA, USA) to perform an EWAS in DNA extracted from peripheral white blood cells (PWBC) 
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of very young children with pVSD and DS (pVSD-DS) and healthy controls of the same age to identify 
any loci associated with pVSD in children with DS, and compare these data with loci found in non-DS 
children with pVSD.
Methods
Study population
Sampling of the participants for this case-control study has been previously described in detail (35). 
Cases were diagnosed with both DS and pVSD. In all cases (n=10), pVSD was diagnosed by two 
paediatric cardiologists using echocardiography and/or cardiac catheterisation and/or surgery data. 
Control children (n=195) had no chromosomal abnormalities or major congenital malformations 
according to the medical records and regular health checks by physicians of the child health care 
centres.
DNA isolation and methylation protocol
Genomic DNA was isolated from 0.2 mL EDTA-whole blood using the Total Nucleic Acid Extraction 
kit on a MagNA PureLC (Roche Molecular Biochemicals, Mannheim, Germany). Isolated genomic 
DNA (500 ng of input per sample) was sodium bisulphite treated using the EZ-96 DNA methylation 
kit (Shallow; Zymo Research, Irvine, CA, USA) according to Illumina’s protocol. The Illumina Infinium® 
HumanMethylation450 BeadChips were processed according to the manufacturer’s protocol.
Preprocessing of data
A quality control protocol was performed including a sample call rate check, colour balance check 
and control dashboard check. DNA methylation levels of probes on the sex chromosomes were used 
to match the gender of the child in order to identify sample mix-ups. Beta Mixture Quantile dilation 
(BMIQ) was used as intra-array normalisation (128). Probes with detection P values>0.01 in more 
than 5% of samples (n=1,721), probes with single-nucleotide polymorphisms (MAF>0.05, European 
population, 1000 Genomes Project) (n=17,196), and probes on the sex chromosomes (n=11,648) 
were excluded from analysis. 
Statistical analysis
To adjust for potential confounding due to cell mixtures, Houseman’s method was applied to predict 
the proportions of leukocyte subtypes with the model trained on the validation data set from 
Reinius et al. (86,87). Top 500 cell type-informative CpGs were used for prediction. We included the 
proportions of the subtypes that showed differentiation between pVSD-DS and control samples as 
covariates in the regression model. 
Permutational multivariate analysis of variance (PERMANOVA) was used to test for the overall 
difference between pVSD-DS and controls based on the Euclidean distances between sample 
methylation profiles adjusting for children’s gender and age, maternal smoking status, bisulphite 
plates and blood cell mixtures (R package ‘vegan’) (129). The first two principal coordinates are 
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plotted with the percentage of explained variability indicated. Principal component analysis (PCA) 
is performed on the methylation residuals after adjusting for cell mixtures using linear regression. 
Methylation β-values were converted to M-values using: M-value=log2 (β-value/(1-β-value)) (84). 
To test for the association between case-control status and individual CpG methylation, a multiple 
linear regression model was fitted using the methylation M-value as the outcome and case-control 
status as the primary covariate, adjusting for the independent methylation predictors child’s gender 
and age and maternal smoking status, and the potential confounders bisulphite plate and blood cell 
mixtures (R package ‘CpGassoc’) (85). Bonferroni correction for 455,741 tests was used to adjust the 
level of significance and associations were considered epigenome-wide significant where P values 
were less than 1.1e-7. 
The one-sided Kolmogorov-Smirnov (KS) test was used to test for enrichment of differential CpGs in 
a particular type of region based on the distribution of regional P values in comparison to the overall 
P value distribution. 
Gene ontology (GO) term enrichment analysis was performed using Fisher’s exact tests. We focused 
on GO terms of biological processes only. GO terms with less than 10 genes were excluded for 
testing. A gene was considered to be differentially methylated when it contained one CpG that 
reached Bonferroni significance.
Previously, we conducted an EWAS on pVSD in non-DS children, and identified one significant CpG 
in the PRDM16 gene after Bonferroni correction. To conduct enrichment analysis of potential pVSD-
associated CpGs in the pVSD-DS-associated CpGs identified herein, we relaxed the significance level 
to expand the list of differential CpG loci. At different significance levels (raw P cut-off: 0.01-0.00001), 
we used Fisher’s exact test to test for enrichment of these potential pVSD-associated CpGs in the 
differentially methylated pVSD-DS CpG loci. Lastly, a gene-level analysis of the PRDM16 gene was 
performed.
Statistical analyses were performed in the R environment for statistical computing (R 3.0.1). 
Results
Characteristics of the children
In total, 10 case children and 196 control children were included for analysis. Characteristics of the 
children and their mothers are shown in Table 1. Mothers of case children used significantly less 
often folic acid supplements in the periconception period compared to mothers of control children, 
20% and 56% respectively (P=0.047). Maternal age at conception was not significantly different 
between cases and controls, 32.2 and 30.3 years of age respectively (P=0.096).
Predicting leukocyte proportions based on methylation data
Leukocyte proportions predicted by Houseman’s method showed differential cell populations of 
CD4+ T-cells, B-cells, neutrophils and eosinophils between case and control samples. Therefore, 
these cell proportions were used to adjust for confounding due to cell mixtures (Supplementary 
Table S1). 
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Table 1 | Characteristics of children and their mothers
Cases DS-pVSD 
(n=10)
Controls  
(n=196)
P value
Child
Age at study moment (in months) 16.3 16.4 0.927
Gender (female) n(%) 5 (50) 108 (55) 0.757
Mother
Age at conception (in years) 32.2 30.3 0.096
Periconceptional folic acid use n (%) 2 (20) 109 (56) 0.047
Body mass index (kg/m²) 25.3 24.7 0.771
Global analysis of methylation profiles 
PCA revealed that pVSD-DS leukocytes have a distinctive methylation profile (Figure 1A). pVSD-DS 
leukocytes show global hypermethylation in all autosomes except chromosome 21 (Figure 1B). 
Chromosome 21 is the only autosome that is lower methylated in pVSD-DS children in comparison 
with healthy control children. 
Epigenome-wide association analysis
Epigenome-wide association analysis was performed to identify differentially methylated CpG 
loci. We observed widespread differentially methylated CpGs indicated as strong deviation of the 
distribution of association P values from the null distribution (Figure 2A). The association P values 
were significantly lower in the DHS, enhancer, CDMR, DMR, RDMR, CpG shore and TSS1500 regions 
based on the KS test (Supplementary Table S2). Using Bonferroni correction for 455,741 tests, we 
identified 3,889 differentially methylated CpGs within 1,625 genes. Among these, 2,096 CpGs 
within 869 genes showed a mean methylation difference of at least 10%. 1,593 of these CpGs were 
hypermethylated in case samples and 503 in control samples. These CpGs were mostly enriched in 
chromosome 5, 8, 19, 21 and 22 (Fisher’s test, P<0.05, Figure 2B ).
Functional analysis
Using GO term enrichment analysis, a total of 4,084 GO terms were scored. Bonferroni significant 
GO terms are shown in Table 2. The top five enriched GO terms include “anatomical structure 
development”, “single-multicellular organism process”, “multicellular organismal process”, “single-
organism developmental process” and “developmental process”.
Enrichment analysis 
Enrichment analysis showed that candidate pVSD-associated CpG loci from our previous study 
on pVSD in non-DS children were enriched in the significant pVSD-Down loci (Table 3), and the 
enrichment was very robust to the P value threshold used.
Gene-level analysis of PRDM16 shows that several CpGs in PRDM16 are significantly differently 
methylated between pVSD-DS and control children (Table 4) . 
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Figure 1 | Global methylation difference between pVSD-DS and healthy children
(A) CMD (colour magnitude diagram) plot of methylation profiles in pVSD-DS and control children
(B) Histogram of methylation profiles for each chromosome in pVSD-DS and control children.
Red: mean methylation pVSD-Down > control; Blue: mean methylation pVSD-Down < control. 
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Figure 2 | Widespread differential CpG methylation between pVSD-DS and control
(A) Quantile-quantile plot of linear regression test for case-control status
(B) Distribution of Bonferroni significant CpGs on the chromosomes
* Enrichment P<0.05
Processed on: 27-10-2016
505572-L-sub01-bw-Wijnands
5
77EWAS in pVSD and Down syndrome | 
Ta
bl
e 
2 
| G
O
 Te
rm
 e
nr
ic
hm
en
t a
na
ly
si
s
G
O
.ID
Te
rm
A
nn
ot
at
ed
Si
gn
ifi
ca
nt
Ex
pe
ct
ed
Fi
sh
er
G
O
:0
04
88
56
an
at
om
ic
al
 s
tr
uc
tu
re
 d
ev
el
op
m
en
t
35
90
44
9
31
3.
92
5.
6e
-2
0
G
O
:0
04
47
07
si
ng
le
-m
ul
tic
el
lu
la
r o
rg
an
is
m
 p
ro
ce
ss
49
02
56
7
42
8.
65
1.
1e
-1
8
G
O
:0
03
25
01
m
ul
tic
el
lu
la
r o
rg
an
is
m
al
 p
ro
ce
ss
50
65
57
8
44
2.
9
9.
0e
-1
8
G
O
:0
04
47
67
si
ng
le
-o
rg
an
is
m
 d
ev
el
op
m
en
ta
l p
ro
ce
ss
31
78
40
0
27
7.
9
1.
0e
-1
7
G
O
:0
03
25
02
de
ve
lo
pm
en
ta
l p
ro
ce
ss
40
69
48
5
35
5.
81
1.
6e
-1
7
G
O
:0
00
72
75
m
ul
tic
el
lu
la
r o
rg
an
is
m
al
 d
ev
el
op
m
en
t
36
13
43
8
31
5.
93
1.
1e
-1
6
G
O
:0
04
87
31
sy
st
em
 d
ev
el
op
m
en
t
31
13
38
9
27
2.
21
1.
4e
-1
6
G
O
:0
00
71
54
ce
ll 
co
m
m
un
ic
at
io
n
42
91
49
8
37
5.
22
1.
0e
-1
5
G
O
:0
02
30
52
si
gn
al
in
g
41
90
48
5
36
6.
39
6.
2e
-1
5
G
O
:0
04
47
00
si
ng
le
 o
rg
an
is
m
 s
ig
na
lin
g
41
90
48
5
36
6.
39
6.
2e
-1
5
G
O
:0
00
73
99
ne
rv
ou
s 
sy
st
em
 d
ev
el
op
m
en
t
15
97
22
5
13
9.
65
2.
3e
-1
4
G
O
:0
00
96
53
an
at
om
ic
al
 s
tr
uc
tu
re
 m
or
ph
og
en
es
is
19
28
25
7
16
8.
59
1.
5e
-1
3
G
O
:0
04
86
46
an
at
om
ic
al
 s
tr
uc
tu
re
 fo
rm
at
io
n 
in
vo
lv
ed
 in
 m
or
ph
og
en
es
is
15
13
21
2
13
2.
3
2.
9e
-1
3
G
O
:0
04
00
11
lo
co
m
ot
io
n
11
70
17
4
10
2.
31
3.
7e
-1
3
G
O
:0
04
88
69
ce
llu
la
r d
ev
el
op
m
en
ta
l p
ro
ce
ss
26
43
32
8
23
1.
11
3.
9e
-1
3
G
O
:0
04
46
99
si
ng
le
-o
rg
an
is
m
 p
ro
ce
ss
96
34
93
6
84
2.
43
1.
6e
-1
2
G
O
:0
03
01
54
ce
ll 
di
ffe
re
nt
ia
tio
n
24
82
30
9
21
7.
04
1.
8e
-1
2
G
O
:0
04
47
63
si
ng
le
-o
rg
an
is
m
 c
el
lu
la
r p
ro
ce
ss
87
34
86
0
76
3.
73
2.
6e
-1
1
G
O
:0
00
71
65
si
gn
al
 tr
an
sd
uc
tio
n
37
06
42
2
32
4.
07
2.
6e
-1
1
G
O
:0
03
00
30
ce
ll 
pr
oj
ec
tio
n 
or
ga
ni
za
tio
n
88
3
13
5
77
.2
1
3.
4e
-1
1
G
O
:0
00
71
66
ce
ll 
su
rf
ac
e 
re
ce
pt
or
 s
ig
na
lin
g 
pa
th
w
ay
21
24
26
4
18
5.
73
1.
8e
-1
0
G
O
:0
00
71
55
ce
ll 
ad
he
si
on
81
3
12
4
71
.0
9
2.
8e
-1
0
G
O
:0
02
26
10
bi
ol
og
ic
al
 a
dh
es
io
n
81
5
12
4
71
.2
7
3.
3e
-1
0
G
O
:0
04
84
68
ce
ll 
de
ve
lo
pm
en
t
14
03
18
8
12
2.
68
4.
4e
-1
0
Processed on: 27-10-2016
505572-L-sub01-bw-Wijnands
78 | Chapter 5
Ta
bl
e 
2 
| (
Co
nt
in
ue
d)
G
O
.ID
Te
rm
A
nn
ot
at
ed
Si
gn
ifi
ca
nt
Ex
pe
ct
ed
Fi
sh
er
G
O
:0
04
86
99
ge
ne
ra
tio
n 
of
 n
eu
ro
ns
10
08
14
4
88
.1
4
9.
9e
-1
0
G
O
:0
02
20
08
ne
ur
og
en
es
is
10
75
15
0
94
2.
2e
-0
9
G
O
:0
00
09
02
ce
ll 
m
or
ph
og
en
es
is
89
4
13
0
78
.1
7
2.
3e
-0
9
G
O
:0
00
69
28
ce
llu
la
r c
om
po
ne
nt
 m
ov
em
en
t
11
26
15
5
98
.4
6
3.
1e
-0
9
G
O
:0
05
08
96
re
sp
on
se
 to
 s
tim
ul
us
58
96
60
7
51
5.
57
6.
5e
-0
9
G
O
:0
04
85
13
or
ga
n 
de
ve
lo
pm
en
t
22
24
26
6
19
4.
47
8.
0e
-0
9
G
O
:0
03
29
89
ce
llu
la
r c
om
po
ne
nt
 m
or
ph
og
en
es
is
95
0
13
4
83
.0
7
9.
2e
-0
9
G
O
:0
04
88
12
ne
ur
on
 p
ro
je
ct
io
n 
m
or
ph
og
en
es
is
53
9
87
47
.1
3
1.
1e
-0
8
G
O
:0
00
09
04
ce
ll 
m
or
ph
og
en
es
is
 in
vo
lv
ed
 in
 d
iff
er
en
tia
tio
n
66
1
10
1
57
.8
1.
3e
-0
8
G
O
:0
00
71
67
en
zy
m
e 
lin
ke
d 
re
ce
pt
or
 p
ro
te
in
 s
ig
na
lin
g 
pa
th
w
ay
82
2
11
9
71
.8
8
1.
5e
-0
8
G
O
:0
00
74
09
ax
on
og
en
es
is
48
8
80
42
.6
7
2.
2e
-0
8
G
O
:0
04
86
67
ce
ll 
m
or
ph
og
en
es
is
 in
vo
lv
ed
 in
 n
eu
ro
n 
di
ffe
re
nt
ia
tio
n
53
4
85
46
.6
9
3.
1e
-0
8
G
O
:0
03
11
75
ne
ur
on
 p
ro
je
ct
io
n 
de
ve
lo
pm
en
t
65
6
99
57
.3
6
3.
5e
-0
8
G
O
:0
04
88
58
ce
ll 
pr
oj
ec
tio
n 
m
or
ph
og
en
es
is
63
9
97
55
.8
8
3.
6e
-0
8
G
O
:0
04
88
70
ce
ll 
m
ot
ili
ty
85
3
12
1
74
.5
9
3.
8e
-0
8
G
O
:0
05
16
74
lo
ca
liz
at
io
n 
of
 c
el
l
85
3
12
1
74
.5
9
3.
8e
-0
8
G
O
:0
03
01
82
ne
ur
on
 d
iff
er
en
tia
tio
n
92
8
12
8
81
.1
5
7.
8e
-0
8
G
O
:0
04
86
66
ne
ur
on
 d
ev
el
op
m
en
t
75
6
10
9
66
.1
1
8.
2e
-0
8
G
O
:0
03
29
90
ce
ll 
pa
rt
 m
or
ph
og
en
es
is
65
0
97
56
.8
4
8.
5e
-0
8
G
O
:0
00
74
11
ax
on
 g
ui
da
nc
e
34
0
60
29
.7
3
9.
7e
-0
8
G
O
:0
01
64
77
ce
ll 
m
ig
ra
tio
n
78
7
11
2
68
.8
2
1.
1e
-0
7
G
O
:0
03
15
89
ce
ll-
su
bs
tr
at
e 
ad
he
si
on
19
8
41
17
.3
1
1.
4e
-0
7
G
O
:0
00
99
66
re
gu
la
tio
n 
of
 s
ig
na
l t
ra
ns
du
ct
io
n
16
55
20
1
14
4.
72
3.
0e
-0
7
G
O
:0
06
50
07
bi
ol
og
ic
al
 re
gu
la
tio
n
77
58
75
5
67
8.
39
4.
6e
-0
7
Processed on: 27-10-2016
505572-L-sub01-bw-Wijnands
5
79EWAS in pVSD and Down syndrome | 
Ta
bl
e 
2 
| (
Co
nt
in
ue
d)
G
O
.ID
Te
rm
A
nn
ot
at
ed
Si
gn
ifi
ca
nt
Ex
pe
ct
ed
Fi
sh
er
G
O
:0
00
71
69
tr
an
sm
em
br
an
e 
re
ce
pt
or
 p
ro
te
in
 ty
ro
si
ne
 k
in
as
e 
si
gn
al
in
g 
pa
th
w
ay
57
8
86
50
.5
4
5.
4e
-0
7
G
O
:0
05
17
16
ce
llu
la
r r
es
po
ns
e 
to
 s
tim
ul
us
45
64
47
5
39
9.
09
5.
6e
-0
7
G
O
:0
04
85
83
re
gu
la
tio
n 
of
 re
sp
on
se
 to
 s
tim
ul
us
21
45
24
8
18
7.
57
5.
9e
-0
7
G
O
:0
02
30
51
re
gu
la
tio
n 
of
 s
ig
na
lin
g
18
88
22
1
16
5.
09
1.
2e
-0
6
G
O
:0
00
69
35
ch
em
ot
ax
is
55
6
82
48
.6
2
1.
4e
-0
6
G
O
:0
04
23
30
ta
xi
s
55
6
82
48
.6
2
1.
4e
-0
6
G
O
:0
01
06
46
re
gu
la
tio
n 
of
 c
el
l c
om
m
un
ic
at
io
n
18
95
22
1
16
5.
71
1.
6e
-0
6
G
O
:0
00
71
60
ce
ll-
m
at
rix
 a
dh
es
io
n
12
9
29
11
.2
8
1.
6e
-0
6
G
O
:0
05
07
93
re
gu
la
tio
n 
of
 d
ev
el
op
m
en
ta
l p
ro
ce
ss
13
47
16
5
11
7.
79
2.
6e
-0
6
G
O
:0
05
07
94
re
gu
la
tio
n 
of
 c
el
lu
la
r p
ro
ce
ss
69
28
67
8
60
5.
81
3.
3e
-0
6
G
O
:0
04
20
60
w
ou
nd
 h
ea
lin
g
56
2
81
49
.1
4
4.
2e
-0
6
G
O
:0
04
85
14
bl
oo
d 
ve
ss
el
 m
or
ph
og
en
es
is
39
9
62
34
.8
9
5.
3e
-0
6
G
O
:0
00
15
25
an
gi
og
en
es
is
32
4
53
28
.3
3
5.
7e
-0
6
G
O
:0
03
12
95
T 
ce
ll 
co
st
im
ul
at
io
n
64
18
5.
6
5.
8e
-0
6
G
O
:0
07
23
58
ca
rd
io
va
sc
ul
ar
 s
ys
te
m
 d
ev
el
op
m
en
t
71
3
97
62
.3
5
6.
0e
-0
6
G
O
:0
07
23
59
ci
rc
ul
at
or
y 
sy
st
em
 d
ev
el
op
m
en
t
71
3
97
62
.3
5
6.
0e
-0
6
G
O
:0
03
12
94
ly
m
ph
oc
yt
e 
co
st
im
ul
at
io
n
65
18
5.
68
7.
3e
-0
6
G
O
:0
00
75
99
he
m
os
ta
si
s
45
9
68
40
.1
4
9.
9e
-0
6
G
O
:2
00
00
26
re
gu
la
tio
n 
of
 m
ul
tic
el
lu
la
r o
rg
an
is
m
al
 d
ev
el
op
m
en
t
10
35
13
0
90
.5
1.
0e
-0
5
G
O
:0
00
20
09
m
or
ph
og
en
es
is
 o
f a
n 
ep
ith
el
iu
m
37
3
58
32
.6
2
1.
0e
-0
5
G
O
:0
05
08
70
po
si
tiv
e 
re
gu
la
tio
n 
of
 T
 c
el
l a
ct
iv
at
io
n
15
6
31
13
.6
4
1.
1e
-0
5
G
O
:0
00
70
44
ce
ll-
su
bs
tr
at
e 
ju
nc
tio
n 
as
se
m
bl
y
55
16
4.
81
1.
2e
-0
5
Processed on: 27-10-2016
505572-L-sub01-bw-Wijnands
80 | Chapter 5
Table 3 | Enrichment of pVSD-associated CpGs in an earlier EWAS study on perimembranous ventricular 
septal defects at different significance levels
P value cutoff threshold 0.1 0.05 0.01 0.005 0.001 5.00E-04 1.00E-05
Number of significant 
CpGs from previous study
45844 23081 4732 2429 545 277 14
Odds ratio 1.54 1.71 2.23 2.01 3.3 4.82 8.94
Lower CI 1.4 1.52 1.78 1.43 1.83 2.37 0.21
Upper CI 1.68 1.92 2.76 2.73 5.5 8.77 59.5
P value 2.24E-19 9.80E-18 5.20E-11 5.63E-05 9.45E-05 3.29E-05 0.113
Discussion
  
In this study, we examined epigenome-wide DNA methylation in children with both DS and pVSD. 
Children with both DS and pVSD show global hypermethylation of PWBC DNA in all autosomes 
except chromosome 21. Significantly differently methylated CpGs from our previous study on pVSD 
in nonsyndromic children are enriched in children with pVSD and DS [Wijnands et al. unpublished]. 
This might indicate that these CpGs may also be involved in the pathogenesis of pVSD in children 
with DS. Also PRDM16, a candidate-gene previously found in our EWAS on nonsyndromic pVSD 
and known as a repressor of TGFβ signaling (transforming growth-factor beta), seems differently 
methylated between pVSD-DS and controls. 
We observed differential cell populations of CD4+ T-cells, B-cells, neutrophils and eosinophils 
between pVSD-DS cases and healthy controls. It has been shown before that DS is characterised 
by defects in the immune system including mild to moderate T and B cell lymphopenia (130). This is 
supported by the fact that many differentially methylated genes are involved in development and 
functioning of white blood cells (75). Based on our data, we conclude that blood leukocyte mixture 
is a potential confounder for this association study, therefore we applied Houseman’s method to 
correct for cell type proportions (87). 
Looking at our data, chromosome 21 is the only autosome not hypermethylated in case children. 
Previous research showed hypermethylation over hypomethylation in DS placenta villi in all 
autosomes including chromosome 21 (121). It remains to be seen whether these inconsistent 
findings could perhaps be explained by differences in tissue, intraindividual changes over time 
during different stages in development or differences in the genetic defect. 
We measured DNA extracted from PWBC at a mean age of 17 months. Choosing the appropriate 
tissue is key, however, in clinical practice it is difficult if not impossible in many cases to obtain heart 
tissue, especially from healthy control children. Interestingly, the results of our functional analyses 
are comparable with the results of a recent study on heart tissue. Serra-Juhé et al. showed in fetal 
heart tissue the five top enriched gene-ontology based sets which comprised similar to our top 
five enriched GO terms the sets “anatomical structure development”, “single-multicellular organism 
process” and “single-organism developmental process” (131). This is a distinct observation since our 
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data is based on methylation in DNA leukocytes, while Serra-Juhé et al. did not find these sets to be 
enriched in blood and point out the importance of analysing the affected tissue.
DS is associated with a broad spectrum of phenotypes and the clinical presentation is complex and 
variable (25). The DS phenotype can be caused by three genetic defects which are non-disjunction 
resulting in trisomy of chromosome 21 (95%), unbalanced translocation of chromosome 21 (3-4%) or 
mosaicism of chromosome 21 (1-2%) (26). Epigenetics has been proposed as a causative mechanism 
of maternal meiotic non-disjunction resulting in trisomy 21. Unfortunately the genetic defect in our 
study group is unknown. 
Strength of our study population is that DS cases have a homogenous CHD phenotype. Sailani 
et al. recently showed in DS monozygotic twins discordant for CHD that the direction of DNA 
methylation differs between VSD and AVSD (132). These differences in DNA methylation (either up- 
or downregulation) between different heart phenotypes highlight the importance of a homogenous 
case sampling. 
Some limitations of this study have to be addressed. Firstly, some critical remarks on the Illumina 
Infinium® HumanMethylation450 BeadChip are in place. It has been shown that it is critical to correct 
for the two different probe design types (133). We did not perform a between-array normalisation 
because the case samples have a trisomy of chromosome 21 resulting in (epi)genomic imbalance. 
Therefore we used BMIQ normalisation, after which the peaks of the type I probes and type II 
probes matched very well (Supplementary Figure S3). Though no between-array normalisation 
was employed, the overall distributions over all chromosomes or separate chromosomes were very 
similar. There was no obvious deviation of the methylation distribution of pVSD-DS samples from 
the control samples.
Secondly, the differential methylation we have found could be considered the outcome of an 
interaction between both pVSD and DS. Unfortunately, we do not have data on DS children without a 
heart defect. Therefore, it is not possible to differentiate between differential methylation involved in 
DS and differential methylation involved in pathophysiology of pVSD. Global DNA hypermethylation 
has been reported in several studies, however, it is not consistently reported which percentage 
of these DS participants also has a CHD (119-121). In our data, enrichment analysis suggests that 
methylation changes previously found in pVSD children might also contribute to pVSD in DS. The 
results are very robust to the threshold used to pick up the a priori defined CpG loci.
Several EWAS on DS have been performed showing a state of global hypermethylation, however, 
epigenetic data focussing on CHD in DS is limited (119-121). This study implicates that perturbations 
in DNA methylation might play a role in the pathogenesis of pVSD in DS. Children at 17 months of age 
with both DS and pVSD show global hypermethylation of PWBC DNA. Our data suggest that CpGs 
associated with pVSD in nonsyndromic children may also be involved in the pathogenesis of pVSD 
in children with DS. Future research will have to emphasise the role of aberrant DNA methylation in 
the pathophysiology of CHD in DS. 
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Supplementary material
Table S1 | Differential cell distribution
Cell type Case Control P value
Neutrophil 0.272 0.388 0.00104
CD4+ T 0.176 0.122 0.00853
CD8+ T 0.259 0.264 0.861
B cell 0.141 0.0821 1.89e-06
Eosinophil 0.0234 0.00523 0.00742
Monocyte 0.0883 0.0951 0.548
NK cell 0.00631 0.0111 0.466
Table S2 | One-sided Kolmogrov-Smirnov test on enrichment of differential CpGs in a particular type of region
Region P value Region P value
DHS 1.29e-92 N Shore 4.9e-101
Enhancer 4.98e-64 S Shore 4.21e-101
CDMR 1.1e-23 TSS1500 9.84e-21
DMR 7.4e-08 TSS200 0.988
RDMR 2.78e-128 UTR3 0.813
Island 0.998 UTR5 0.997
N Shelf 0.999 1st Exon 0.985
S Shelf 0.992 Body 0.747
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Figure 3 | Density plot of the beta values for the two probe design types (Infinium I and Infinium II) after BMIQ 
normalisation
pVSD, Perimembranous ventricular septal defect. DS, Down syndrome. 
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Abstract 
Background Maternal high blood pressure and smoking affect placental function, accompanied by 
increased risk of fetal growth restriction and low birthweight. Mothers who experience pregnancies 
complicated by fetal growth restriction are at increased risk of CV disease in later life. We aimed to 
study if the maternal cardiovascular (CV) risk profile is associated with human embryonic growth 
trajectories and whether the mode of conception affects this association.
Methods In a prospective periconception birth cohort conducted in a tertiary hospital, 111 singleton 
ongoing pregnancies without pre-existing maternal disease, reliable pregnancy dating and 
nonmalformed live borns were investigated. Spontaneously conceived pregnancies with a reliable 
first day of the last menstrual period and a regular menstrual cycle of 25 to 31 days only (n=66) and 
in vitro fertilisation (IVF)/intra-cytoplasmic sperm injection (ICSI) pregnancies (n=45) were included. 
Women underwent weekly three-dimensional ultrasound scans (3D US) from 6 up to 13 weeks 
gestational age. To estimate embryonic growth, serial crown-rump length (CRL) measurements 
were performed using V-Scope software in a BARCO I-Space. Maternal characteristics and CV risk 
factors were collected by self-administered questionnaires. The CV risk profile was created based on 
a score of risk factors, including maternal age, body-mass index, CV disease in the family, diet and 
smoking. Quartiles of the CV risk score were calculated. Associations between the CV risk score and 
embryonic growth were assessed using square root transformed CRL in multivariable linear mixed 
model analyses.
Results From the 111 included pregnancies 696 3D US datasets were obtained of which 637 
(91.5%) CRLs could be measured. In the total group, CV risk score was inversely but not significantly 
associated with embryonic growth (-0.03√mm; P=0.291). Stratified by mode of conception, the CV 
risk score was inversely and significantly associated with embryonic growth (β=-0.04√mm; P=0.025, 
adjusted for possible confounders) in the IVF/ICSI group. Compared with the first quartile, embryos 
in the upper quartile were 10.4% smaller at 6+0 weeks (4.4mm vs. 4.9mm) and 3.1% smaller at 12+0 
weeks (56.5mm vs. 58.4mm) of gestation. Although the CV risk score was slightly, but significantly, 
higher in women conceiving spontaneously compared to those undergoing IVF/ICSI treatment 
(CV risk score=2.06 (SD 1.23) and 1.60 (SD 1.15) respectively), no association was established with 
embryonic growth in that particular group.
Conclusions This small study suggests that the maternal CV risk profile is inversely associated 
with first trimester embryonic growth trajectories in IVF/ICSI pregnancies, but not in spontaneously 
conceived pregnancies. Differences in embryonic growth between pregnancies conceived 
spontaneously and after IVF/ICSI treatment in relation with CV risk factors substantiate the 
importance of more investigation into differences in sensitivity of endometrial, endothelial, placental 
and embryonic tissues.
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Introduction
The periconception period is critical for gametogenesis, embryogenesis and placentation (14). Events 
during this time window can result in subfertility and vascular-related pregnancy complications, 
such as fetal growth restriction and pre-eclampsia that mainly originates in the placenta and 
largely present in the second half of pregnancy (134,135). Unhealthy lifestyle such as an insufficient 
diet, smoking and (social) alcohol use, occur in more than 80% of pregnancies and detrimentally 
affect reproduction. These poor behaviours partially act through interactions with vascular-
related pathways such as one-carbon (1-C) metabolism, which has been implicated in growth and 
development of the gametes, embryo, placenta and fetus (14,136-138). 
Previous studies showed that women with CV disease or risk equivalents are more likely to experience 
a pregnancy complicated by fetal growth restriction and low birthweight (139). Furthermore, 
mothers with pregnancies complicated by fetal growth restriction are at an increased risk of CV 
disease in later life (140-142). 
We hypothesise that the maternal cardiovascular risk profile is associated with human embryonic 
growth trajectories (Figure 1). The suggested mechanism behind this hypothesis is that increased 
maternal CV disease risk will result in endothelial dysfunction and reduced endometrium receptivity 
which will result in impaired placental function and embryonic growth. However, this might be 
different in pregnancies conceived after in vitro fertilisation (IVF) with or without intracytoplasmic 
sperm injection (ICSI) since the endometrial receptivity and endocrine environment are altered. 
This is important since the human endometrium decidualises in response to endocrine rather 
than embryonic cues (Macklon and Brosens, 2014). Studies on endometrial histology show a wide 
range of abnormalities during various stimulation protocols (Zandstra, et al., 2015). To consider the 
possible indirect effects of IVF/ICSI treatment through influences on placentation and endometrium 
receptivity we also presented the stratified analysis.
Increased
maternal
CVD risk
Endothelial
dysfunction
Placental
dysfunction
Impaired
embryonic
growth
IVF/ICSI treatment
Reduced
endometrial
receptivity
Figure 1 | Hypothesis
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Methods
This study was embedded in the Predict Study, a prospective periconception hospital-based 
birth cohort, conducted at the department of Obstetrics and Gynaecology at the Erasmus MC, 
University Medical Centre in Rotterdam, the Netherlands (27). All women of at least 18 years of age 
with intrauterine singleton pregnancies of 6-8 weeks of gestation at enrolment were eligible for 
participation during 2009 and 2010. 
Ultrasound scans
Women received weekly transvaginal three-dimensional ultrasound scans (3D US) from enrolment 
up to 13 weeks gestational age (GA). Ultrasound scans were performed with a 6-12 MHz transvaginal 
probe using GE Voluson E8 equipment and 4D View software (General Electrics Medical Systems, 
Zipf, Australia). The obtained 3D-data sets were transformed to Cartesian (rectangular) volumes and 
transferred to the BARCO I-Space (Barco N.V., Kortrijk, Belgium) at the department of Bioinformatics, 
Erasmus MC, University Medical Centre. This is a four-walled CAVETM-like (Cave Automatic Virtual 
Environment) virtual reality system, allowing depth perception and interaction with the projected 
images (143). CRL measurements were performed offline in the I-Space using the V-Scope software by 
placing the callipers at the outer side of crown and rump in the mid-sagittal plane (144). The BARCO 
I-Space and V-scope software use the benefit of the third dimension which enables the performance 
of highly precise and reliable first trimester embryonic measurements in vivo (27,145,146). All CRL 
measurements were performed three times by the same researcher and the mean of these three 
measurements was used in the analyses. 
Questionnaires 
At enrolment participants completed a self-administered general questionnaire containing items 
on maternal age, anthropometrics, ethnicity, education, family history, obstetrical history, and 
periconception exposures such as folic acid supplement use and diet. Data on fetal gender and 
pregnancy outcome were obtained after birth from medical records. Ethnicity and educational level 
were classified according to the definitions of Statistics Netherlands (67). Smoking was defined as 
smoking any number of cigarettes until the moment of pregnancy recognition. Folic acid supplement 
use was defined as the daily intake of a folic acid supplement of 0.4-0.5 mg. Diet was determined 
using six questions on the adequacy of the intake based on Dutch guidelines of the main food 
groups: whole wheat, vegetables, fruit, unsaturated oils, meat and fish. Based on the answers to 
these questions the validated Preconception Dietary Risk (PDR) score was calculated, which ranges 
from zero to six, where a score of six points represents a highly inadequate food group intake (147).
Cardiovascular risk score
We constructed the CV risk score based on risk assessment tools from the Framingham Heart Study 
and the American Heart Association comprised of maternal age, body-mass index (BMI), CV disease 
in the family, diet and smoking (148,149). The CV risk score ranged from zero to eight, where a score 
of eight indicates the highest number of risk factors. CV risk factors were weighed according to their 
increased risk for CV disease and known effect on fetal growth. 
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Pregnancy dating
Data on the first day of the last menstrual period (LMP) and data of regularity and duration of the 
menstrual cycle were obtained in a personal interview by the researcher performing the ultrasound 
at the first visit. GA was calculated from the LMP in spontaneously conceived pregnancies, from 
the date of oocyte retrieval plus 14 days in pregnancies conceived through IVF/ ICSI procedures, 
from the LMP or insemination date plus 14 days in pregnancies conceived through intra-uterine 
insemination, and from the day of embryo transfer plus 17 or 18 days in pregnancies originating 
from the transfer of cryopreserved embryos, depending on the number of days between the oocyte 
retrieval and cryopreservation of the embryo. When the menstrual cycle was regular, but >3 days 
different from 28 days, the GA was adjusted for the duration of the menstrual cycle. 
If the first day of the LMP was unknown in spontaneously conceived pregnancies, or if the observed 
CRL differed by >6 days from the expected CRL according to the Robinson curve, pregnancies 
were excluded from the analysis (150). We included spontaneously conceived pregnancies and 
pregnancies conceived through IVF/ICSI using biological oocytes from the participating mother-to-
be only. Ectopic pregnancies and pregnancies that ended in a miscarriage before 16 weeks GA and 
congenital malformations were excluded. 
Statistical analysis
To assess associations between the CV risk score and serial CRL measurements we performed a linear 
mixed model analysis. CRL measurements were entered as response and CV risk score as a function 
of GA as predictor. Square root transformation of the serial CRL measurements was performed to 
achieve linearity with GA and a constant variance. To model the within subject correlation we used 
random intercepts and GA. 
Firstly, we presented a multivariable analysis. Secondly, we presented a stratified analysis. For both 
analyses, we started with a univariable model adjusted for GA only. In the second or fully adjusted 
model we adjusted for all potential confounding variables. As potential confounders we considered 
the moment of initiation of folic acid use, parity, ethnicity, educational level, fetal gender and 
interaction terms between all aforementioned covariates and GA. The third and final model was 
derived from the fully adjusted model after hierarchical backward elimination of all covariates with 
P<0.20 (151). In all analyses, P<0.05 was considered statistically significant. 
Data analysis was performed using IBM SPSS Statistics for Windows software (version 20.0; IBM, 
Armonk, NY, USA) and SAS for Windows software (version 9.2; SAS Institute Inc., Cary, NC, USA). 
Ethical approval
This study has been approved by the Central Committee on Research in The Hague and the local 
Medical Ethical and Institutional Review Board of the Erasmus MC, University Medical Centre. At 
enrolment, all participants signed a written informed consent form.
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Results
Two hundred and fifty-nine singleton pregnancies were enrolled (Figure 2). We excluded 69 
pregnancies in total, because they were conceived by oocyte donation (n=2) or ended in a 
miscarriage (n=43). Pregnancies were also excluded in case of an ectopic pregnancy (n=1), unknown 
first day of the LMP (n=12), missing questionnaires (n=3) or if they resulted in fetal/neonatal death 
(n=5) or in case of fetuses with a congenital malformation (n=3). Excluded pregnancies were 
comparable in baseline characteristics (Supplementary Table S1). In addition, 52 women with one 
or more pre-existing diseases, past medical history or malformations were excluded (diabetes 
mellitus (n=2), thyroid disease (n=9), asthma (n=9), hypertension (n=6), epilepsy (n=3), thrombosis 
(n=5), rheumatic disorder (n=3), heart disease (n=3), cancer (n=3), uterine anomaly (n=2), Ehlers-
Danlos syndrome (n=1), hematologic disease (n=2), psychiatric disorder (n=4), gastrointestinal 
disease (n=3), metabolic disorder (n=1) and previous gynaecological surgery (n=3)). An additional 
number of 27 spontaneously conceived pregnancies were excluded because GA was not based on a 
strictly regular menstrual period of 28 ± 3 days. In total, 111 pregnancies were available for analysis, 
including 67% derived from the Obstetrics and Gynaecology outpatient clinic at the Erasmus MC, 
University Medical Centre, and 33% from outside the hospital. Of these 111 pregnancies 45 were 
conceived through IVF/ICSI treatment. 
Eligible pregnancies:
n=259
Total # of pregnancies:
n=138
Unreliable GA:
n=27
Reliable GA:
n=111
Reliable 1st day LMP
and regular menstrual
cycle 25-31 days:
n=66
IVF/ICSI treatment:
n=45
Oocyte donation n=2
Miscarriage n=43
Ectopic pregnancy n=1
Pregnancy dated by CRL n=12
Fetal/neonatal death n=5
Congenital malformation n=3
Missing questionnaires n=3
Maternal pre-existing disease n=52
Figure 2 | Flowchart of the study population
CRL, crown-rump length; GA, gestation age; LMP, last menstrual period.
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Median GA at enrolment was 6+6 (range 6+0-8+6) weeks and the median number of ultrasound visits 
per pregnancy was 6 (range 4-8). In total 696 3D US were performed. A number of 637 (91.5%) 3D 
US scans were of sufficient quality to measure CRL. Information from medical records was obtained 
for 111 pregnancies (100%). 
Maternal and pregnancy characteristics are shown in Table 1. Women in the spontaneously 
conceived and in the IVF/ICSI group were on average 32.1 (SD 4.7) and 32.9 (SD 4.3) years of age 
respectively. Women in the two groups were both highly educated (68% and 53% respectively) 
and the majority of Dutch origin (74% and 84% respectively). These characteristics were not 
significantly different between spontaneously conceived and IVF/ICSI pregnancies. In the IVF/ICSI 
group, all women (100%) initiated folic acid supplement use preconceptional compared to 72% of 
women with spontaneously conceived pregnancies. In the IVF/ICSI group women were less likely 
to smoke compared to the women in the spontaneously conceived pregnancy group (9% vs. 24% 
respectively, P=0.039). Both groups showed a comparable GA at delivery and birth weight. Fetal 
pregnancy complications occurred in 15% of spontaneously conceived pregnancies and 7% of IVF/
ICSI pregnancies (P=0.172). The mean CV risk scores were for the spontaneous and IVF/ICSI group 
2.06 (range 0.17-6.17) and 1.60 (range 0.17-4.33) (P=0.049), respectively (Table 2). From all CV risk 
factors, only smoking was significantly different between both groups 
Table 3 and Table 4 show the results of the linear mixed model analyses. In the total group, CV risk 
score was inversely but not significantly associated with embryonic growth (-0.03√mm; P=0.291) 
(Table 3). Stratified by mode of conception, the univariable model of CRL as a function of GA 
adjusted CV risk score showed no association between CV risk score and CRL (β=-0.01√mm; P=0.75) 
in spontaneous pregnancies (Table 4). In the IVF/ICSI pregnancies, the association between CV risk 
score and CRL was marginally statistically significant (β=-0.03√mm; P=0.08). 
In spontaneous pregnancies, CV risk score was not significantly associated with embryonic growth 
trajectories in neither the saturated (β=-0.00√mm; P=0.93) nor the final model after backward 
elimination (β=-0.01√mm; P=0.72). In IVF/ICSI pregnancies on the other hand, the association 
between CV risk score and CRL was significantly associated with embryonic growth trajectories in 
both the saturated (β=-0.04√mm; P=0.03) and the final model (β=-0.04√mm; P=0.03). The estimated 
multivariable regression lines for the final models are shown in Figure 3 for the lowest CV risk (first 
quartile, mean 0.54 (SD 0.28)) and the highest CV risk (fourth quartile, mean 3.15 (SD 0.58)) in 
spontaneously conceived pregnancies, and for the lowest CV risk (first quartile, mean 0.54 (SD 0.28)) 
and the highest CV risk (fourth quartile, mean 3.65 (SD 0.93)) in IVF/ICSI pregnancies. Compared 
with the first CV risk quartile, embryos in the upper quartile were 10.4% smaller at 6+0 weeks (4.4mm 
vs. 4.9mm) and 3.1% smaller at 12+0 weeks (56.5mm vs. 58.4mm) of gestation in the IVF/ICSI group. 
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Table 1 | General maternal characteristics 
Variable Spontaneous pregnancies 
n=66 (59%)
IVF/ICSI pregnancies, 
n=45 (41%)
P value
Maternal
Age in years (mean ± SD) 32.1 (4.7) 32.9 (4.3) 0.397
Body mass index (kg/m2) 24.6 (3.8) 24.0 (3.4) 0.348
Ethnicity 0.149
Dutch 49 (74) 38 (84)
Western-other 4 (6) 4 (9)
Non-Western 13 (20) 3 (7)
Educational level 0.277
Low 4 (6) 5 (11)
Intermediate 16 (25) 16 (36)
High 43 (68) 24 (53)
Folic acid supplement use 0.407
No 1 (2) 0 (0)
Yes 65 (99) 45 (100)
Preconception initiation 46 (72) 45 (100) 0.000
Periconception
Smoking 16 (24) 4 (9) 0.039
Alcohol 35 (53) 13 (29) 0.064
Nulliparous 38 (58) 37 (82) 0.018
Primigravida 20 (30) 27 (60) 0.002
Conception NA
Spontaneous 63 (96) 0 (0)
Assisted reproductive technology 3 (5) 45 (100)
Newborn
Birth weight in grams (mean ± SD) 3347 (621) 3341 (543) 0.606
Gestational age at delivery, weeks + days 39+1 (26+5-42+0) 39+1(31+3-41+3) 0.926
Male gender 32 (48) 16 (36) 0.177
Fetal complication 10 (15) 3 (7) 0.172
Low birthweight (<2500g) 5 (8) 2 (4) 0.505
Premature delivery (<37 weeks) 4 (6) 2 (4) 0.712
SGA (<10th customised centile) 7 (11) 1 (2) 0.086
Data are presented as number of observations (%) unless otherwise specified. 
SD, standard deviation. SGA; small for gestational age. 
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Table 2 | Cardiovascular risk score 
Cardiovascular risk factor Item 
score
Spontaneous 
pregnancies 
n=66
IVF/ICSI 
pregnancies 
n=45
P value
Positive family history of mother with CV disease 1 15 (23) 6 (13) 0.215
Positive family history of father with CV disease 1 12 (18) 9 (20) 0.810
Smokinga 2 16 (24) 4 (9) 0.039
Overweight (BMI 25-30) 1 22 (34) 10 (22) 0.399
Obesity (BMI ≥30) 2 4 (6) 4 (9) 0.399
Age ≥36 years 1 15 (23) 10 (23) 1.000
PDR score 
0 0 2 (3) 0 (0)
1 1/6 9 (14) 7 (16)
2 2/6 12 (18) 11 (24)
3 3/6 17 (26) 16 (36)
4 4/6 22 (33) 6 (13)
5 5/6 3 (5) 5 (11)
6 1 1 (2) 0 (0)
Mean CV risk score (SD) range 0-8 2.06 (1.23) 1.60 (1.15) 0.049
BMI, body-mass index; PDR, preconception dietary risk; CV, cardiovascular; SD, standard deviation.
a Smoking was defined as smoking any number of cigarettes until the moment of pregnancy recognition.
Table 3 | Effect estimates of cardiovascular risk score for embryonic crown-rump length (CRL) derived from 
linear regression models
CRL (√mm) n=111 (696 3D US)
Model β CV risk score (SE) P value
1. Unadjusted -0.02532 (0.02368) 0.2856
2. Fully adjusted -0.03171 (0.02514) 0.2079
3. Adjusted -0.02516 (0.02381) 0.2912
3D US, 3D ultrasound scans; CV, cardiovascular.
Model 1: CRL adjusted for gestational age (GA) and mode of conception.
Model 2: Analysis adjusted for GA, mode of conception, moment of folic acid use, parity, ethnicity, educational level, fetal gender 
and interaction terms between all aforementioned covariates and GA.
Model 3: Analysis adjusted for GA, mode of conception, parity, gender, and interaction terms between GA and mode of 
conception, GA and parity , and GA and gender. 
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Table 4 | Effect estimates of cardiovascular risk score for embryonic crown-rump length (CRL) derived from 
linear regression models stratified for mode of conception
Model Spontaneous pregnancies CRL (√mm)  
n=66 (406 3D US)
IVF/ICSI pregnancies CRL (√mm)  
n=45 (290 3D US)
β CV risk score (SE) P value β CV risk score (SE) P value
1. Unadjusted -0.01185 (0.03658) 0.7462 -0.03323 (0.01898) 0.0817
2. Fully adjusted -0.00400 (0.04420) 0.9280 -0.04378 (0.01941) 0.0254
3. Adjusted -0.01472 (0.04063) 0.7175 -0.04269 (0.01889) 0.0251
Model 1: CRL adjusted for gestational age (GA).
Model 2: Analyses of both groups adjusted for GA, parity, ethnicity, educational level, fetal gender and interaction terms between 
all aforementioned covariates and GA. Analysis of the spontaneously conceived pregnancy group is additionally adjusted for 
moment of folic acid use.
Model 3: Analysis of the spontaneously conceived pregnancy group with reliable GA is adjusted for ethnicity and educational 
level. Analysis of the IVF/ICSI group is adjusted for GA, ethnicity, parity, gender, and interaction terms between GA and ethnicity, 
GA and parity, and GA and gender. 
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Figure 3 | Regression lines crown-rump length versus gestational age
Estimated multivariable regression lines for high and low CV risk score in spontaneously conceived 
pregnancies (A) and IVF/ICSI pregnancies (B) and after transformation to the original scale for spontaneously 
conceived pregnancies (C) and IVF/ICSI pregnancies (D).
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Discussion 
In a prospective periconception hospital-based birth cohort we observed that the maternal CV risk 
profile is inversely associated with embryonic growth trajectories in IVF/ICSI pregnancies, but not in 
spontaneously conceived pregnancies.
So far, only a few longitudinal ultrasound studies on human embryonic growth trajectories have 
been conducted (152-154). Strengths of our study are that serial CRL measurements were measured 
both very accurately in a virtual reality system as well as in triplicate by the same researcher. The 
mean measurement was used in the analyses providing greater precision. Furthermore, we used 
strict criteria to estimate GA because GA is the main determinant of CRL. We excluded women with 
an unknown first day of the LMP or with a discrepancy between LMP and CRL dates of more than 
6 days, and adjusted GA for the duration of the menstrual cycle when regular but more than three 
days different from 28 days. However, misclassification of GA may have occurred due to recall bias of 
the LMP and physiological variations in the timing of ovulation and implantation. 
In the present study the CV risk score was significantly associated with embryonic growth trajectories 
in pregnancies conceived with IVF/ICSI treatment only, which seems surprising since CV score was 
significantly lower in women undergoing IVF/ICSI treatment. This result can be explained by either 
information bias of smoking or a real higher sensitivity of these embryos to environmental maternal 
conditions and exposures due to the cause of subfertility or the IVF/ICSI treatment. Also differences 
in pregnancy related factors such as uterine fluid or endometrium receptivity could be of importance 
(155,156). Endometrial histology observations show a wide range of abnormalities during various 
stimulation protocols (157). Furthermore, studies suggest that the culture medium used for in vitro 
fertilisation affects fetal growth and birth weight (157-159). 
This is the first study investigating the association between a maternal CV risk profile and human 
embryonic growth trajectories. In the future, the extension of the CV risk score with biomarkers such 
as total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol is 
challenging to substantiate these first findings. We restricted our analysis to asymptomatic women 
without any disease and therefore diabetes mellitus and CV disease were not added to the risk score, 
which may have underestimated the effect sizes. It should be noted that by using CV family history 
as a risk factor a genetic contribution of derangements in CV pathways cannot be excluded. 
There is some evidence that a number of CV risk factors, such as high blood pressure, smoking or 
increased maternal age, influence embryonic growth (74,135,160). Whether this is a direct or indirect 
effect needs to be clarified. The 1-C metabolism pathway as an intermediate could be a possible 
explanation. The relation between 1-C metabolism and poor dietary intake, smoking and age is 
evident, as well as hyperhomocysteinaemia as a risk factor for CV disease (161). Since embryogenesis 
is vulnerable to maternal nutrient deficiencies such as insufficient folate and methionine, it 
is possible that alterations in 1-C metabolism affect critical processes such as DNA synthesis, 
S-adenosylmethionine mediated DNA and histone methylation, polyamine and phospholipid 
biosynthesis, and protein, lipid and chromatin methylation (14,162). This might affect embryonic 
and fetal growth or could even result in congenital malformations.
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It is possible that the difference in CRL can only be detected or is only present in the first 8-9 weeks 
after conception. An explanation is that due to the gradual dissolving trophoblastic plugs of the 
spiral arteries the nutritional environment of the embryonic tissues is massively changing through 
which the reflection of epigenetic embryonic effects are diluted and cannot be detected anymore. 
We have observed the same effect in our other studies as well (163,164). Nevertheless, the early 
effects on the embryo may still have long term consequences taking into account that the embryonic 
genome is epigenetically programmed (14,50,165). It is known that the periconception period is 
highly important and sensitive with respect to epigenetic programming of the gametes, embryo 
and placenta by DNA methylation of genes implicated in growth and development (14). Therefore, 
differences in this early time window can have long term health and disease consequences which 
is in line with the developmental origins of health and disease hypothesis. We have previously 
shown that embryonic growth is associated with subsequent fetal growth and birth weight (166). 
Mook-Kanamori et al. shows that first-trimester growth restriction is associated with increased 
risks of preterm birth, low birth weight, small size for gestational age at birth and postnatal 
growth acceleration until the age of 2 years (135). Furthermore, it has been reported that impaired 
first trimester fetal growth is associated with an adverse cardiovascular risk profile in school age 
children, which suggests that early fetal life might be a critical period for cardiovascular health in 
later life (167). The numbers in the current study were too small to address the association between 
embryonic growth and aforementioned adverse pregnancy outcomes.
The current study is based on self-reported periconception exposures. As a result, recall bias cannot 
be excluded. Since subfertile women have more difficulties to become pregnant and are possibly 
more aware of any adverse exposures, they may recall their exposures to potential risk factors better. 
On the other hand, social desired answers cannot be excluded. Recall bias is minimised by blinding 
the study participants to the hypothesis, however, it cannot be excluded. The generalisability of 
this study is restricted to pregnancies ending in live borns only. CRL data were not available for 
most miscarriages since there was no fetal heart action during the first ultrasound visit. The very 
few ultrasounds scans available were of poor quality whereby a precise measure of CRL could not 
be provided.
In conclusion, this prospective periconception birth cohort study shows that a maternal CV risk 
score is inversely associated with human embryonic growth in IVF/ICSI pregnancies. Using a CV risk 
assessment tool in preconception care could possibly identify mothers-to-be with an increased risk 
of impaired fetal growth (24). A population based study should be performed to investigate the 
external validity of our results as well as the association between maternal CV score and adverse 
pregnancy outcomes.
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Supplementary material
Table S1 | Excluded pregnancies
Variable Exclusions group 1 
(n=69)
Exclusions group 2 
(n=52)
Inclusions  
(n=138)
Maternal
Age in years (mean ± SD) 33.2 (6.2)NS 32.7 (4.9)NS 31.8 (4.8)
Body mass index (kg/m2) 24.6 (4.9)NS 25.5 (5.0)NS 24.3 (3.6)
Ethnicity 
Dutch 25 (36)NS 39 (75)NS 105 (76)
Western-other 3 (4)NS 3 (6)NS 13 (9)
Non-Western 11 (16)NS 9 (17)NS 19 (14)
Educational level 
Low 6 (9)NS 6 (12)NS 11 (8)
Intermediate 10 (14)NS 16 (31)NS 40 (29)
High 20 (29)NS 26 (50)NS 82 (59)
Folic acid supplement use
No 0 (0)NS 1 (2)NS 1 (1)
Yes 39 (56)NS 51 (98)NS 137 (99)
Preconception initiation 32(46)NS 41 (79)NS 109 (79)
Periconception
Smoking 5 (7)NS 7 (13)NS 24 (17)
Alcohol 17 (25)NS 21 (40)NS 64 (46)
Nulliparous 24 (35)NS 28 (54)NS 91 (66)
Primigravida 9 (13)NS 14 (27)NS 55 (40)
Conception 
Spontaneous 19 (27)# 39 (75)NS 66 (48)
Assisted reproductive technology 5 (7)# 13 (25)NS 45 (33)
Newborn
Birth weight in grams (mean ± SD) 3095 (988)NS 3330 (471)NS 3305 (595)
Gestational age at delivery, weeks + days 37+2 (14+3-41+1)# 39+0 (35+4-41+3) NS 39+1 (26+5-42+0)
Male gender 9 (13)NS 28 (54)NS 63 (46)
Fetal complication
Low birthweight (<2500g) 2 (3)NS 2 (4)NS 11 (8)
Premature delivery (<37 weeks) 4 (6)NS 3 (6)NS 10 (7)
SGA (<10th customised centile) 0 (0)NS 1(2)NS 11 (8)
Numbers may not add up to the total sample size due to missing values
Exclusions group 1: oocyte donation, miscarriage, ectopic pregnancy, unknown first day of the last menstrual period, missing 
questionnaires, fetal/neonatal death or congenital malformation
Exclusions group 2: maternal pre-existing diseases, past medical history or malformations
NS No statistically significant difference between this excluded group and the included group
# Statistically significant difference (P value <0.05) between this excluded group and the included group
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Abstract 
Background Lipid derangements during early postnatal life may induce stable epigenetic changes 
and alter metabolic programming. We investigated associations between serum lipid profiles in 
very young children and DNA methylation of tumor necrosis factor-alpha (TNFα) and leptin (LEP). 
Secondly, we explored if the maternal serum lipid profile modifies DNA methylation in the child. 
Methods In 120 healthy children at 17 months of age, DNA methylation of TNFα and LEP was 
measured in DNA derived from whole blood. Linear mixed models were used to calculate exposure-
specific differences and associations. 
Results Total cholesterol in children was associated with decreased methylation of TNFα (-5.8%, 
P=0.036), and HDL-cholesterol was associated with decreased methylation of both TNFα (-6.9%, 
P=0.013) and LEP (-3.4%, P=0.021). Additional adjustment for gestational age at birth, birth weight, 
sex, breastfeeding and educational level attenuated the effects, TNFα (-6.1%, P=0.058) and LEP 
(-3.1%, P=0.041). In mothers, HDL-cholesterol only was associated with decreased methylation of 
TNFα in the child (-8.7%, P=0.001). 
Conclusion Our data support the developmental origins of health and disease hypothesis by 
showing that total cholesterol and HDL-cholesterol levels in very young children are associated 
with epigenetic metabolic programming, which may affect their vulnerability for developing 
cardiovascular diseases in later life. 
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Introduction
Periconception, prenatal and early postnatal life conditions seem to contribute to the risk of 
developing late-onset diseases, including cardiovascular and metabolic diseases (168-171). 
Dyslipidaemia in childhood is becoming increasingly common and depending on the cut-off points 
used up to 20 percent has at least one abnormal lipid level (172). Poor lifestyles and nutrition are partly 
responsible for this problem. Cardiovascular risk factors, including dyslipidaemia in childhood, seem 
to contribute to the risk of developing cardiovascular disease (CVD) in adulthood (173). Not only the 
formation of lifestyle and diet habits but also developmental programming could be considered a 
potential mechanism (169,170,173). 
The link between early life events and disease risk in later life is often described in relation to DNA 
methylation, an epigenetic mechanism important for development. Early childhood has been 
described as a critical developmental window during which perturbations are associated with 
intergenerational metabolic programming (174). Persons at age 50 exposed to the Dutch famine in 
early gestation have a more atherogenic lipid profile than those who are not exposed to famine (42). 
A number of genes are known to influence metabolic pathways, including the non-imprinted genes 
tumor necrosis factor-alpha (TNFα) and leptin (LEP). TNFα is a proinflammatory cytokine which has 
been associated with cardiovascular risk, lipid metabolism and insulin resistance (175). Leptin levels 
have been associated with obesity, hypertension, insulin resistance and type 2 diabetes mellitus. We 
have previously shown that LEP methylation in very young children is associated with the duration 
of breastfeeding and sex (176). 
Whether derangements in serum lipid levels during early postnatal life may influence epigenetic 
regulation of gene expression and alter metabolic programming is currently unknown. We 
hypothesise that a derangement in biomarkers of the lipid profile during early postnatal life is 
associated with epigenetic changes and altered metabolic programming. Therefore, we studied in a 
cross-sectional study associations between serum lipid levels related to increased risks of CVD (total 
cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein 
(LDL) cholesterol concentrations) and DNA methylation of LEP and TNFα in healthy young children 
at the age of 17 months. In addition, effect modification of maternal lipids was studied on the 
observed associations.
Methods
Study population
In a cross-sectional study, we investigated 120 healthy children (boys n=70, girls n=50) at a mean 
age of 17 months (SD 2.5). These subjects were previously described and served as controls in a 
case-control study on congenital heart disease (116). All children were recruited from the public 
child health care centres of ‘Careyn’ in the Rotterdam area in the Netherlands. Children were eligible 
as controls when they did not have a major congenital malformation or chromosomal abnormality 
according to the regular check up at the child health care centre up to the study moment. 
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Data collection 
At the standardised study moment of 17 months, we collected data about exposures and conditions 
in the periconception, prenatal and postnatal period. Self-administered questionnaires were send 
before the hospital visit, which were checked by the researcher for completeness and consistency at 
the hospital. Extracted data were maternal folic acid supplement use, age and educational level, and 
child’s gestational age at birth, age at study moment, gender, birth weight, duration of breastfeeding 
and ethnicity. During the hospital visit fasting venous blood samples were drawn from all mothers 
and nonfasting venous blood samples from all children. Immediately after blood sampling, an EDTA 
tube was put on ice and a serum separator tube was kept at room temperature. Both tubes were 
centrifuged at 4000 x g for 10 minutes at 4°C and separated within 1h. All samples were stored at -80°C 
and analysed anonymously in batches within five months after collection. Serum concentrations 
of total cholesterol, HDL-cholesterol and triglycerides were analysed using commercially available 
assays (Wako Diagnostics, Japan). HDL-cholesterol was analysed using the direct HDL assay from 
Wako Diagnostics. LDL-cholesterol values were estimated using the Friedewald formula (177). 
DNA methylation measurements 
DNA methylation of 2 genes associated with growth and metabolism was measured in 120 children. 
Genomic DNA was isolated from whole blood using the salting out method. One-half microgram 
of genomic DNA was bisulphite-treated using the EZ 96-DNA methylation kit (Zymo Research) on a 
total of two 96-well plates. 
In the LEP gene, DNA methylation of seven CpG sites was measured in triplicate using a mass 
spectrometry-based method (EpiTYPER, Sequenom) (Supplementary Table S2). Methylation per 
CpG was used to estimate the mean methylation. In the TNFα gene, five CpG sites were measured 
in triplicate and used to estimate mean methylation. These measurements were part of a study on 
cardiometabolic loci.
Statistical analysis
We applied linear mixed models on the raw data without imputation of missing values to calculate 
exposure-specific differences and associations. All the analyses accounted for bisulphite plate 
and correlation between the CpG dinucleotides within a locus. CpG dinucleotides were entered 
simultaneously with the variable under study as fixed effect with overall DNA methylation as 
outcome. Serum lipid concentration levels were treated as continuous variables. Absolute changes 
in DNA methylation are presented as regression coefficient ß with standard error (SE). Z-scores have 
been calculated so that the resulting estimated effect sizes indicate the methylation change per 
standard deviation change. Relative changes in percentage of DNA methylation are calculated by 
dividing the mean methylation with the exposure (i.e. serum lipid levels) by mean methylation 
without the exposure. Additional analyses were performed adjusting for gestational age at birth, 
birth weight, sex, breastfeeding and educational level. Blood biomarker levels of children were 
additionally adjusted for maternal blood biomarker levels. Since multiple comparisons are made 
we applied Bonferroni correction. For power calculations we used a simplified model assuming a 
bivariate linear regression analysis with mean methylation as response and the blood biomarkers as 
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predictor, ignoring bisulphite batches. Since we performed a Bonferroni correction we used an alpha 
of 0.00625. We used a SD of 4% in mean methylation of TNFα and a SD of 3% in mean methylation 
of LEP. In TNFα, the power to detect 1% and 1.5% absolute methylation difference was 50% and 95% 
respectively. In LEP, the power to detect 1% and 1.5% absolute methylation difference was 85% 
and 99% respectively. All statistical analyses were done using IBM SPSS Statistics 20.0 for Windows 
software (IBM, Armonk, NY, USA). 
Ethics committee approval
The study protocol was approved by the Central Committee for Human Research (CCMO) in The 
Hague, the Netherlands, and the Medical Ethical and Institutional Review Board of the Erasmus 
MC, University Medical Centre in Rotterdam, the Netherlands. All mothers gave their written 
informed consent and mothers and their partner gave written informed consent on behalf of their 
participating child. 
Results
Characteristics and methylation
The characteristics of the 120 mothers and children are shown in Table 1. Boys had a significantly 
higher birth weight, adjusted for gestational age, than girls. 
Average DNA methylation in the child for TNFα and LEP was 17.3% and 23.6%, respectively. Boys had 
a significantly lower mean methylation of LEP than girls, 22.8% and 24.7%, respectively (P=0.010). 
Methylation of the separate CpG sites is shown in Supplementary Table 1. DNA methylation of TNFα 
and LEP was significantly correlated (Pearson’s r=0.327, P=<0.001). The serum lipid profiles correlated 
between mothers and children significantly for total cholesterol (Pearson’s r=0.311, P=0.001), HDL-
cholesterol (Pearson’s r=0.256, P=0.006) and LDL-cholesterol (Pearson’s r=0.223, P=0.016), but not 
for triglycerides. 
Total cholesterol, triglycerides and lipoproteins in the child
Total cholesterol in the child was significantly associated with decreased methylation of TNFα (-5.8%, 
P=0.036) (Table 2). Additional adjustment for HDL-cholesterol in the child attenuated the effect 
(-4.9%, P=0.072). 
HDL-cholesterol was associated with decreased methylation of both TNFα (-6.9%, P=0.013) and 
LEP (-3.4%, P=0.021) (Figure 1). Adjustment for maternal HDL-cholesterol slightly attenuated 
the association between HDL-cholesterol in the child, TNFα (-4.9%, P=0.078), and LEP (-3.5%, 
P=0.023). Additional adjustment for gestational age at birth, birth weight, sex, breastfeeding 
and educational level further attenuated the effects, TNFα (-6.1%, P=0.058) and LEP (-3.1%, 
P=0.041). TNFα methylation was not associated with sex, maternal educational level or duration of 
breastfeeding. LEP methylation was significantly associated with sex and duration of breastfeeding, 
but not with maternal educational level. Additional adjustments for ethnicity did not change the 
results. Triglycerides and LDL-cholesterol were not significantly associated with DNA methylation. 
Bonferroni correction attenuated to nonsignificant estimates. 
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Table 1 | Child and mother characteristics
All children 
(n=120)
Boys  
(n=70)
Girls  
(n=50)
P valuec
Child
Age (months) 17.0 (15.1-18.6) 17.2 (15.5-18.8) 17.0 (15.0-18.3) 0.409
Birth weighta (g) 3455 (3115-3818) 3545 (3185-3917) 3348 (3066-3666) 0.044
Mean gestational age at birth (weeks) 39.6 (1.83) 39.6 (1.88) 39.6 (1.78) 0.927
Total cholesterol (mmol/L) 3.86 (0.80) 3.83 (0.76) 3.90 (0.86) 0.652
Triglycerides (mmol/L) 1.22 (0.70) 1.21 (0.65) 1.24 (0.76) 0.795
HDL-cholesterol (mmol/L) 1.01 (0.26) 1.21 (0.65) 0.99 (0.20) 0.591
LDL-cholesterol (mmol/L) 2.30 (0.70) 2.27 (0.67) 2.35 (0.73) 0.556
Leptin (mmol/L) 2.82 (0.64) 2.71 (0.44) 2.96 (0.80) 0.068
Overall mean methylation at study momentb 
TNFα 17.3 (0.50) 17.7 (0.60) 16.8 (0.70) 0.369
LEP 23.6 (0.30) 22.8 (0.50) 24.7 (0.50) 0.010
Mother 
Age at birth (years) 30.9 (21.5-42.8) 31.0 (22.5-39.4) 30.7 (21.5-42.8) 0.711
Periconception folic acid supplement use 34 (28) 20 (29) 14 (28) 0.945
Total cholesterol (mmol/L) 4.77 (0.88) 4.78 (0.95) 4.75 (0.80) 0.837
Triglycerides (mmol/L) 1.03 (0.51) 1.07 (0.97) 0.97 (0.40) 0.225
HDL-cholesterol (mmol/L) 1.47 (0.35) 1.44 (0.34) 1.51 (0.36) 0.243
LDL-cholesterol (mmol/L) 2.83 (0.77) 2.86 (0.80) 2.80 (0.74) 0.671
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TNFα, tumor necrosis factor-alpha; LEP, leptin.
a Adjusted for gestational age.
b Overall mean (SE) is estimated from the linear mixed model adjusted for bisulphite batch and CpG dinucleotides, accounting 
for the correlation between individual CpG dinucleotides. Sex mean (SE) is estimated from the linear mixed model adjusted for 
sex, bisulphite batch and CpG dinucleotides, accounting for the correlation between individual CpG dinucleotides. 
c P values for comparisons between boys and girls.
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Figure 1 | HDL-cholesterol in children 17 months of age and DNA methylation in TNFα (A) and DNA methylation 
in LEP (B) 
Total cholesterol, triglycerides and lipoproteins in the mother
HDL-cholesterol in the mother was associated with lower methylation of TNFα in the child (-8.7%, 
P=0.001) (Table 2). HDL-cholesterol in mothers and children was significantly correlated, but 
additional adjustment for HDL-cholesterol in the child did not substantially change the association 
with TNFα results (-7.5%, P=0.008). 
Total cholesterol, triglycerides and LDL-cholesterol levels in mothers were not associated with DNA 
methylation in the child. Bonferroni correction did not significantly affect the association between 
HDL-cholesterol and TNFα methylation.
Discussion
In this cross-sectional study we observed in children at 17 months of age associations between HDL-
cholesterol and decreased methylation of both TNFα and LEP, and between total cholesterol and 
decreased methylation of TNFα. Since total cholesterol consists of HDL-cholesterol, LDL-cholesterol 
and very low density lipoprotein-cholesterol and the association between total cholesterol and 
TNFα methylation diminished after adjusting for HDL-cholesterol, we conclude that the association 
between total cholesterol and DNA methylation is mainly driven by HDL-cholesterol.
Furthermore, we observed that maternal HDL-cholesterol was associated with decreased methylation 
of TNFα in the child, which did not modify the association between HDL-cholesterol in the child and 
TNFα methylation. Due to the cross-sectional design of our study we were not able to determine 
the direction of this association. Whether there is a link between maternal HDL and a child’s HDL 17 
months postnatal – as a result of a shared dietary pattern –or whether maternal HDL is a proxy for 
maternal HDL periconceptional entailing programming effects in utero remains to be elucidated. 
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We also observed that DNA methylation of LEP and TNFα was significantly correlated (Pearson’s 
r=0.332, P=<0.001). It is suggested that TNFα is involved in the regulation of plasma leptin 
concentration in obese subjects, however evidence is inconclusive (178). LEP and TNFα methylation 
levels are previously described as epigenetic biomarkers and could predict in obese patients the 
response to a low-calorie diet, in which lower methylation levels predict more successful weight 
loss (179). 
Hypercholesterolaemia in young children is associated with an increased risk of cardiovascular 
disease (173). Most research focuses mainly on the extremes as already pointed out by Gluckman et 
al. (180). However, here we report differences in epigenetic programming within the normal range 
of blood lipids. Since lower levels of leptin are related to cardiovascular and metabolic risks, such as 
obesity, it seems obvious that even within the normal range exposure for a long period of time to 
slightly higher HDL-cholesterol levels is associated with beneficially decreased LEP methylation. This 
will result in higher LEP expression and higher concentrations of leptin as shown by our group and 
others before (176). For TNFα the associations observed within the normal range of HDL-cholesterol 
seem to be different from those reported above this range (181). Since increased TNFα is associated 
with cardiovascular risk, we expected that higher HDL-cholesterol levels are associated with 
increased TNFα methylation and therefore lower expression of TNFα. However, this may not apply 
to HDL-cholesterol within the normal range of blood lipids. It has been reported that a complex 
nutriepigenomic network might regulate TNFα (182). 
Our data are in line with current evidence for the effects of cardiovascular and metabolic risk factors 
on global and DNA hypomethylation. Hyperhomocysteinaemia has been associated with increased 
CVD risk, especially atherosclerosis (183). Hyperhomocysteinaemia has been related to global DNA 
hypomethylation, in which the methyl donor folate restores global DNA methylation to normal 
levels (184). Also umbilical cord blood homocysteine is inversely correlated with genome-wide 
methylation, assessed using mean LINE-1 DNA methylation (185). With regard to lipids, Cash et al. 
showed that lower levels of LINE-1 DNA methylation are associated with higher LDL-cholesterol 
and lower HDL-cholesterol levels in 355 adult Samoans (181). However, they dichotomised the 
data into risk levels of LDL-cholesterol and HDL-cholesterol. In our study group, only 5 children 
showed increased LDL-cholesterol and none of them decreased HDL-cholesterol levels according 
to the reference values used at the Erasmus MC clinical chemistry laboratory (normal range LDL 
0.5-3.5 mmol/l and HDL 0.4-1.5 mmol/l).
Recent studies show that maternal cholesterol can be transported to the fetus via the placenta 
(186). It has been described that during pregnancy maternal total cholesterol concentrations were 
associated with birth weight, abdominal circumference and mid-upper arm circumference (187). 
Since both LEP and TNFα are non-imprinted genes which are demethylated postconceptional and 
remethylated from the early blastocyst stage onwards, epigenetic reprogramming in the early 
embryo under the influence of maternal lipid levels should also be considered. Maternal lipid levels 
17 months after the index delivery as a proxy for periconceptional maternal lipid levels may reveal 
an epigenetic programming effect. Therefore, a programming effect of in utero exposure established 
at 17 months of age cannot be excluded. However, since DNA methylation is responsive to the 
environment in early postnatal life, also a direct programming effect of the child lipids should be 
considered.
Processed on: 27-10-2016
505572-L-sub01-bw-Wijnands
110 | Chapter 7
In contrast to what has been observed by Tobi et al., methylation levels measured with the same 
technique and at the same laboratory in our very young children were lower for LEP (23.6% vs. 
28.6%) and higher for TNFα (17.3% vs. 9.6%) (188). These differences may be explained by differences 
in age at the study moment and residual confounding by (un)known pre- and postnatal exposures. 
Differences in absolute levels are however not a problem when the associations between absolute 
differences remain the same. A limitation is that although we have previously shown the association 
between LEP methylation and leptin levels in the same study population of very young children, we 
were not able to measure the expression of TNFα (176). 
Some strengths and limitations of this study need to be addressed. Due to ethical constraints we 
were not able to measure nonfasting blood biomarkers in children. However, small differences in 
lipid levels have been observed when measured in a fasting or nonfasting state (189). Moreover, 
a large variation in lipid levels has been observed across different age, sex, race and even over a 
period of time (190,191). Strength of our study is that we adjusted for these potential confounders 
which did not substantially affect the results. Also preterm birth is associated with less favorable 
lipid profiles (192). In our study population, 10 children were born premature. However, excluding 
these 10 children from the analyses showed comparable results (data not shown). 
We measured DNA methylation in DNA derived from whole blood which is a heterogeneous 
collection of different cell types. Therefore, cell heterogeneity should be considered as a potential 
confounder of DNA methylation measurements (193). On the other hand, our genes of interest are 
housekeeping genes expressed in all tissues for which blood cell heterogeneity seems not a very 
important issue (113). 
We describe several associations between lipid levels and altered DNA methylation, however, it 
is difficult to relate these findings to potential clinical consequences. The effects of alterations in 
DNA methylation are complex and biologic implications of small changes in DNA methylation are 
unknown. Unfortunately we were not able to measure gene expression. Furthermore, it has been 
reported that global DNA methylation levels persist within an individual from birth to age three 
which supports the belief that factors that influence global DNA methylation may confer long-term 
effects (194). 
Finally, due to the cross-sectional design of the study we cannot infer causality and therefore also 
not exclude that methylation status influences serum lipid levels. Whether altered DNA methylation 
is induced through serum lipid levels in utero or postnatal remains to be elucidated. 
In conclusion, our data support the developmental origins of health and disease hypothesis by 
showing that total cholesterol and HDL-cholesterol levels in very young children are associated 
with pre- or postnatally induced epigenetic metabolic programming, which may affect their 
cardiometabolic risk in later life. Due to the cross-sectional design of the study no causal relationship 
can be assessed and therefore the results have to be interpreted with caution. Further investigation 
and replication of these findings in both the normal and abnormal range of lipids is warranted to 
unravel potential mechanisms. Future health implications remain to be elucidated. 
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Supplementary material
Table S1 | Methylation of the CpG sites of TNFα and LEP
Locus All children (n=120) Boys (n=70) Girls (n=70)
TNFα 17.3 (0.50) 17.7 (0.70) 16.8 (0.70)
#CpG 1.2.3 20.6 (0.61) 20.7 (0.86) 20.5 (0.84)
#CpG 5 28.0 (0.73) 28.6 (1.10) 27.1 (0.91)
#CpG 6 9.1 (0.49) 9.4 (0.68) 9.0 (0.71)
#CpG 9 17.9 (0.58) 18.2 (0.84) 17.5 (0.75)
#CpG 10 10.6 (0.60) 10.9 (0.76) 10.1 (0.96)
LEP 23.6 (0.30) 22.8 (0.50) 24.6 (0.50)
#CpG 1 25.1 (0.5) 24.5 (0.61) 25.9 (0.76)
#CpG 8 16.0 (0.6) 15.5 (0.64) 16.8 (1.04)
#CpG 16.17 15.6 (0.3) 14.7 (0.39) 16.86 (0.55)
#CpG 19.20.21 13.2 (0.3) 12.6 (0.36) 14.03 (0.40)
#CpG 22 45.1 (0.9) 43.9 (1.15) 46.9 (1.38)
#CpG 25 43.9 (0.8) 42.9 (1.06) 45.2 (1.26)
#CpG 27 6.3 (0.2) 6.1 (2.50) 6.4 (0.41)
Values are presented as mean (SE) per CpG site. The overall mean (SE) is estimated from the linear mixed model adjusted for 
bisulphite batch and CpG dinucleotides, accounting for the correlation between individual CpG dinucleotides. Sex mean (SE) is 
estimated from the linear mixed model adjusted for sex, bisulphite batch and CpG dinucleotides, accounting for the correlation 
between individual CpG dinucleotides. 
Table S2 | Primer design 
Gene Name Genomic location Primer forward
CpG sites analysed Primer reverse
TNFα chr6_qbl_hap2:2790712-2791113 GGGTATTTTTGATGTTTGTGTGTT
CpG 1-3. 5. 6. 9. 10 CAATACTCATAATATCCTTTCCAAAAAA
LEP chr7:127668290-127668646 GTTTTTGGAGGGATATTAAGGATTT
CpG 1. 8. 16&17. 19-21. 22. 25. 27 CTACCAAAAAAAACCAACAAAAAAA
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In this thesis we investigated CHD and CVD risk factors using periconception epidemiologic and 
epigenetic studies. This chapter discusses the methodological considerations, main findings and 
clinical implications. Finally, recommendations for future research are provided.
Methodological considerations
Study design
The majority of data used for this thesis were collected in the HAVEN study, a case-control study. 
In observational studies, a prospective cohort study is considered the gold standard. However, the 
relatively low prevalence of CHD, that is, 9 per 1000 live births makes a prospective preconception 
cohort study not feasible since a very large number of subjects is required. In order to study 250 case 
children with CHD almost 28.000 subjects should be included. Therefore, in case of a rare disease, a 
case-control study is an accepted valid alternative. 
Since case-control studies are retrospective, they are susceptible to different types of bias. Selection 
bias is an important issue and may occur when cases are more likely to participate in the study. In 
the HAVEN study, the response rate was 74.7% for case families and 61.4% for control families. We 
had no permission from the medical ethical committee to collect data on non-responders and those 
who did not want to participate. 
Information bias can arise from measurement error. Two common types are misclassification bias and 
recall bias (195). In order to minimise misclassification bias, children where included at a standardised 
study moment of 17 months of age. Most CHDs are detected and diagnosed during the first year of 
life. Therefore, the study moment in early childhood reduces the chance of misclassification. Case 
children were included in the period between 2003 and 2010. In the Netherlands, a standardised 
routine 20-week ultrasound scan (“SEO / Structureel Echografisch Onderzoek”) has been introduced 
in 2007. From that moment the prenatal detection rate of CHD increased significantly resulting in 
both an increased total birth prevalence rate as well as a higher rate of terminated pregnancies 
(29). Since we included only a selection of eight different phenotypes, a selection of more severe 
phenotypes before 2007 is unlikely. Recall bias is minimised by blinding the study participants to the 
hypothesis. Furthermore, an empirical study on parental recall bias in a case-control study showed 
that parental recall is mostly nondifferential (196). This means that exposure misclassification 
is unrelated to the case status. However, it cannot be excluded that mothers with a child with a 
CHD are more likely to recall their exposure to potential risk factors. The study moment two years 
after the periconception period reflects the maternal biomarkers and nutritional status during the 
most sensitive window of CHD development (197). Finally, all self-administered questionnaires 
were checked by the researcher for completeness and consistency during the hospital visit. Also 
standardised anthropometric measurements including height, weight and blood pressure were 
performed in the hospital to limit measurement errors. 
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Study population
In this case-control family study children were enrolled together with their mother and father. 
Case children were recruited in collaboration with the departments of Paediatric Cardiology of the 
Erasmus MC, University Medical Centre in Rotterdam, Leiden University Medical Centre in Leiden, VU 
University Medical Centre and Academic Medical Centre in Amsterdam, the Netherlands. Although 
case children are recruited from four different university medical centres, there were only two 
paediatric cardiologists involved who diagnosed the children. Also, they were trained in the same 
medical centre. Diagnoses were confirmed by echocardiography and/or cardiac catheterisation 
and/or surgery after birth. Included CHD phenotypes comprised of pVSD, transposition of the great 
arteries, pulmonary valve stenosis, coarctation of the aorta, tetralogy of Fallot, atrioventricular septal 
defect, hypoplastic left heart syndrome and aortic valve stenosis. The selection of these phenotypes 
was based on experimental and epidemiological data that showed that hyperhomocysteinaemia 
and related gene-environment interactions are involved in the pathogenesis. 
Control children were recruited in collaboration with the child health care centres of ‘Careyn’ in 
the Rotterdam area in the Netherlands. Child health care centres are part of the Dutch healthcare 
system were all newborns get a regular check-up by a physician at standardised moments on health, 
growth and development. Control children were eligible when they did not have a major congenital 
malformation or chromosomal abnormality according to the medical records and regular health 
checks by physicians of the public child health centres. To exclude the influence of a shared (epi)
genetic background between family members cases and control families were unrelated. 
Accuracy of the data 
The accuracy of data refers to whether the measured value is the true value. Epigenome-wide 
DNA methylation was measured using the Illumina Infinium® HumanMethylation450 BeadChip 
(450k array). This array was released in 2011 and is an extension of the previous Illumina Infinium® 
HumanMethylation27 BeadChip (27k array). As a result of this extension, the 450K array uses two 
different types of chemical assays (Infinium Type I and Infinium Type II) (198). Since the 450K is 
relatively cheap and covers >480,000 CpG loci it is used by many researchers for epigenome-wide 
association studies. However, with an exponential increase in 450K data and more experience in 
analysing the 450K array over the last years, some disadvantages are reported. Type I and Type II 
probes are not directly comparable and correction for this probe-design is required (198). Multiple 
correction strategies have become available. We used the dasen procedure to normalise methylation 
data. This method involves background adjustment of the methylated and unmethylated intensities 
followed by separate quantile normalisation of methylated Type I, unmethylated Type I, methylated 
Type II and unmethylated Type II intensities (83). The 450K array covers 99% of RefSeq genes with 
an average of 17 CpG sites per gene region which makes it very comprehensive, however, within 
the rapid growing research field of epigenetics the 450K will soon be replaced by the Infinium® 
MethylationEPIC BeadChip which covers >850,000 CpG loci.
To increase accuracy of the methylation data in our candidate genes, DNA methylation was measured 
in triplicate using a mass spectrometry based method (EpiTYPER, Sequenom) in a laboratory 
with extensive experience. CpG loci containing fragments of too little or high mass for the mass 
spectrometer to resolve were excluded from the analysis. 
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Blood vs. Target tissue
For clinical settings, DNA methylation would be most relevant if it could be measured in easily 
accessible tissue such as leukocytes. Studies suggest that DNA methylation in blood is overall highly 
correlated with DNA methylation in internal tissues, however tissue-specific methylation patterns 
and differences in CpG loci across tissues are reported (112,199). However, in a human study using 
the Illumina Infinium® HumanMethylation27 and HumanMethylation450 BeadChip it was observed 
for certain CpG sites that methylation levels that are higher in the target tissue (such as heart tissue) 
than surrogate tissue (such as blood) in one individual, are on average also higher methylated in 
the target tissue than the surrogate tissue in other individuals (112). Also, the magnitude of such 
differences is similar across individuals. 
Main results
Transgenerational effects and the risk of congenital heart diseases
In Chapter 2 we observed that grandparents with CVD are at increased risk of having a grandchild 
with CHD. We propose that the underlying mechanism could be that CVD and CHD share variations 
in vascular and metabolic pathways in which poor nutrition and lifestyle (shared environment) will 
affect epigenetic (re)programming of the germ line (i.e. grandparents) and embryonic cardiac tissue 
(i.e. grandchild).
There are several epidemiologic studies providing evidence for transgenerational epigenetic 
inheritance, and also animal studies suggest that environmental exposures do have the ability 
to affect up to the fourth generation (200). Looking at transgenerational effects it is important to 
distinguish between intergenerational inheritance and true transgenerational inheritance. The 
impact of in utero exposure can affect not only the developing embryo but also its germline (which 
is the DNA blueprint for the grandchildren) (Figure 1) (201). Intergenerational effects are therefore 
defined as parental of grandparental exposures. Only when effects are shown in great-grandchildren 
(F3 generation) without direct exposure it could indicate transgenerational inheritance. Within our 
study we did not observe significant associations in the stratified analysis for great-grandparents 
and therefore could not show transgenerational effects. Hence, we can only conclude that the 
association observed between grandparents with CVD and grandchildren with CHD shows a pattern 
of intergenerational inheritance. 
Periconception parental factors and the risk of congenital heart diseases
In Chapter 3 we observed four parental conditions that increase the risk of CHD in the child. That 
is, maternal use of medication, advanced age and positive family history of CHD, and paternal 
exposure to phthalates. These risk factors – except a positive family history – have been associated 
with derangements of one-carbon metabolism which is an underlying mechanism of CHD. Multiple 
drug exposures have been linked to CHDs in the past (31). However, we were not able to verify our 
medication data in pharmacy records and could not exclude possible recall bias or type II errors. We 
consider medication use as a measure of health, although it can antagonise enzymes in folic acid 
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metabolism, or influence folic acid absorption or degradation and inhibit the folic acid methylation 
cycle, which in turn might increase the risk of CHD in the child. 
Mother – F0 generation (initially exposed)
Fetus – F1 generation
Gametes – F2 generation
Figure 1 | Intergenerational effects: maternal exposure extending to herself, the fetus and the gametes
Advanced maternal age has been described before as a risk factor for CHD in a study of over 1 million 
subjects (202). Advanced maternal age can alter one-carbon metabolism and lead to moderate 
to severe hyperhomocysteinaemia by reducing the bioavailability of substrates, cofactors and 
intermediates, and that way increase the risk of CHD (35). Adkins et al. investigated the association 
between parental age and DNA methylation in the newborn by using the 27K methylation array 
and pyrosequencing replication. They found that levels of DNA methylation in umbilical cord blood 
are strongly correlated with maternal age with a general trend towards hypomethylation of CpG 
islands with increasing age. Proposed mechanisms underlying this differences are changes in DNA 
methylation of the oocytes which could influence disease risk in the child. 
We have shown that paternal exposure to phthalates is associated with an increased risk of pVSD 
in the child. This has been described by Snijder et al. before (65). Occupations probably exposed to 
phthalates and therefore at risk are plastic workers, painters, electricians, hairdressers and printers. 
Recently, Wang et al. have described the same association (203). Evidence is growing that endocrine 
disrupting chemicals including phthalates have the ability to alter the human epigenome (204). It 
remains to be elucidated whether this will result in intergenerational or transgenerational disease 
risk. 
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DNA methylation in young children
The epigenetic studies described in this thesis include both candidate-gene studies as well as 
hypothesis-free studies. In Chapter 4 and Chapter 5 we explored epigenome-wide DNA methylation 
using a hypothesis-free approach to study novel epigenetic marks associated with nonsyndromic 
and syndromic pVSD. In Chapter 7 we studied DNA methylation of candidate-genes in association 
with serum lipid levels. 
The interpretation of EWAS data is complicated due to the complex interplay between genetic and 
environmental exposures (205). The differences in DNA methylation described in this thesis are 
small (<7%). Whether these differences will result in aberrant gene expression and have functional 
relevance has to be shown. It is thought that epigenetic mechanisms like DNA methylation 
contribute to the development of a “thrifty phenotype” (prenatal and early life exposures influence 
the development of adult diseases) and small epigenetic alterations (epigenetic fine-tuning) 
accumulatively affect metabolic pathways (206). Hence, in case of adverse exposures in utero it 
is feasible that the epigenetic modifications like DNA methylation are small. It is likely that CHD 
aetiology is the result of a combination of multiple small risk factors including CHD-associated 
epigenetic modifications. 
Cardiovascular risk factors and embryonic growth 
In Chapter 6 we observed that mothers with a stronger CVD risk profile and conceiving after IVF/ICSI 
treatment had a significant higher risk of a smaller embryo during early pregnancy. Future research 
will have to demonstrate whether the observed differences in embryonic growth in our study will 
translate into differences in fetal growth and birth weight. The implications of impaired embryonic 
growth on both short and long term are currently unknown. It has been described that embryonic 
growth is positively associated with birth weight, which in turn is associated with health in later 
life (135,166,207). Following the developmental origins of health and disease paradigm linking 
birthweight to lifelong health, a smaller embryo is associated with lower birthweight and has an 
increased risk of chronic diseases like CVD (208). 
Clinical implications and future perspectives
In order to move epigenetics from scientific research to clinical practice many steps have to be 
made. It should be noticed that aberrant DNA methylation can provide insides into many aspects of 
biology and pathophysiology, however, DNA methylation could very well function as a biomarker. 
That means that aberrant DNA methylation could predict disease risk, however it does not have to be 
causally involved in the disease (209). Within epigenetic epidemiology, a causal relationship between 
DNA methylation and the outcome cannot be proven. Animal studies could be helpful to further 
unravel the potential role of aberrant DNA methylation such as PRDM16 in CHD pathophysiology, 
since it remains to be elucidated whether the described small methylation differences will result in 
aberrant gene expression and phenotype. It is crucial that our findings are replicated in other studies 
to eliminate false positive outcomes. Unfortunately, we were not able to find an independent study 
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with the same phenotype and methylation data available and could therefore not replicate our 
findings. (Epi)genetic manipulation of PRDM16 in animal models is a suggested solution to provide 
more scientific evidence for the role of PRDM16 in pVSD development.
Epigenetic epidemiology does often not provide the evidence that makes it directly useful in clinical 
practice in terms of diagnosis or treatment. However, valorisation of knowledge coming from an 
emerging field like epigenetic epidemiology is critical to improve perinatal health by pursuing 
primary prevention (210). Herein lies the responsibility of the scientific community to inform both 
health care providers as well as the target population. All couples planning pregnancy should have 
access to evidence-based preconception care in order to be informed about modifiable and non-
modifiable risk factors, even though the attributable risk may seem small for the individual at first 
sight. In the Netherlands, this preconception care is available to all couples planning pregnancy 
through the mobile phone platform www.slimmerzwanger.nl (‘Smarter Pregnancy’) which provides 
an online personal coaching program focusing on diet and lifestyle habits (24). 
General conclusion
To further improve clinical practice in CHDs, not only research and care, but also genetics and 
epigenetics should collaborate strongly. The complex relationship between epigenetic mechanisms 
such as DNA methylation and the pathophysiology of CHDs remains to be unravelled. This thesis is 
a new starting point for future research on CHD. We provide new DNA methylation loci associated 
with pVSD and propose that methylation of PRDM16 is involved in pVSD pathophysiology in both 
nonsyndromic children and children with Down syndrome. Parental nongenetic risk factors are 
described, which enables health care professionals to provide better counselling on CHD risk factors. 
The observations in this thesis emphasise the importance of periconception care in relation to CHD 
and embryonic growth. The potential reversibility of epigenetics offers interesting possibilities for 
primary and secondary prevention and treatment. 
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Summary
Congenital heart diseases (CHD) are the most common birth defects worldwide with over 1 million 
children born each year. The origin is largely unknown and approximately only 15% can be traced 
to a known cause. The aims of this thesis were to study environmental and epigenetic determinants 
in association with CHD. Furthermore, a first approach was done to study the intergenerational 
effects of these exposures during early development. Furthermore, we investigated CVD risk factors 
which are common in women of reproductive age and can have an impact on pregnancy course 
and outcome.
In the introduction we provide the background for this thesis (Chapter 1). Most studies were 
conducted within the HAVEN study, a Dutch acronym of the case-control study designed to 
investigate determinants in the pathogenesis of CHDs and conducted in the western part of the 
Netherlands. The study described in Chapter 6 is based on the Rotterdam Periconception Cohort 
(Predict study). 
In the first part of this thesis we associate different determinants with the pathogenesis of CHDs. 
In Chapter 2 we investigated grandparents and their grandchildren. We showed that grandparents 
suffering from CVD have a significant increased risk of having a grandchild with a CHD. This risk 
was particularly increased in paternal grandfathers (father’s father) with CVD. Having two or more 
grandparents with CVD was associated with an approximately threefold risk for CHD grandchildren.
In Chapter 3 we investigated the association between nongenetic parental conditions and the 
risk of having a child with pVSD. Maternal use of medication, advanced age and a positive family 
history of CHD increased the risk of having a child with a pVSD. Paternal exposure to phthalates 
also increased this risk. Preconception counselling is an opportunity to identify these risk conditions 
which are partially modifiable and as such can contribute to the future prevention of pVSD.
In Chapter 4 we present the results of a hypothesis-free epigenome-wide association study to 
investigate novel CpG loci in association with pVSD. We used a methylation microarray to study over 
450,000 CpG loci. In leukocytes, we identified eight CpG loci with differential methylation in relation 
with pVSD. The most significant CpG was mapped to PRDM16. We validated this CpG with bisulphite 
pyrosequencing. Based on these findings and previous literature PRDM16 is suggested to play a 
potential role in the pathogenesis of pVSD. PRDM16 functions as a repressor of TGFß signaling which 
is crucial during embryonic development. Also the other CpG loci are mapped to genes involved 
in cardiogenesis and embryogenesis. Although this epidemiologic study cannot demonstrate the 
causality of these associations it provides enough evidence to substantiate these findings in future 
(animal) studies. 
In Chapter 5 we studied pVSD associated CpG loci from the previous epigenome-wide association 
study in children with pVSD and Down syndrome (DS) (trisomy 21). Approximately 50% of children 
born with DS have a CHD. Our data suggested that the CpG loci associated with nonsyndromic pVSD 
may also be involved in the pathogenesis of pVSD in DS. Furthermore, children with DS showed 
global hypermethylation in all autosomes except chromosome 21. This study suggests that the 
underlying mechanism of pVSD in children with and without DS share a common factor. 
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In the second part of this thesis we studied exposures to CVD risk factors during the periconception 
period. 
In Chapter 6 we investigated a maternal CVD risk profile including age, body-mass index, CVD in 
the family, diet and smoking in association with embryonic growth. Mothers with a strong CVD risk 
profile and a pregnancy conceived after IVF/ICSI treatment had a significant higher estimated risk 
of a smaller embryo during early pregnancy. This association was not found in women with a strong 
CVD risk profile and spontaneous conceived pregnancy. This dissimilarity might be explained by 
differences in pregnancy related factors such as sensitivity of endometrial, endothelial, placental 
and embryonic tissues.
In Chapter 7 we investigated serum lipid levels in young children and their mothers and the 
relation with DNA methylation of the candidate-genes TNFα and leptin. We showed that total 
cholesterol and HDL-cholesterol in children is associated with aberrant DNA methylation of TNFα 
and leptin. In mothers, HDL-cholesterol was associated with decreased methylation of TNFα in the 
child. We suggest that early epigenetic metabolic programming in young children may affect their 
vulnerability of developing CVD in later life. 
In the general discussion we interpret the findings of the studies described and their implications for 
clinical practice (Chapter 8). We also provide a starting point for future research including new DNA 
methylation loci associated with pVSD. The results reported in this thesis emphasise the importance 
of healthy periconception nutrition and lifestyle and suggest a potential role for epigenetic changes 
in CHD. Furthermore, maternal CVD risk factors seem to have an impact on the early development of 
the embryo conceived after IVF/ICSI treatment. 
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Samenvatting 
Congenitale hartafwijkingen zijn de meest voorkomende aangeboren afwijking ter wereld en 
komen voor bij meer dan 1 miljoen pasgeboren kinderen per jaar. De oorzaak is meestal onbekend. 
In slechts ongeveer 15% van de kinderen kan de oorzaak worden achterhaald. Het doel van dit 
proefschrift was om verschillende omgevingsdeterminanten en epigenetische variaties in relatie 
tot congenitale hartafwijkingen (CHA) te onderzoeken. De intergenerationele effecten van deze 
blootstellingen gedurende de vroege ontwikkeling worden beschreven. Daarnaast worden factoren 
onderzocht die het risico op cardiovasculaire ziekten verhogen. Deze cardiovasculaire risicofactoren 
komen steeds vaker voor en kunnen bij vrouwen van vruchtbare leeftijd invloed hebben op het 
verloop en de uitkomst van de zwangerschap.
De achtergrond van dit proefschrift wordt beschreven in de introductie (Hoofdstuk 1). De meeste 
studies werden uitgevoerd binnen de HAVEN studie (Hart Afwijkingen, Vasculaire status, Erfelijkheid 
en Nutriënten), een patiënt-controle onderzoek uitgevoerd in de regio West Nederland. De studie 
beschreven in Hoofdstuk 6 is gebaseerd op onderzoeksgegevens uit het Rotterdam Periconceptie 
Cohort (Predict studie).
In het eerste gedeelte van dit proefschrift wordt het onderzoek beschreven naar nieuwe oorzaken 
van CHA. 
In Hoofdstuk 2 zijn de grootouders en kleinkinderen onderzocht. Grootouders met cardiovasculaire 
ziekten lijken een significant hoger risico te hebben op het krijgen van een kleinkind met een CHA. 
Dit risico was het hoogst wanneer de paternale grootvader (vader van vader) cardiovasculaire 
ziekten had. Het risico op een kleinkind met een CHA was bijna driemaal verhoogd wanneer meer 
dan twee grootouders cardiovasculaire ziekten hadden. 
In Hoofdstuk 3 onderzochten we het verband tussen niet-genetische risicofactoren van de ouders 
en het risico op het krijgen van een kind met een pVSD. We toonden aan dat blootstelling van het 
kind tijdens de vroege ontwikkeling aan een viertal specifieke ouderlijke factoren het risico op een 
pVSD verhoogd. Een moeder die medicatie gebruikt, van gevorderde leeftijd is of met een positieve 
familie-anamnese voor CHA, heeft een hoger risico op het krijgen van een kind met een pVSD. 
Vaders die worden blootgesteld aan ftalaten (weekmaker) hebben ook een verhoogd risico. Deze 
risicofactoren zijn deels te vermijden door het aanbieden van preconceptionele counseling. 
In Hoofdstuk 4 presenteren we de resultaten van een hypothese-vrije epigenoom-wijde 
associatiestudie. Hiervoor werden meer dan 450,000 CpG loci getest in relatie tot het pVSD. In 
witte bloedcellen werden acht CpG loci gevonden die variaties vertoonden in DNA methylering 
en geassocieerd zijn met het pVSD. De meest significante CpG bevond zich in het PRDM16 gen. 
Deze bevinding werd bevestigd met een andere meetmethode (bisulphite pyrosequencing). Op 
basis van deze nieuwe bevindingen en eerder onderzoek beschreven in de literatuur zou PRDM16 
mogelijk betrokken kunnen zijn bij het ontstaan van een pVSD doordat het onder andere het TGFß 
signaal onderdrukt, een cruciale cytokine tijdens de embryonale ontwikkeling. Ook de overige 
gevonden CpG loci bevinden zich in genen die op basis van eerder onderzoek betrokken lijken 
bij hartontwikkeling en embryogenese. De causaliteit van deze bevindingen kan niet worden 
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aangetoond op basis van dit epidemiologische onderzoek. Het is daarom noodzakelijk dat deze 
bevindingen worden bevestigd in andere (dier)studies. 
In Hoofdstuk 5 hebben we de eerder gevonden CpG loci uit Hoofdstuk 4 bestudeerd in kinderen 
met pVSD en het syndroom van Down (trisomie 21). Ongeveer 50% van de kinderen met het 
syndroom van Down wordt geboren met een hartafwijking. De eerder gevonden CpG loci in 
kinderen met een geïsoleerde (niet-syndromale) pVSD lijken ook geassocieerd te zijn met pVSD in 
het syndroom van Down. Opvallend was de globale hypermethylering in alle autosomen behalve 
chromosoom 21 in deze kinderen. Dit onderzoek suggereert overeenkomsten in het onderliggende 
ontstaansmechanisme van geïsoleerde pVSDs als dat bij kinderen met het syndroom van Down. 
In het tweede gedeelte van dit proefschrift bestudeerden wij de invloed van blootstelling aan 
cardiovasculaire risicofactoren in de periconceptionele periode. 
In Hoofdstuk 6 werden vrouwen met een sterk cardiovasculair risicoprofiel geïdentificeerd met 
behulp van een maternale cardiovasculaire risicoscore gebaseerd op leeftijd, body-mass index, hart- 
en vaatziekten in de familie, dieet en roken. Moeders met een hoger cardiovasculair risicoprofiel 
die zwanger waren na een IVF/ICSI behandeling hadden een significant hoger risico op een kleiner 
embryo in de eerste weken van de zwangerschap. Dit was niet het geval bij moeders met een sterk 
cardiovasculair risicoprofiel en een spontane zwangerschap. 
In Hoofdstuk 7 onderzochten we het serumgehalte van lipiden in jonge kinderen en hun moeders 
en de relatie met DNA methylering van de kandidaatgenen TNFα en leptine. Dit onderzoek 
liet zien dat totaal cholesterol en HDL-cholesterol waarden in jonge kinderen geassocieerd 
lijken met veranderingen in DNA methylering van TNFα en leptine. Het HDL-cholesterol van de 
moeder was geassocieerd met minder methylering van TNFα in het kind. Deze epigenetische 
metabole programmering zou het kind meer kwetsbaar kunnen maken voor het ontwikkelen van 
cardiovasculaire ziekten later in het leven. 
In de discussie gaan we in op de interpretatie van de belangrijkste bevindingen van dit proefschrift 
en de implicaties voor de klinische praktijk (Hoofdstuk 8). De gevonden CpG loci bieden 
aanknopingspunten voor toekomstig onderzoek naar CHA. De resultaten van dit proefschrift 
benadrukken het belang van gezonde periconceptionele voeding en leefstijl en suggereren dat 
epigenetische veranderingen een mogelijke rol spelen bij het ontstaan van CHA. Daarnaast zijn 
cardiovasculaire risicofactoren van de moeder van invloed op de vroege ontwikkeling en groei van 
het embryo. 
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List of abbreviations
1-C One-carbon
3D US Three-dimensional ultrasound scan
3’ UTR Three prime untranslated region
5’ UTR Five prime untranslated region
ATC Anatomical Therapeutical Classification
AUC Area under the receiver operating curve
AVSD Atrioventricular septal defect
BMIQ Beta Mixture Quantile dilation
BMP Bone morphogenetic proteins
C14orf109 Chromosome 14 open reading frame 109
CDK4 Cyclin-dependent kinase-4
CDKN1A Cyclin-dependent kinase inhibitor 1A
CDMR Cancer-specific differentially methylated region
CHD Congenital heart disease
CMD Colour magnitude diagram
CpG 5’-cytosine-phosphoguanosine
CRL Crown-rump length
CTBP2 C-terminal-binding protein 2
CVA Cerebrovasculair accident
CVD Cardiovascular disease
DHS DNase I hypersensitive
DMR Differentially methylated region
DNA Deoxyribonucleic acid
DOHaD Developmental origins of health and disease
DS Down syndrome
ESAM Endothelial cell adhesion molecule
EVI1 Ectropic virus integration site 1
EWAS Epigenome-wide association study
FDR False discovery rate
GA Gestational age
GO Gene ontology
HDL High-density lipoprotein
HGF Hepatocyte growth factor
HIF3A Hypoxia-inducible factor 3 alpha
HNRNPU Heterogeneous nuclear ribonucleoprotein U
HSC Hematopoietic stem cells
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IC Intermittent claudication
ICSI Intracytoplasmic sperm injection
IVF In vitro fertilisation
KS Kolmogorov-Smirnov
LDL Low-density lipoprotein
LEP Leptin
LMP Last menstrual period
MAF Minor allele frequencies
MOAP1 Modulator of apoptosis 1
MTHFR Methylenetetrahydrofolate reductase
NFIA Nuclear factor I/A
NK Natural killer
OR Odds ratio
PC Principle component
PCA Principal component analysis
PDR Preconception Dietary Risk
PERMANOVA Permutational multivariate analysis of variance
PPFIA4 Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein alpha-4
PRDM16 PR domain containing 16
pVSD Perimembranous ventricular septal defect
PWBC Peripheral white blood cells
RDMR Reprogramming-specific differentially methylated region
SAH S-adenosylhomocysteine
SAM S-adenosylmethionine
SD Standard deviation
SE Standard error
SEM Structural equation modelling
SGA Small for gestational age
SKI Sloan-Kettering Institute proto-oncogene
TGFβ Transforming growth factor beta
TNFα Tumor necrosis factor-alpha
TSS1500 Left 1500bp from transcription start site
TSS200 Left 200bp from transcription start site
VSD Ventricular septal defect
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1. PhD Training
Master of Science in Health Sciences, specialisation Clinical  
Epidemiology, NIHES
2008-2011
Year Workload 
(ECTS)
General courses
Study Design 2008 4.3
Clinical Trials 2008 0.7
Case-control studies 2008 0.7
Methods of Clinical Research 2008 0.7
Introduction to Decision-making in Medicine 2008 0.7
Topics in Health and Diseases in the Elderly 2008 0.7
Principles of Research in Medicine and Epidemiology 2008 0.7
Introduction to Data-analysis 2009 1.0
Regression Analysis 2009 1.9
Topics in Meta-analysis 2009 0.7
Survival Analysis 2009 1.9
Methods of Public Health Research 2010 0.7
History of Epidemiologic Ideas 2010 0.7
Advanced courses
Intervention Research and Clinical Trials 2009 0.9
Diagnostic Research 2009 0.9
Courses for the Quantitative Researcher 2009 1.4
Introduction to Clinical Research 2009 0.9
Prognosis Research 2009 0.9
Advanced Topics in Decision-making in Medicine 2009 1.9
Medical Demography 2010 1.1
Bayesian Statistics 2010 1.1
Missing Values in Clinical Research 2010 0.7
Pharmaco-epidemiology and Drug Safety 2011 1.9
Advanced Topics in Clinical Trials 2011 1.9
Advanced Analysis of Prognosis Studies 2011 0.9
Principles of Epidemiologic Data-analysis 2011 0.9
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Repeated Measurements 2012 1.4
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General academic skills courses
A First Glance at SPSS for Windows 2009 0.15
The Basic Introduction Course on SPSS (MOLMED) 2010 1.0
Working with SPSS for Windows 2010 0.15
Scientific Writing in English for Publication 2010 2.0
International training
At Harvard T.H. Chan School of Public Health, Boston, MA, USA
Introduction to Management of Health Care Organisations 2010 2.0
Ethical Basis of the Practice of Public Health 2010 2.0
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Nederlandse Vereniging voor Toxicologie, sectie Teratologie en 
Reproductietoxicologie, Zeist, The Netherlands
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Bo Hjelt Foundation, Rotterdam, The Netherlands 2011 1.0
Research meeting, Department of Obstetrics and Prenatal Medicine, 
Rotterdam, The Netherlands
2011-2013 2.0
Annual Juriy Wladimiroff Research Meeting, Rotterdam, The Netherlands 2012 1.0
Science lunch cluster 12, Rotterdam, The Netherlands 2012-2013 2.0
Seminars and workshops
Weekly research meetings, Department of Obstetrics and Prenatal 
Medicine, Rotterdam, The Netherlands
2008-2013 5.0
Annual Juriy Wladimiroff Research Meeting, Rotterdam, The Netherlands 2011-2013 0.4
Workgroup Epigenetic Epidemiology, Rotterdam, The Netherlands 2011 1.0
Symposium Jonge Zwangerschap, Rotterdam, The Netherlands 2012 0.2
Erasmus MC PhD Day, Rotterdam, The Netherlands 2012-2013 0.4
Advice to Young Scientists: How to build a career in Research, Rotterdam, 
The Netherlands
2013 0.2
(Inter)national conferences
7th World Congress on Developmental Origins of Health and Disease, 
Portland, OR, USA
2011 1.0
59th Annual Meeting Society of Gynecological Investigations, San Diego, 
CA, USA 
2012 1.0
2nd European Periconception Health Congress, Rotterdam, The 
Netherlands
2012 1.0
8th World Congress on Developmental Origins of Health and Disease, 
Singapore
2013 1.0
9th World Congress on Developmental Origins of Health and Disease, 
Cape Town, South Africa
2015 1.0
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International work experience
Harvard T.H. Chan School of Public Health, Department of Biostatistics, 
Boston, MA, USA (6 weeks)
2013 2.0
2. Teaching activities
Lecturing
Curriculum Bachelor Medicine, Erasmus University, minor Congenital 
heart diseases, topic Gene-environment interactions
2011-2012 1.0
Supervising Master’s theses
Supervising elective research programs (21 weeks) of medical students:
Gerdien Zeilmaker, Erasmus University, Rotterdam, The Netherlands 2011 1.5
Remco Visser, Erasmus University, Rotterdam, The Netherlands 2012 1.5
Fleur Bruinier, Erasmus University, Rotterdam, The Netherlands 2013 1.5
Other skills
Preconception counselling of subfertile couples 2010-2012 3.0
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Kim Wijnands werd geboren op 17 maart 1988 te Amersfoort, 12 minuten na haar tweelingbroer 
Ralph. Na het behalen van haar VWO diploma in 2006 op middelbare school ’t Atrium te Amersfoort 
begon zij met haar studie Geneeskunde aan de Erasmus Universiteit te Rotterdam. 
Vanaf het derde jaar van haar Geneeskunde opleiding startte zij ook met een Research Master 
aan het Netherlands Institute for Health Sciences. Haar masteronderzoek verrichtte zij op de 
afdeling Verloskunde & Gynaecologie onder supervisie van prof.dr. Régine Steegers-Theunissen. 
Als onderdeel van deze Research Master nam zij in 2010 deel aan de Summer School van Harvard 
T.H. Chan School of Public Health, Boston, Verenigde Staten. In 2011 behaalde zij haar doctoraal 
Geneeskunde en haar Master of Science graad in Health Sciences met een specialisatie in Clinical 
Epidemiology. Hierna startte zij in mei 2011 als promovendus binnen de HAVEN studie onder 
begeleiding van prof.dr. Régine Steegers-Theunissen (Verloskunde & Gynaecologie) en prof.dr. 
André Uitterlinden (Interne Geneeskunde). Gedurende haar onderzoek werkte zij onder meer op de 
afdeling Biostatistiek op Harvard T.H. Chan School of Public Health, Boston, Verenigde Staten, voor 
het uitvoeren van statistische analyses. 
Na tweeënhalf jaar promotieonderzoek vervolgde zij in 2014 haar opleiding Geneeskunde en liep 
twee jaar co-schappen binnen de regio Rotterdam. In maart 2016 studeerde zij cum laude af als arts. 
Aansluitend is zij begonnen als arts-assistent (niet in opleiding tot specialist) Interne Geneeskunde 
in het Maasstad Ziekenhuis te Rotterdam. 
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Het schrijven van dit dankwoord betekent dat er een einde is gekomen aan een hele bijzondere 
en mooie periode. Promoveren doe je niet alleen, door de jaren heen zijn er een heleboel mensen 
geweest die hebben bijgedragen aan dit proefschrift. Een aantal mensen wil ik in het bijzonder 
bedanken. 
 
Allereerst mijn supervisor en promotor, prof.dr. R.P.M. Steegers-Theunissen. Beste Régine, alweer een 
hele tijd geleden (in 2008) leerden wij elkaar kennen toen ik als jonge master studente onderzoek 
kwam doen bij jou op de afdeling. Ik wil je bedanken voor het vertrouwen en de vele kansen die 
ik vanaf de eerste dag van jou heb gekregen. Je enthousiasme en passie voor de wetenschap zijn 
aanstekelijk en je positiviteit en aanmoedigingen bij tegenslagen heb ik altijd enorm gewaardeerd. 
Ik heb veel geleerd, niet alleen over het onderzoek maar ook over mijzelf. Ik ben enorm gegroeid op 
jouw afdeling en daarvoor zal ik je altijd dankbaar blijven. Hopelijk werken we in de toekomst nog 
eens samen.
Prof.dr. A.G. Uitterlinden, beste André. Het epigenetische onderzoek binnen de HAVEN studie zou 
niet mogelijk zijn geweest zonder de investeringen van de mensen op jouw lab. Ik ben dankbaar 
voor de prettige samenwerking de afgelopen jaren. Zelf ben je wat verderop in mijn promotietraject 
persoonlijk betrokken geraakt. Je verfrissende inzichten en kritische beoordeling zijn van groot 
belang geweest bij het afronden van mijn laatste artikelen. 
De leden van de kleine commissie, prof.dr. C.M. van Duijn, prof.dr. V.W.V. Jaddoe en prof.dr. J.J.M. 
Takkenberg, hartelijk dank voor het kritisch lezen en beoordelen van mijn proefschrift. Prof.dr. A.C. 
Gittenberger–de Groot, prof.dr. P.J. van der Spek, prof.dr. R.M.W. Hofstra en dr. A.T.J.I. Go, hartelijk 
dank voor het plaatsnemen in de grote commissie. 
Alle co-auteurs, hartelijk dank voor de plezierige samenwerking en jullie bijdrage aan de artikelen in 
dit proefschrift. Dear Jun and Xihong, thank you sincerely for our successful collaboration and your 
hospitality in Boston. 
Mijn voorgangsters binnen de HAVEN studie, dr. A.C. Verkleij-Hagoort, dr. L.M.J.W. van Driel, dr. 
H.P.M. Smedts en dr. S.A. Obermann-Borst, veel dank voor het zorgvuldig includeren en verzamelen 
van een unieke dataset. Ook al ken ik jullie niet allemaal persoonlijk, jullie moesten eens weten hoe 
vaak ik jullie proefschriften heb gelezen. Lieve Sylvia, jij maakte me niet alleen wegwijs binnen de 
HAVEN studie, maar heette me ook welkom op de afdeling. Altijd mocht ik jou bellen of mailen voor 
advies, en iedere keer had je een antwoord of oplossing. Ik weet nog toen ik zag hoe jij in SPSS in een 
handomdraai een Linear Mixed Model uit je mouw schudde en dacht ‘oh jee help, moet ik dat ook 
kunnen?’, en jij antwoordde met de woorden ‘wacht maar wat jij allemaal kunt als je je proefschrift 
aan het afronden bent’. Gelukkig kreeg je gelijk. 
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Veel dank gaat ook uit naar dr. M.F. Wildhagen voor het bouwen van de HAVEN (familie)database. 
Wekenlang heb ik data ingevoerd, wat gelukkig een stuk eenvoudiger was door een goed 
functionerende database. Veel dank ook naar Bertrand van Zelst van het Klinische Chemie Lab voor 
het zorgvuldig opslaan van onze samples. 
Beste Michael, jij maakte mij wegwijs op het geneticalab en leerde mij wat er allemaal komt kijken 
bij het meten van DNA methylering. Het lukte je elke keer om alles op een eenvoudige manier uit te 
leggen zodat ook ik feeling kreeg met de epigenetische data. Jouw bijdrage aan zowel de EWAS als 
pyrosequence data zijn erg waardevol geweest voor het onderzoek. 
De afgelopen acht jaar heb ik zoveel leuke mensen mijn collega mogen noemen dat ik ongetwijfeld 
iemand ga vergeten (sorry daarvoor). Om natuurlijk te beginnen met iedereen van de 22ste, lieve 
Annelien, Caroline, Eline, Fatima, Jinke, John, Jorine, Manon, Marijana, Matthijs en Stefanie: bedankt 
voor de vele gezellige koffiebreaks, lunches, borrels en congressen. Van San Diego tot Kaapstad, 
van de koffiebar tot WP, het was me allemaal even waardevol. In het bijzonder wil ik Emilie, Irene 
en Nicole noemen, een groot deel van ons onderzoek hebben we samen doorlopen. Wat was het 
fijn samen te brainstormen over het onderzoek, gelukkig hebben we daarbuiten ook veel kunnen 
delen. Succes met de laatste loodjes. Wat een geluk dat Régine de gave heeft om altijd een te gekke 
onderzoeksgroep om zich heen te verzamelen. 
Ik had daarnaast de luxe om ook verspreid door het hele Erasmus MC nóg meer waardevolle 
collega’s te hebben. Lieve Amber, Anke, Babs, Chantal, Christine, Claudia, Hein, Jacky, Jashvant, 
Leonie, Marieke, Melek, Nienke, Nina, Ruben, Sabine, Sevilay, Vera, Wendy, Yvonne en Zoë, bedankt 
voor de geweldige tijd. Van een fantastisch skiweekend tot de woensdagmiddag lunches, het was 
altijd gezellig! 
En dan mijn paranimfen, lieve Babs en lieve Eef. Kleine ukkies worden groot! Wat hebben jullie 
jarenlang jullie best gedaan om keurige ukkie (that would be me) wat ongemanierder te maken, 
en wat hebben jullie gefaald al zeg ik het zelf ;). Ik had mij geen fijnere roomies kunnen wensen en 
ben blij dat ik jullie inmiddels mijn vriendinnen mag noemen. Jullie adviezen, steun en luisterende 
oor hielden gelukkig niet op buiten Ee2269. Dank dat jullie er altijd zijn. Ik ben blij en trots dat jullie 
4 november naast mij staan. Want jullie weten het, vroeger was ik fan van Audrey, maar inmiddels 
ben ik ook fan van jullie. En mocht het grote prietpraat boek ter sprake komen, het ging sowieso 
anders… 
Joost, thanks dat er zó vaak geborreld mocht worden, en sorry dat we jullie soms van het eten af 
hielden. Gelukkig was je er meestal ook gewoon bij! Te gek dat je het zo goed met SJ kunt vinden. 
Mijn geneeskundemaatjes, lieve Bianca, Esther en Floor, vanaf de allereerste dag in de Eurekaweek 
samen aan de studie. En wat zijn we naar elkaar toe gegroeid in een nieuwe stad tijdens de vele 
colleges, etentjes en treinreizen. Ik geniet nog altijd van onze maandelijkse etentjes en updates. 
Het is te gek om te zien hoe ieder zijn eigen weg is ingeslagen. Een orthopeed, radioloog, arts voor 
verstandelijk gehandicapten en internist in spé, wie had dat gedacht in 2006!
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Meiden van Artemis, bedankt voor de vele leuke borrels en etentjes. Mede door jullie leerde ik 
inzien hoe ontzettend leuk Rotterdam is. Lieve Cor, Deb, Lies, Lot, Sab, Siets en Soof in het bijzonder, 
dank voor jullie medeleven en betrokkenheid bij soms zware tijden met werken én daarnaast een 
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